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ABSTRACT 
It is well characterized that tumors depend upon angiogenesis in order to progress 
and form metastases. In this regard, strategies to inhibit neovascularization have been 
developed either aimed to target endothelial cells directly or indirectly via suppression of 
pro-angiogenic growth factors produced by the tumor or surrounding stromal cells. 
Several anti-angiogenic agents are present endogenously in our body as cleavage 
products of larger precursor proteins. Angiostatin is one of the most widely studied 
inhibitors of angiogenesis and encompasses the first 3 or 4 kringle domains of human 
plasminogen (PIg). Of particular interest, is the fifth kringle of human Plg (K5), which 
displays higher anti-angiogenic potency than angiostatin. In fact, kringles 1 to 5 exhibit 
greater inhibitory activity against endothelial cells than angiostatin, and this finding 
suggests that K5 domain acts synergistically to enhance the anti-angiogenic effect of 
angiostatin. Employing a gene-based approach for the delivery of an anti-angiogenic 
agent provides sustained, biologically relevant levels of the therapeutic protein of interest 
and circumvents the limitations associated with direct recombinant protein use, such as 
the necessity for prolonged repeated administration, high dosages, high expense and risk 
of toxicity. Therefore, we proposed that the K5 domain --Qn its OWll- could act as a potent 
anti-angiogenic and anti-tumor protein within the context of a cancer gene therapy 
strategy. 
In our first study, we assessed the angiostatic properties of the K5 peptide domain 
III an orthotopic brain cancer model. We demonstrated that the disulfide bridging 
conformation of K5, necessary to maintain its functionality, is conserved upon secretion 
by gene-modified mammalian cells. Kringle 5 retrovirally gene-engineered human U87 
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glioma celIs produced functional soluble KS protein capable of suppressing growth 
factor-induced endothelial celI migration in vitro and inhibiting glioma-induced 
angiogenesis in vivo. Interestingly, secreted KS prote in blocked the recruitment of tumor-
associated CD4S+Mac3+0rl" macrophages in vivo and inhibited the migration of CD206+ 
human monocyte-derived macrophages in vitro. Moreover, in a clinicalIy relevant 
orthotopic glioma model, soluble KS induced long-term survival in a majority of test 
animaIs. Thus, these findings validate the use of a gene therapy approach to deliver Plg 
KS protein and suggest that KS acts as a novel 2-pronged anti-tumor agent, mediating its 
inhibitory effect via its action on host-derived endothelial ceUs and tumor-associated 
macrophages. 
To determine if KS mediated its anti-tumor effect by modulating other immune 
effector cells, we tested the use of soluble KS in a murine DAl3 mammary 
adenocarcinoma mode!. Soluble KS produced by retrovirally gene-modified DAl3 ceUs 
led to long-term survival (over 1 year) of immunocompetent BALB/c mice however, we 
failed to observe tumor rejection in immunodeficient NOD-SCID and BALB/c nude 
mice. Further analysis revealed that KS enhances the recruitment of tumor-infiltrating 
CD3+ lymphoid cells, in particular the natural killer T (NKT)-lymphocyte phenotype. 
Consistent with our previous findings, we demonstrated that KS led to a significant 
decrease in tumor-associated microvessel length and density. Interestingly, KS tumors 
were characterized by a robust neutrophilic infiltrate. This may be explained by the 
ability of KS to act as a strong chemotactic agent for human neutrophils in vitro as weU 
as its ability to promote CD64+ activation within the CD 11 b + neutrophil phenotype. 
These findings confirm that KS acts as a potent angiostatic agent and possesses a novel 
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pro-inflammatory role via its ability to recruit tumor-associated neutrophils and NKT-
lymphocytes, leading to a strong anti-tumor response. 
Tumor-associated macrophages (TAM) are key immune effector cells implicated 
in promoting tumor progression and metastasis. It would thus be desirable to explore 
strategies to reduce T AM infiltration within the tumor microenvironment. In our first 
study, we demonstrated that soluble K5 protein blocks macrophage recruitment. In 
addition, the recent observation that angiostatin reduces macrophage infiltration in an 
atherosc1erosis model prompted our laboratory to further explore the use of angiostatin as 
an anti-macrophage agent. We demonstrated that angiostatin suppresses the in vitro 
migration of both murine peritoneal macrophages and human monocyte-derived CD206+ 
macrophages. Furthermore, we showed that angiostatin led to a decrease in the 
gelatinolytic activity of macrophage-produced matrix metalloproteinase-9, which may 
explain, in part, the observed angiostatin-mediated inhibition of migration. Additionally, 
we detected the presence of the /3-subunit of A TP synthase on the cell-surface of 
macrophages. A TP synthase was previously found to be a receptor for angiostatin on the 
cell-surface endothelial cells. We propose that the presence of A TP synthase on the 
surface of macrophages may promote interaction with angiostatin and prevent migration, 
similar to what has been reported with endothelial cells. Our findings suggest that 
angiostatin holds promise as an inhibitory agent against macrophages. 
Overall, our data supports the use of Plg K5 protein as a potent anti-angiogenic 
agent and reveals that K5 as weIl as angiostatin possess novel immune modulatory 
properties that potentially enhance their utility as therapeutic agents against cancer. 
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RÉSUMÉ 
Il a été largement cerné que les tumeurs dépendent de l'angiogenèse afin 
d'accomplir leur progression et former des métastases. À cet effet, des méthodes visant à 
inhiber la néovascularisation ont été élaborées afin de cibler les cellules endothéliales de 
façon directe ou indirecte via la suppression des facteurs de croissance pro-angiogéniques 
produits par la tumeur ou les cellules stromales environnantes. Plusieurs agents anti-
angiogéniques demeurent présents endogéniquement dans notre organisme en tant que 
produits afférents à de plus vastes protéines et ce en tant que précurseurs. L' angiostatine 
s'avère être un des inhibiteurs les plus étudiés et englobe les trois ou quatre premiers 
domaines kringle du plasminogène humain. II importe de noter qu'il s'agit du cinquième 
kringle du Plg humain (K5) qui démontre une capacité anti-angiogénique plus élevée que 
l'angiostatine. En effet, les kringles 1 à 5 présentent une activité inhibitrice supérieure 
face aux cellules endothéliales que ne le démontre l' angiostatine. De plus, cette 
découverte suggère que la région K5 agit synergiquement afin d'augmenter l'effet anti-
angiogénique de l'angiostatine. L'utilisation d'une approche de thérapie génique dans le 
transfert d'un agent anti-angiogénique fournit un niveau biologique significatif et 
soutenu de la protéine concernée et circonvient les limites associées à l'usage direct du 
recombinant de protéines telle que par exemple la nécessité d'administrer le produit de 
façon prolongée et répétée, en dosage élevé et en tenant compte du risque élevé de 
toxicité. Nous proposons donc que le domaine K5 agit de lui-même comme puissant 
agent anti-angiogénique et comme protéine anti-tumeur dans le cadre d'une thérapie 
génique contre le cancer. 
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Lors de notre première étude, nous avons constaté les propriétés angiostatiques de 
la peptide du domaine K5 à même un modèle orthotopique de cancer du cerveau. Nous 
avons démontré que les ponts disulfides participant à la conformation du K5, nécessaire 
au maintien de la fonctionnalité de ce dernier, sont conservés lors de la sécrétion 
provenant de cellules mammaliennes génétiquement modifiées. Les cellules gliomiques 
humaines U87 génétiquement modifiées de façon rétrovirale produisent de la protéine KS 
soluble fonctionnelle capable de réduire les facteurs induits de la croissance de cellules 
endothéliales migrant in vitro et inhibant l'angiogénèse gliomiquement induite in vivo. Il 
importe de noter que la protéine K5 secrétée bloque le recrutement des macrophages in 
vivo CD4S+Mac3+Grr associé à la tumeur et inhibe la migration in vitro des 
macrophages CD206+ dérivé des monocytes. De plus, au sein d'un modèle orthotopique 
significatif de cellules gliomique, du K5 soluble entraîne la survie à long terme de la 
majorité des animaux testés. Ainsi, ces résultats valident l'approche préconisée par 
l'usage de la thérapie génique afin de transférer la protéine Plg K5 et suggèrent que le K5 
agit en soi comme agent anti-tumeur à double action qui s'interpose via son effet d'hôte 
dérivé sur les cellules endothéliales et les macrophages associés à la tumeur. 
Afin de déterminer si le KS a interposé son effet anti-tumeur en modulant d'autres 
cellules immunitaires effectrices, nous avons testé l'usage du K5 soluble dans un DAl3 
murin au sein d'un modèle adénocarcinomique mammaire. Le K5 soluble, produit de 
façon rétrovirale par les cellules DAl3 génétiquement modifiées, mène à la survie à long 
terme (au-delà d'un an) des souris BALB/c immuno-compétententes. Par contre, nous 
n'avons pas observé de rejet de la tumeur chez les souris NOD-SCID et chez les souris 
BALB/c nues immunodéficitaires. Une analyse a de surcroît révélé que le KS augmente 
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le recrutement de cellules lymphatiques CD3+ qui infiltrent la tumeur et particulièrement 
le phénotype du Natural Killer T du lymphocyte (NKT). De pair avec nos résultats 
précédents, nous avons démontré que le K5 mène à la réduction significative de la 
longueur et de la densité des micro-vaisseaux afférents à la tumeur. Il importe de 
souligner que les tumeurs K5 se caractérisent par un infiltrat neutrophilique robuste. Ceci 
qui s'explique par la capacité du K5 à agir comme puissant agent chimiotactique pour les 
neutrophiles humains in vitro ainsi que par son aptitude à promouvoir l'activation du 
CD64+ au sein du phénotype neutrophilique CDllb+. Ces résultats confirment que le K5 
agit comme puissant agent angiostatique et qu'il possède en soi un rôle pro-inflammatoire 
à travers sa capacité à recruter des neutrophiles associés au tumeurs et des lymphocytes 
NKT, menant ainsi à une forte réponse anti-tumeur. 
Les macrophages associés à la tumeur (T AM) demeurent des effecteurs 
immunitaires clés impliqués dans la promotion et la progression des métastases. Il serait 
donc désirable d'explorer des stratégies visant à réduire l'infiltration de TAM au sein du 
micro-environnement de la tumeur. Dans notre première étude, nous avons démontré que 
la protéine K5 soluble bloque le recrutement des macrophages. De plus, de récentes 
observations révèlent que l'angiostatine réduit l'infiltration de macrophages dans un 
modèle d'athérosclérose incitant notre laboratoire à davantage explorer l'utilisation de 
l'angiostatine comme agent anti-macrophage. Nous avons démontré que l'angiostatine 
réduit la migration in vitro à la fois des macrophages péritonéaux murins et des 
macrophages CD206+, dérivés des monocytes. De surcroît, nous avons démontré que 
l'angiostatine mène à la réduction de l'activité gélatinolytique de la matrice 
. métalloprotéinase-9 produite par les macrophages, ce qui expliquerait, en partie, la 
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réduction observée de la migration au moyen de l'angiostatine. De plus, nous avons 
détecté la présence de la sous-unité ~ de la synthase ATP sur la surface cellulaire du 
macrophage. 11 a été précédemment démontré que la synthase A TP est un récepteur 
d'angiostatine sur la surface cellulaire des cellules endothéliales. Nous proposons que la 
présence de la synthase ATP sur la surface des macrophages risquerait de promouvoir 
l'interaction avec l'angiostatine et éviter la migration, similairement à ce qui a été 
démontré chez les cellules endothéliales. Nos résultats suggèrent que l'angiostatine 
démontre un potentiel comme agent inhibiteur face aux macrophages. 
Tout compte fait, nos données appuient l'utilisation de la protéine Plg K5 comme 
puissant agent anti-angiogénique et nos données révèlent que le K5 tout comme 
l'angiostatine possède en soi des propriétés immunitaires modulatrices qui augmentent 
potentiellement leur emploi en tant qu'agent thérapeutique anti-cancer. 
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PREFACE 
The use of recombinant angiostatic proteins for cancer treatment has encountered 
sorne drawbacks primarily due to short protein half-life in circulation, difficulty in 
protein production and maintenance of protein functional activity in transport and 
storage. Therefore, the use of gene therapy techniques to provide sustained high-Ievel 
anti-angiogenic protein expression at the tumor site would overcome the limitations 
associated with recombinant protein use. In this regard, the aim of the research performed 
as part of this thesis was to assess the utility of human plasminogen kringle 5 protein as 
an anti-tumor agent in brain and breast models within the context of a cancer gene 
therapy strategy. In addition, given the pivotaI role that tumor-associated macrophages 
play in promoting tumor growth and progression, we investigated the ability of 
angiostatin, a weIl characterized anti-angiogenic agent, to affect macrophage migration. 
During the course of my doctoral studies, 1 have developed nov el anti-angiogenic 
gene therapy strategies for the treatment of cancer. 1 have elected to present my research 
in a manuscript-based format. Three manuscripts are presented in their integrality as 
distinct chapt ers of this thesis in accordance with the strict guidelines for thesis 
preparation from the Faculty of Graduate Studies and Research at McGill University 
("Guidelines for Thesis Preparation ''): 
.:. Chapter 2: Perri SR, Nalbantoglu J, Annabi B, Koty Z, Lejeune L, François M, 
Di Falco MR, Béliveau R, Galipeau J. Plasminogen Kringle 5-Engineered Glioma 
Cells Block Migration of Tumor-Associated Macrophages and Suppress Tumor 
Vascularization and Progression. Cancer Research. 2005 Sept 15;65(18): 8359-
65. 
x 
.:. Chapter 3: Perri SR, Martineau D, Francois M, Lejeune L, Durocher Y, Galipeau 
J. Plasminogen Kringle 5 Blocks Tumor Progression by Anti-Angiogenic and 
Pro-Inflammatory Pathways. Molecular Cancer Therapeutics. 2007;6(2): 1-9. 
(Figure seZected as Cover Art) . 
• :. Chapter 4: Perri SR, Annabi B, Galipeau J. Angiostatin Blocks Macrophage 
Migration. 2007. (manuscript submitted to The FASEB Journal). 
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CHAPTER 1 
GENERAL INTRODUCTION 
1 
CHAPTERl:GENERALINTRODUCTION 
1.1 BASIC PRINCIPLES OF V ASCULOGENESIS & ANGIOGENESIS 
1.1.1 Vasculogenesis 
Vasculogenesis refers to the de nova fonnation of blood vessels from undifferentiated 
endothelial precursor cells called angioblasts that migrate and assemble to fonn a primary 
capillary plexus. Growth factors, such as vascular endothelial growth factor (VEGF) and basic 
fibroblast growth factor (bFGF), and VEGF receptor 2 induce the primitive capillary plexus to 
differentiate, fonn new blood vessels and branch from pre-existing capillaries, a process known 
as angiogenesis (1). Fibronectin or matrix receptors which mediate interactions between 
endothelial cells and matrix macromolecules also affect vasculogenesis. Vasculogenesis leads 
to the fonnation of immature, poody functional vasculature and it was initially believed to 
occur only during embryonic development. However, it was recently reported that 
vasculogenesis also occurs in the adult organism. Circulating endothelial cells (stem cell 
derivatives) as well as bone marrow-derived endothelial cells were identified in adults and it 
was described that VEGF, granulocyte-monocyte colony-stimulating factor (GM-CSF), bFGF 
and insulin-like growth factor (IGF)-I promote these endothelial precursor cells to differentiate 
and mobilize to sites of interest (2, 3) such as angiogenic tumor microenvironments or to areas 
necessitating revascularization post trauma (ex: following cardiac ischemia) (1). 
1.1.2 Angiogenesis 
Angiogenesis is derived from 2 Greek words: angio meaning blood vessel and genesis 
meaning beginning. Angiogenesis is the fonnation ofblood vessels from pre-existing ones and 
consists of 2 distinct processes: endothelial cell sprouting and intussusceptive microvascular 
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growth (IMO), which refers to the splitting of vessel lumens (4). Sprouting angiogenesis 
involves endothelial cell migration, proliferation and tube formation (4). In contrast, IMO 
separates existing vessel lumens by forminglinserting tissue folds and columns of interstitial 
tissue into vessellumen (4). 
1.1.2.1 Vasodilation & Endothelial Cell Permeability 
The angiogenic process is initiated with vasodilation, which involves nitric oxide. 
VEOF increases vascular permeability of pre-existing capillaries or post-capillary venules and 
allows extravasation of plasma proteins, which serve to create a provisional scaffold for 
migrating activated endothelial cells. Permeability is required for angiogenesis however, 
excessive vascular leakage is associated with circulatory collapse, intracranial hypertension, 
formation of adhesion, metastasis, premenstrual discomfort and blindness (1). Endothelial ceIls 
present within capillaries or postcapillary venules receive pro-angiogenic stimuli from 
paracrine growth factors such as VEOF and bFOF, which are produced by surrounding tumor 
or stromal cells as weIl as the extracellular matrix (5). 
1.1.2.2 Basement Membrane Degradation 
Emigration of endothelial ceIls from their initial resident site involves the loosening of 
interendothelial ceIl contacts and periendothelial (pericyte) ceIl support, destabilizing mature 
vessels. Angiopoietin (Ang) 2, an endogenous inhibitor of Tie2 (6) receptor (tyrosine kinase 
receptor exclusively expressed by endothelial cells) signaling, may be implicated in detaching 
smooth muscle cells and loosening the matrix (7). Loosening of the pericyte covering is 
foIlowed by vascular basement membrane and extracellular matrix degradation to allow 
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endothelial cells to migrate toward a chemotactic angiogenic stimuli (8). Plasminogen activator 
proteinases, matrix metalloproteinases (MMP), chymase or heparanase families affect 
angiogenesis by degrading matrix molecules and by activating or releasing growth factors 
sequestered in the extracellular matrix such as bFGF, VEGF and IGF-I (9). For ex ample, 
MMP-3, MMP-7 and MMP-9 influence angiogenesis in bones (10) and tumors (11). Tissue 
inhibitors of MMPs 1 and 3 or PEX, which is the endogenous MMP-2 fragment that prevents 
binding ofMMP-2 to U vP3, inhibit tumor angiogenesis (12). 
1.1.2.3 Endothelial Cell Proliferation & Migration 
Following matrix degradation, dividing endothelial cells can migrate to distant sites 
forming a migration column. Generally, normal quiescent endothelial cells trailing behind the 
migrating ceUs quickly proliferate and replace ceUs that have been triggered to move toward 
developing capillary sprouts (5). Sprouting endothelial ceUs form tubes and connect to other 
blood vessels to aUow for blood flow. The endothelial ceU migration pro cess is influenced by 
specific growth factors such as VEGF (13), placental growth factor (PLGF), VEGF-B, VEGF-
C, VEGF-D and their respective receptors VEGFR2, VEGFR3 (14) and neuropilin-l (a co-
receptor of VEGFR2) (15). Unlike VEGF, Angl alone do es not induce endothelial network 
organization. Angl phosphorylates Tie2 and acts as a chemotactic agent for endothelial ceUs. 
Angl induces sprouting and enhances the effect of VEGF by stabilizing endothelial ceU 
networks initiated by VEGF via stimulating endothelial - periendothelial ceU interactions, but 
do es not induce endothelial ceU proliferation (16, 17). This implies that Angl plays a role in 
the later stages of angiogenesis. Endothelial cell spreading is also mediated by molecules 
involved in ceU-ceU or ceU-matrix interactions, such as U vP3 integrin, which is responsible for 
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localizing MMP-2 at the endothe1ial cell surface (18). As a consequence, antagonists of av~3 
integrin inhibit angiogenesis. 
1.1.2.4 Endothelial Cell Differentiation & Vessel Stabilization 
In normal angiogenesis, a migration column leads to a differentiation zone, where 
endothelial cells alter shape and adhere to one another to create a lumen. Endothelial cell 
proliferation within the vascular wall induces an increase in the blood vessel diameter. The 
final step in the maturation of the endothelial network involves remodeling and "pruning" of 
the capillary-like vessels to a uniform size and conversion of their irregular organization into a 
structured network of branching vessels (1). This maturation process involves intussusception, 
a pro cess whereby large vessels split to form smaller vessels. Assembly of endothelial cells into 
solid cords precedes lumen formation. Endothelial cell thinning, referred to as intercalation, 
followed by fusing of preexisting vesse1s allows vessels to increase their diameter and length. 
VEGF 189 decreases luminal diameter, in contrast to VEGF 121 and VEGF 165 and their associated 
receptors that increase lumen formation as well as increase vessellength. Angl in combination 
with VEGF also increases luminal diameter (17), whereas thrombospondin (TSP)-l is an 
endogenous inhibitor of lumen formation (1). Recruitment of perivascular cells leads to the 
production of a vascular basal lamina around the newly formed blood vessels. A ligand for the 
endothelial Tie2 receptor, Angl, is an endogenous inhibitor of vascular permeability and 
tightens pre-existing vesse1s. Administration of Angl to adult vesse1s prevents plasma leakage 
without affecting the morphology of vascular structures (19). Activation of AngllTie2 
(tyrosine kinase 2) receptor initiates endothelial cells to become quiescent, matures vessels with 
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the completion of the basement membrane and recruits mesenchymal cells which eventually 
become pericytes (5). 
1.1.2.5 Endothelial Cell Survival 
In the adult, subsequent to new vessel assembly, the vasculature usually remains 
quiescent with endothelial cells being among the longest-lived cells outside of the nervous 
system. Endothelial cell survival is essential since it has been reported that reduced survival 
results in vascular regression in the embryo (20). Tie2 is involved in vascular maintenance 
since low levels of phosphorylated Tie2 have been detected in the adult quiescent vasculature. 
However, endothelial cell apoptosis is also important and represents a natural mechanism of 
vessel regression in the ovary following birth and in the retina. Several angiogenic inhibitors 
utilized for therapeutic purposes also exert their effects by inducing endothelial cell apoptosis. 
Lumen obstruction caused by spasms, thrombi, the shedding of dead endothelial cells or a 
change in angiogenic gene profile as well as nutrient deprivation and lack of survival signaIs 
induces endothelial cell apoptosis (21-23). For instance, premature babies exposed to hyperoxia 
possess decreased retinal VEGF levels and vessel regression is induced (1, 24). Ang1 
promotes, in contrast to Ang2, which suppresses endothelial cell survival in the absence of 
angiogenic stimuli, and has been described to be implicated in regression of co-opted tumor 
vessels (1, 17). As mentioned previously, antagonists of U v P3 integrin disrupt the interaction of 
proliferating endothelial cells with matrix macromolecules and lead to endothelial cell 
apoptosis (1, 18). Other factors inducing endothelial cell apoptosis include: nitric oxide, 
reactive oxygen species, angiostatin, TSP-1, the metallospondin METH-1, interferon (IFN)-y, 
tissue factor pathway inhibitor and vascular endothelial growth inhibitor (VEGI) (1). 
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1.1.3 Physiological & Pathological Angiogenesis 
Angiogenesis is required for a few adult tissues necessitating regeneration such as the 
female reproductive organs, organs undergoing growth or injured tissue, as weIl as in chronic 
inflammatory conditions. Neovascularization is associated with several pathological pro cesses 
besides tumor growth such as arthritis, endometriosis, diabetic retinopathy and macular 
degeneration (5). In order to adapt to the local physiological requirements of host-associated 
vasculature, endothelial cells acquire specific characteristics. For example, the development of 
the blood-brain barrier requires normal angiotensinogen levels as weIl as an interaction 
between astroglial cells expressing glial fibrillary acidic protein and pericytes (25). 
1.1.4 Tumor Vasculature 
Normal physiological angiogenesis IS regulated by a balance of pro- and anti-
angiogenic signaIs and results in the formation of mature and stable blood vessels. This is in 
stark contrast to the pathological angiogenesis associated with tumors, which is non-quiescent 
and leads to continuous tumor blood vessel growth. The heterogeneous nature of tumors leads 
to heterogeneity in tumor vasculature. Tumor-associated vasculature is abnormal in several 
ways: it is multilayered, irregularly shaped, enlarged, dilated, tortuous and possesses a slow and 
inefficient blood flow incapable of meeting metabolic demands (26). Furthermore, it contains 
protruded extensions bridging and splitting of vessels, contains intracellular and transcellular 
holes, displays uncontrolled permeability and undergoes continuous remodeling (1). Tumor 
vessels are often leaky and haemorrhagic due to excess production of VEGF, which is also 
referred to as vascular permeability factor (VPF). Tumor vessel blood flow is irregular, moves 
slowly and tends to oscillate, leading to dysfunctional capillaries with heterogeneous vascular 
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patterns. In contrast to physiological angiogenesis, tumor vessels do not undergo a maturation 
processs and thus, remain immature and leaky. This is thought to be due to the expression of 
Ang2 (antagonist of Angl), which promotes destabilization of blood vessels and vascular 
remodeling in the presence of angiogenic stimulators (5). Perivascular cens are mural cens 
(cens of the blood vessel wall) related to the vascular smooth muscle lineage that usually 
remain in close contact with endothelial cells, however these perivascular cells become more 
loosely associated with tumor-associated endothelium as well as less abundant (27, 28). In 
normal vessels, the association of pericytes with endothelium leads to a decrease in the 
proliferation of endothelial cells as well as reduces the dependence on host-tissue VEGF-A 
production (29). The molecular mechanisms involved in tumor blood vessel abnormalities are 
under much investigation, however it is widely accepted that an imbalance between the 
expression of positive and negative regulators of angiogenesis results in drastic vascular 
differences. 
1.1.5 Vasculogenic Mimicry 
In light of these distinguishing features, tumor blood vessels are referred to as "mosaic" 
in the literature, meaning that the tumor vessels are lined with both endothelial cells and 
malignant "vasculogenic" tumor cells, commonly referred to as "vasculogenic mimicry" (l, 
30-32). This concept was tirst observed in melanoma and describes the ability of aggressive 
melanoma cells to express endothelium-associated genes and form extracellular matrix-rich 
vasculogenic-like networks in three-dimensional culture conditions similar to an endothelial 
cell feature (31,33, 34). In fact, patients with a melanoma that has undergone vasculogenic 
mimicry have a poor prognosis (35). Vasculogenic tumor cells have been reported for other 
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malignancies as well. Given this salient feature of sorne tumors, epitopes specific for tumor 
endothelial cells have been targeted for anti-cancer therapeutic purposes. For instance, Ellerby 
et al. (36) exploited this characteristic by designing short peptides composed of 2 functional 
domains: a tumor vessel "homing" motif and a programmed cell death inducing sequence. The 
synthetic peptides demonstrated selective toxicity for angiogenic endothelial cells and resulted 
in an anti-cancer response in mice. 
1.1.6 Angiogenic Switch 
Angiogenesis associated with growing tumors has been described as undergoing 2 
phases separated by the "angiogenic switch" (37). The first phase is the avascular phase 
corresponding to small and occult lesions with a diameter of no more than 1-2 mm. Lesions of 
this size remain dormant by maintaining a steady state between proliferation and apoptosis. In 
fact, it has been reported by Black et al., that dormant tumors have been discovered during 
autopsies ofindividuals who died of non-cancer related causes (38). These findings support the 
view that only a small fraction of dormant tumors enter the second phase, referred to as the 
vascular phase whereby the tumor grows exponentially. Similarly, dormant metastases may be 
activated by the removal of the primary tumor mass (39). The angiogenic switch can be tumed 
"on" by oncogene-driven tumor expression of pro-angiogenic factors (40) such as VEGF, 
bFGF, interleukin (IL)-8, PLGF, TGF-p, platelet-derived endothelial growth factor (PD-EGF), 
pleiotrophin and several other angiogenic proteins (41). 
Tumor angiogenesis can also be modulated by hypoxia. Low oxygen tumor conditions 
activate hypoxia-inducible transcription factors (HIF-1a, HIF, 1p and HIF-2a), which induce 
upregulation of several angiogenic factors such as VEGF, VEGFR1, VEGFR2, neuropilin-1, 
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Ang-2, nitric oxide synthase, TGF~-l, PDGF-BB, endothelin-l, IL-8, IGF-II, Tiel, 
cyclooxygenase-2 and others (1, 42). During nonnoxia (nonnal oxygen conditions), the 
expression of hypoxia-inducible target genes is suppressed by the von Hippel Lindau tumor 
suppressor gene product (1). It has been shown that tumors that lack HIF-1a or HIF-1~ fail to 
develop a vascular system and hypoxia does not lead to VEGF expression (43). Pro-angiogenic 
factors can also be released by fibroblasts within the tumor microenvironment (44) and by 
progenitor endothelial cells that are recruited from the bone marrow by the tumor (45). 
1.1. 7 Angiogenic-Independent Tumors 
Although angiogenesis is a prerequisite for the majority of tumors to progress, sorne 
tumors such as astrocytomas are called "non-angiogenic" tumors as they do not require 
neovascularization. Instead, they co-opt with existing nonnal brain blood vessels and acquire a 
blood supply without initiating angiogenesis. Astrocytomas are very oxygen-sensitive and 
exploit the vas cul ar-ri ch brain parenchyma by growing along blood vessels, without possessing 
a tumor capsule, invade and can enlarge to a size similar to that of an angiogenic tumor (46). 
The progression of grade III astrocytomas to grade IV astrocytomas/glioblastomas 
(glioblastoma multifonne), causes them to become hypoxic and necrotic, partially due to the 
regression of vessels, as a result of Ang2 upregulation (47) and increased tumor cell 
proliferation. Hypoxic conditions induce the fonnation of new blood vessels and the most 
common hypoxia-induced angiogenic factors are VEGF and VEGFR-2, which along with 
Ang2, promote vascular remodeling and sprouting (46, 48). A distinguishing feature of 
glioblastomas is the appearance of proliferating endothelial cells and a high blood vessel 
density, which differentiates them from lower-grade astrocytomas (49). 
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1.1.8 Transgenic Mouse Models of Angiogenesis 
The development of oncogene-driven mouse tumor models has facilitated the in vivo 
characterization of tumor angiogenesis. The RIPTag model, which employs the rat insulin II 
gene promoter (RIP) to target expression of the simian virus (SV)-40 large T tumor antigen (T-
Ag) oncoprotein to cells of pancreatic islets, results in the formation of pancreatic-islet 
carcinomas (50). Multistage progression to invasive squamous cell carcinoma of the epidermis 
is reproduced in transgenic mice expressing the human papillomavirus type (HPV)-16 under 
the control of the human keratin 14 promoter/enhancer (E6 and E7 oncogenes) (50). These 
animal models require that neovascularization begin early in the dysplastic phase in order for 
tumor formation to occur. The SV 40 Tag, E6 and E7 oncogenes bind and inactivate p53 and 
the retinoblastoma (RB) tumor suppressor gene products however, this is not sufficient to 
induce neovascularization. In order to initiate neovascularization, the angiogenic switch must 
be turned on and it has been described in the pancreatic-islet cancer model that VEGF is 
required for the switch to occur (51). Matrix metalloproteinase (MMP)-9 has been reported to 
release sequestered VEGF and allows VEGF to interact with its receptors (52). Higher levels of 
MMP-9 production also resulted in more vascularized tumors in mammary-tumor-prone mi ce 
(MMTV-neu) that lack TSP-l (angiogenic inhibitor), since higher MMP-9 production causes 
higher levels ofVEGF available for interaction VEGFR-2. In contrast, overexpression of TSP-
1 in MMTV-neu mice leads to delayed tumor growth and can even result in up to 20% 
inhibition of tumor development (53). It has been demonstrated that TSP-l expression is 
inversely correlated with mammary, lung and melanoma tumor progression (54). Watnick et al. 
(55) demonstrated that the ability to grow primary epithelial cells in vivo depended upon the 
level of HRAS expression. Epithelial cells that expressed low levels of RAS remained dormant 
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and non-angiogenic, whereas those that expressed high levels of RAS developed tumors and 
expressed moderate levels ofVEGF-A as weIl as high levels ofTSP-l. Overexpressing VEGF-
A in those cells that expressed low levels of RAS induced tumor formation. The sum of these 
findings supports the notion that angiogenesis is a prerequisite for tumor formation, that a 
balance of pro-angiogenic and anti-angiogenic factors influences the angiogenic switch and that 
oncogene expression can affect the balance (8). However, there is also evidence that indicates 
that this multi-step model, whereby the angiogenic switch is necessary for tumor development, 
yet is not always a requirement for the growth of angiogenic tumors. It has been reported that 
expression of deregulated MYe, BeL2 or BeL-XI led to the formation of angiogenic and 
invasive pancreatic-islet tumors that did not require additional mutations to proceed to the 
premalignant stages (56). There have been however no published reports of human tumors 
bypassing the premalignant stages. 
1. 2 EXPLOITING ANTI-ANGIOGENIC AGENTS THERAPEUTICALLY 
1.2.1 Tumor Dormancy lnduced by Angiogenic lnhibitors 
p An extension of the angiogenic switch model is that the switch may be tumed "on" at 
1 the site of a primary tumor and "off" at sites of distant metastases. This has been observed by 
Folkman and others who have noted an increase in the growth of metastatic tumors following 
the removal of a large primary tumor. In experimental models, it was described that metastatic 
tumor resurgence was not due to seeding of tumor cells at the time of primary tumor resection, 
but due to the fact that the pre-existing micrometastases were being held "in check" by the 
presence of the primary tumor and are induced to grow after removal of the primary tumor (47, 
57, 58). There is overproduction of pro-angiogenic molecules within the primary tumor as weIl 
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as production of inhibitors of angiogenesis, albeit at much lower levels than the angiogenic 
stimulators and thus angiogenesis is sustained and tumor growth ensues. The angiostatic 
molecules produced at the primary tumor site enter the bloodstream and possess a longer half-
life in circulation and therefore angiogenesis at distant sites is tumed off, preventing the growth 
of micrometastases. Primary tumor resection results in an overall decrease in the systemic 
levels of angiostatic agents and thus pro-angiogenic factors secreted by metastatic tumors 
become dominant and the shift in angiogenic balance favors metastatic growth. O'Reilly et al. 
(59) utilized a variant of the Lewis lung carcinoma cell line (LLe-LM) possessing low 
metastatic potential and subcutaneously implanted the cells in mice. Primary tumors were 
resected 14 days post-implantation and mice were compared to those whose primary tumors 
were left intact after a mock surgery (60). The presence of an intact primary tumor resulted in a 
10-fold suppression oflung metastases in contrast to mice with resected primary tumors (60). 
Metastatic lesions in mice with intact primary tumors formed perivascular cuffs devoid of 
neovascularization (60). Thus, this demonstrates that the primary tumor maintains metastatic 
lesions dormant, possibly by secreting anti-angiogenic proteins that inhibit angiogenesis. 
In light of the importance of angiogenesis for tumor growth and progression of dormant 
lesions reviewed above, it would be highly desirable to exploit the utility of angiogenic 
inhibitors to prevent the angiogenic switch from being tumed on, resulting in inhibition of 
tumor progression and metastasis. This strategy could be used therapeutically especially for 
those patients who are at high risk for developing cancer, recurrence of cancer or metastases. 
Anti-angiogenesis therapy targets cells that support tumor growth instead oftargeting the tumor 
itself like conventional therapeutic modalities such as chemotherapy and radiation therapy, and 
therefore presents a new treatment option for patients with refractory malignancies. Vascular 
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endothelial cells are genetically stable nonnal diploid cells, homogeneous and have a low 
mutation rate, therefore they are less likely to develop mutations as compared to unstable 
mutating heterogenous tumor cells. This in turn minimizes the risk for the development of drug 
resistance towards the anti-angiogenesis therapy. 
1.2.2 Angiogenesis Inhibitors 
A variety of angiogenesis inhibitors have been discovered and are classified in two 
distinct groups: direct and indirect inhibitors. 
1.2.2.1 Direct Angiogenic Inhibitors 
Direct angiogenesis inhibitors target microvascular endothelial cells by preventing them 
from responding to endothelial mitogens, and thus inhibit endothelial cell proliferation and 
migration as well as overcome the avoidance of cell death in response to an array of pro-
angiogenic stimuli (61). Angiostatin, an endogenous inhibitor of angiogenesis, is an internaI 
proteolytic fragment of plasminogen (a circulating glycoprotein acting as the inactive precursor 
of plasmin) and has been shown to bind to A TP synthase, angiomotin and annexin II on 
endothelial cells, preventing endothelial cell proliferation and migration (62-64). Another 
endogenous angiogenesis inhibitor, endostatin, is an internaI fragment C-tenninal collagen type 
XVIII. Endostatin has been reported to target integrin-usPI to inhibit endothelial cell 
proliferation and migration, and induces apoptosis of dividing endothelial cells (65, 66). 
Canstatin, an endogenous human basement membrane-derived fragment of the alpha2 chain of 
collagen type IV, has been described to bind integrin U vP3 to inhibit endothelial cell 
proliferation, migration and capillary tube fonnation (67). Avastin (bevacizumab) is a 
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recombinant humanized monoclonal antibody directed against VEGF, developed by 
Genentech. It has shown great promise in treating colorectal, lung and metastatic breast cancer 
and was approved in 2004 as first-line treatment for patients with advanced colorectal cancer 
(68). In June 2006, Avastin was approved as a treatment for second-line advanced colorectal 
cancer (patients previously treated for their cancer). Vitaxin is a humanized monoclonal 
antibody developed by Medlmmune, which targets ŒvP3 integrin and is another direct inhibitor 
of angiogenesis (69). 
Direct inhibitors of angiogenesis have a lower risk of inducing acquired drug resistance 
since they target stable endothelial cells and Boehm et al., report that Lewis lung carcinoma, 
fibrosarcoma as well as melanoma tumors treated with a direct anti-angiogenic agent 
(endostatin) did not develop drug resistance in mice (70). O'Reilly et al., describe the 
successful use of another direct angiogenic inhibitor, angiostatin, in the reduction of Lewis lung 
carcinoma metastases formation (63). 
1.2.2.2 Indirect Angiogenic Inhibitors 
Indirect inhibitors of angiogenesis target tumor cells by preventing the expression or 
blocking the activity of a tumor protein (oncogene product that drives the angiogenic switch) 
that activates angiogenesis, or by blocking the expression of its receptor on endothelial cells 
(39, 40, 71). Unlike direct inhibitors of angiogenesis, indirect inhibitors are prone to develop 
resistance. Studies on the activity of oncogene and tumor suppressor gene products were 
initially conducted in vitro and assessed cancer cell proliferation, resistance to apoptosis, 
immortalization and anchorage independence (40, 71). Oncogene activation demonstrated 
increased cancer-cell proliferation and decreased apoptosis in vitro and this correlated very 
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weIl with in vivo tumor growth. Activating mutations in oncogenes as weIl as in the anti-
apoptotic factor BCL-2 have been demonstrated to upregulate angiogenic pro teins and to 
downregulate anti-angiogenic proteins. For instance, the HER-2/neu blocking antibody 
Herceptin (trastuzumab), which inhibits the tyrosine kinase activity of the HER-2/neu receptor 
also inhibited the angiogenic potential of a tumor by decreasing the expression of VEGF, Ang-
1, TGF-/3, plasminogen activator inhibitor type-1 (PAI-1) and by upregulating the expression of 
TSP-1 (39). Likewise, Arbiser et al. (72) demonstrated that when normal cells in mice were 
immortalized with SV40 tumor antigen, the production of microscopic avascular dormant 
tumors was observed. However, when the immortalized cells were transfected with the Ras 
oncogene, tumor angiogenesis and growth ensued (73). Other studies supporting this concept 
are as follows: activating mutations in Kras and Hras have been shown to upregulate VEGF 
expression and downregulate TSP-1 (angiogenic inhibitor) expression (74, 75) and transfection 
of the Bcl2 oncogene into tumor cells resulted in enhanced VEGF expression (76). 
Furthermore, transfection of human osteosarcoma cells with the Ras oncogene and subsequent 
injection in mice led to increased VEGF expression, decreased thrombospondin expression and 
resulted in large neovascularized tumors as compared to untransfected control mice that only 
formed microscopic avascular dormant tumors that possessed a balanced apoptotic rate (75). In 
a similar fashion, re-activation of tumor suppressors such as p53 can also lead to the inhibition 
of angiogenesis (77, 78). These findings imply that anti-cancer drugs that were initially 
developed to block an oncogene product could also be utilized to target angiogenesis indirectly. 
For example, EGF receptor tyrosine kinase inhibitors such as Iressa (ZD1839), Tarceva 
(OSI1774) and Erbitux (IMC225) block the production of EGF receptor products including 
VEGF, bFGF and TGF-a (79). Other examples of indirect angiogenesis inhibitors target the 
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VEGF receptor on endothelial cells and these include: PTK787/ZK222584 (80), synthesized 
and developed by Novartis Pharma AG and Schering AG, which exhibits strong inhibition of 
VEGFR-2, slightly weaker inhibition of VEGFR-l and also active against other tyrosine 
kinases specifically belonging to the same family as the VEGF receptors such as the PDGF 
receptor tyrosine kinase; SU6668 (81) and SU11248 (80), developed by SUGEN (acquired by 
Pfizer) are capable of inhibiting the tyrosine kinase activity of the VEGF, FGF and PDGF 
receptors (VEGFR-1I2, PDGFR, KIT, FLT3); and ZD6474 (80), developed by AstraZeneca, 
blocks VEGF and EGF receptor tyrosine kinase activity. IFN-a is an exarnple ofboth a direct 
and indirect angiogenesis inhibitor since it inhibits endothelial cell migration (82) and 
suppresses bFGF synthesis at the mRNA and protein level by tumor cells (83). It is interesting 
to note that sorne tumors such as giant-cell tumors of the bone and angioblastornas produce 
mainly bFGF and thus when patients were treated with low daily doses of IFN-a, drug 
resistance was not observed during the course of 1-3.5 years oftherapy (84,85). 
1.2.2.3 Endogenous Inhibitors of Angiogenesis 
The majority of anti-angiogenic agents exist endogenously in the body and have either 
been isolated frorn the body or tissue-derived cell lines. Among the reported endogenous 
angiogenesis inhibitors, at least 50% are proteolytic fragments oflarger precursor proteins (61). 
Endogenous angiostatic agents possess the added benefit of being non-toxic and non-
immunogenic (61). To date, there have been no reports describing toxicities or adverse effects 
for endogenous anti-angiogenic agents. Therapeutically, the use of endogenous inhibitors is 
less likely to cause suppression of hernatopoiesis and gastrointestinal symptoms (86). In fact, 
naturally-occurring angiostatic proteins tend to specifically target newly formed tumor 
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vasculature rather than quiescent nonnal blood vessels. There are several characteristics that 
make endogenous angiogenic inhibitors of particular interest. First, they are typically 
proteolytic fragments of larger precursor proteins that are biologically inactive at suppressing 
angiogenesis. However, these cryptic fragments are processed by nonnal host tissues or tumors 
and exert inhibitory angiogenic effects. Second, the majority of endogenous angiostatic agents 
can directly inhibit endothelial cell proliferation even in the presence of angiogenic stimuli. 
Third, they generally act synergistically with other anti-cancer therapeutic modalities such as 
chemotherapy and radiation therapy. Finally, since endogenous angiogenic inhibitors target 
genetically-stable endothelial ceIls, the risk for acquired drug resistance is minimized, although 
it can occur (87). 
1.2.2.4 Discovery of Angiostatin 
A better understanding of the angiogenic switch led to the possibility that exogenous 
administration of angiogenic inhibitors following removal of the primary tumor could suppress 
the growth of metastases. In order to identify the angiogenic inhibitor responsible for inducing 
donnancy in metastatic lesions, ü'Reilly and colleagues (59) collected over 100 L of urine 
from LLC-LM tumor-bearing mice and purified a protein that was capable of inhibiting 
angiogenesis both in vitro and in vivo. It was also observed that this protein could prevent the 
neovascularization and growth ofmetastatic LLC-LM tumors, even in those mice with resected 
primary tumor. The 38kDa protein possessed an amino tenninus composed of VYLSEXKT, 
which corresponded to an internaI fragment of plasminogen and its molecular weight indicated 
that it encompassed the first 4 of the 5 plasminogen (PIg) kringles (60). This novel angiostatic 
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protein was named "angiostatin." This discovery prompted further investigation to elucidate 
the mechanism of angiostatin generation. 
1.3 PLASMINOGEN & ITS KRINGLE DOMAINS 
Ruman Plg is a circulating glycoprotein that acts as the inactive precursor of plasmin, 
which is an active serine protease that is responsible for dissolving fibrin in blood clots (Figure 
1.1). Plasmin is also implicated in embryonic development, tissue remodeling, inflammation 
and tumor invasion. Plg is produced and secreted by the kidneys as a zymogen and is found in 
plasma and extracellular fluid (61). Full-Iength Plg (glu-PIg) is a tightly compacted structure 
that is only activated by Plg activators upon epsilon-amino caprioic acid (EACA) binding, 
which induces the structure to become less compact and more susceptible to activation (88). It 
is activated by urinary/urokinase-type or tissue-type plasminogen activator (u-PA and t-PA 
respectively), which cleave Plg to form plasmin (88). Plg is composed of 5 internaI kringle 
domains and serine protease domain at its C-terminus (88). A kringle (kringla in Swedish) is a 
type of Scandinavian cookie folded into 2 rings (61). The term was coined to describe a triple 
looped structure linked by 3 pairs of disulfide bonds and was originally used to describe the 
triple disulfide bonds in prothrombin. The kringles are numbered starting from the amino 
terminus. Several proteins contain either 1 or more kringle structures. In addition to the triple 
disulfide linkages, kringle structures possess a sequence of approximately 80 amino acids. 
Typically, amino acids flanking the third and fourth of the 6 conserved cysteine residues that 
form the disulfide bridges are conserved as well, in contrast to other amino acids within the 
kringle structure that are not similar among different 
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Figure 1.1. Plasminogen and its kringle domains. The full-length plasminogen amino 
acid sequence is depicted. Disulfide bonds are displayed as black bars connecting pairs of 
cysteine residues. Glycosylation sites are displayed as red wavy lines in the third kringle 
domain. The plasmin catalytic domain is shown in gray, kringle 5 in purple, kringle 4 in 
red and kringles 1-3 in orange. This schematic was developed by Wahl et al. (90). 
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FIGURE 1.1 
kringle domains. Interactions between K5 and the N-terminal ''jinger domain" of plasminogen 
influence the compact conformation of plasminogen (88). Constructs devoid of the finger 
domain exist only in an extended conformation and are not activated by EACA (88). Lysine-
binding sites in KI and K4 also affect maintenance of the closed conformation (88). 
1.3.1 Proteolytic Cleavage of Plasminogen 
Plg possesses various cleavage sites, which leads to the production of several smaller 
cryptic fragments that can be produced in a context-dependent manner. Hogg and co-workers 
(89) proposed a model to elucidate the proteolytic processing steps that occur in the generation 
of angiostatin and K5 (Figure 1.2). Plasmin reduction is the first step in the formation of 
angiostatin fragments KI-3, KI-4 and KI-4.5. A plasmin reductase reduces the disulfide bonds 
in K5 in the presence of certain cofactors such as reduced glutathione or cysteine. A serine 
protease then cleaves peptide bonds in K5 to yield KI-4.5, which then undergoes further 
cleavage by MMPs to pro duce KI-3 or KI-4. These MMPs may be activated by pro-angiogenic 
signaling pathways such as induction of HIF-l. Phosphoglycerate kinase (PGK), a glycolytic 
outer mitochondrial membrane enzyme that is usually associated with the voltage-dependent 
anion channel (VDACI) (90), has been reported to be the plasmin reductase involved in the 
reduction of K5 and has been observed to be present in the plasma at high levels in tumor-
bearing animaIs (91). Both Stathakis et al. (89, 92) and Soff et al. (93) described that the 
carboxy-terminus of cleaved angiostatin was found within the fifth Plg kringle yielding a 52-
55kDa protein and thus designated the name "angiostatin4.5" (KI-4.5) to refer to KI-4 plus 
approximately 85% ofK5. KI-4.5 was found to be produced via plasmin autoproteolysis, 
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Figure 1.2. Angiostatin formation by tumors. Plasminogen is converted to plasmin by 
the u-PA enzyme followed by plasmin K5 reduction by phosphoglycerate kinase (PGK). 
A serine proteinase and matrix metalloproteinases (MMPs) participate in the formation of 
angiostatin. This schematic was obtained from Geiger et al. (88). 
--- -- - -- -----------
Plasminogen 
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FIGURE 1.2 
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mediated by a free sulfhydryl donor (FSD), or by a plasmin reductase. This form of angiostatin 
has been found in ascites and in human plasma (93). It has also been reported that human 
prostate cancer cells convert Plg to angiostatin via the following mechanism: u-PA or t-PA 
converts Plg to plasmin and in the presence of a FSD, plasmin undergoes autoproteolysis to 
generate angiostatin, where plasmin acts as both the enzyme and the substrate (60, 94, 95). The 
plasmin receptor was shown to be expressed on the cell-surface of activated murine 
macrophages and it induces plasmin autoproteolysis, which generates angiostatin-like 
fragments (96). 
There are other molecules that can induce cleavage of Plg to angiostatin such as elastase 
in Lewis lung carcinoma (86) and in human prostate carcinoma (95) as well as prostate specifie 
antigen (97), which has been reported to also act as an inhibitor of angiogenesis (98). In 
addition, human matrilysin (MMP-7), gelatinase B/type IV (MMP-9) and a macrophage-
derived metalloproteinase (99, 100) have also been implicated in the generation of angiostatin. 
K5 however, is not produced via this pathway. Instead, Plg is cleaved by neutrophil 
elastase to generate angiostatin KI-3, free K4 and what is referred to as "miniplasminogen ", 
comprising the serine protease domain plus K5 (90). MMPs are then responsible for releasing 
K5. Although KI-3 has been found in the circulation of tumor-bearing animaIs as a 
consequence of activation of pro-angiogenic signaling cascades (90), the in vivo generation of 
K5 is still unknown (90). 
It has been found that tumor cells do not produce angiostatin or PIg, but rather secrete 
proteases that cleave circulating Plg into angiostatin. These tumor-derived proteases cleave Plg 
at several sites and thus angiostatin is composed of a different number of kringles that 
independently possess varying degrees of endothelial cell inhibitory properties (61). For 
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example, MMP-2, -3, -7, -9, -12, as weIl as elastase plus pepsm or chymotrypsin or 
Staphylococcus Aureas V8 protease or streptokinase and plasmin autodigestion have aIl been 
reported to release KI, K2-K3, angiostatin (KI-3 or KI-4), or K5 from the parent Plg molecule 
(61). These findings highlight the implications ofPlgiangiostatin cleavage and associated post-
translational modifications as weIl as the importance of proteolysis in angiogenesis 
suppreSSIOn. 
1.3.2 Structural Features of Angiostatin Kringles 
KI, K2, K3 and K4 possess high amino acid sequence similarity (about 50% homology) 
(61). Nuclear magnetic resonance and X-ray crystallography ofKI-4 demonstrate that the high 
sequence homology translates into a similar conformation (61). It was reported that intact Plg 
do es not possess any angiostatic properties and is incapable of affecting endothelial cell 
growth, angiogenesis or tumor growth. However, the cryptic kringle fragments vary 
considerably in their ability to inhibit endothelial cell growth. Of the first 4 kringles, KI 
displays the highest potency at impairing endothelial cell growth, followed by K3, K2 and K4 
(61). In fact, K4 is almost incapable at suppressing endothelial cell proliferation and 
demonstrates high affinity for lysine binding (61). However, since KI has also been shown to 
bind lysine with high affinity (101), it suggests that lysine binding does not play a role in 
manifesting an endothelial cell inhibitory effect (61). Further investigation into the 3-
dimensional structure of K4 revealed that it contains 2 clusters of positively charged lysine 
residues adjacent to 2 cysteines, which interact with lysine 59 to create an exposed positively 
charged area in K4 (61). This cationic cluster is not present in other kringle structures and it 
may be speculated that the lysine-enriched K4 domain interacts with a negatively charged 
) 
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domain in another protein, resulting in a sequestering of K4 to induce a loss-of-function effect 
(61). 
1.3.3 Anti-Endothelial Cell Properties of Angiostatin 
Angiostatin has been characterized as an endothelial cell inhibitor via its ability to 
suppress endothelial cell proliferation, endothelial cell capillary tube formation on a Matrigel 
assay as weIl as FGF- and VEGF-induced endothelial cell migration in a modified Boyden 
chamber through a gelatinized membrane (59, 94, 95). Moreover, KI-3, KI-4 and KI-4.5 have 
been shown to induce apoptosis of endothelial cells in vitro and this has been associated with 
activation of focal adhesion kinase (102). Kl-4.5 was also shown to inhibit extracellular-
matrix-enhanced, t-PA-catalyzed Plg activation, which prevents plasmin generation and may 
explain the mechanism employed by angiostatin to suppress endothelial cell migration (103). 
Angiostatin possesses a longer half-life than angiogenic factors such as VEGF and FGF 
and as a result, primary tumors that produce angiostatin can inhibit their metastases but fail to 
inhibit their own growth (61). Angiostatin has been shown to induce dormancy in metastatic 
and primary tumors such as breast, prostate, colon and lung carcinoma (59, 104) as weIl as 
reduce the growth of a murine hemangioendothelioma in vivo (105). The anti-tumor effect of 
angiostatin has been attributed to its anti-angiogenic property. 
1.3.4 Limitations Associated with Recombinant Angiostatin Use 
Angiostatin requires intact kringle structures to maintain its anti-endothelial cell effect 
and it has been demonstrated that disruption of intrachain and interchain disulfide bonds by 
reducing agents entirely abrogates its inhibitory property. Unfolded or misfolded angiostatin or 
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kringles also causes a loss-of-function effect. For instance, bacterially-expressed angiostatin 
must be properly folded to inhibit endothelial cell growth and angiogenesis. 
The shorter version of angiostatin containing only the first 3 kringles (Kl-3) has been 
demonstrated to be more potent than the Kl-4 proteolytic fragment (86). Thus, Kl-3 was 
selected for anti-cancer therapeutic purposes and is currently undergoing Phase II clinical trials. 
One of the limitations associated with Kl-3 due to its shorter amino acid sequence is that it 
possesses a shorter half-life in vivo and cleared within minutes, thus continuous infusion is 
necessary for effective anti-cancer therapy. This was observed in a Phase 1 clinical trial, 
whereby daily administration of angiostatin for 2 week intervals with a l-week break period to 
monitor toxicity, caused VEGF and bFGF to reSurge in the circulation as early as 1 day into the 
drug-free week (106). Therefore, these results suggested that anti-angiogenic agents would 
require continuous infusion to suppress tumor growth and those agents possessing longer half-
lives would be more efficacious for clinical use. Other shortcomings associated with 
angiostatin use include protein production difficulties and maintenance of functional activity 
during storage and transport (90). These issues have spurred interest in attempting to identify 
angiostatin receptors involved in mediating its anti-angiogenic effects to develop angiostatin 
mimetics, which are more stable, easier to pro duce and possess enhanced pharmacokinetic 
properties (90). 
1.3.5 Putative Endothelial Cell-Surface Receptorsfor Angiostatin 
Although angiostatin is derived from PIg, Plg itself and plasmin do not display any 
angiostatic properties, implying that angiostatin interacts with a different binding site. To date, 
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there are 3 main cell-surface receptor binding targets for angiostatin on endothelial ceIls: the 
mitochondrial F IFo ATP synthase, ŒvP3-integrin and angiomotin. 
1.3.5.1 Discovery of Cell-Surface Expressed ATP Synthase 
Moser et al. (62) sought to determine the endothelial cell binding sites for angiostatin in 
order to identify a putative receptor. Cell binding assays using radiolabeled angiostatin revealed 
that Kl-3 bound to the surface of human umbilical endothe1ial cells (HUVECs) at a different 
site and with a different binding kinetic than Plg (62). Scatchard plot analysis revealed a ~ of 
245 nM and 38 000 binding sites per cell in contrast to Plg with a ~ of 158 nM and 870 000 
sites per cell (62). In addition, it was shown that Plg did not compete with angiostatin for 
HUVEC binding, confirming different binding sites (62). 
In order to identify the endothelial cell binding site for angiostatin, Moser et al. 
prepared an affinity column of angiostatin coupled to Sepharose as weIl as a Pig-coupled 
column as a control. HUVECs were cell-surface biotin-Iabe1ed and plasma membrane extracts 
were subsequently passed over each column and washed to remove unbound material. Bound 
proteins were eluted from each column and subjected to denaturing gel electrophoresis 
followed by immunoblot analysis. Specifie bands were se1ected to undergo further proteomic 
analysis. The Plg affinity column yie1ded a 44 kDa protein band, which was confirmed to be 
annexin II by immunoassays. In contrast, the angiostatin affinity column yielded several 
protein bands ranging from 20-65 kDa, with a dominant band at 55 kDa. Gel extraction, tryptic 
digestion and mass fingerprinting revealed that the 55 kDa band was composed of the Œ- and p-
subunits of the FIFo ATP synthase. 
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This finding was quite controversial since FJFo ATP synthase was believed to be strictly 
a component of the mitochondrial inner membrane and this discovery implied that a form of 
F jFO ATP synthase was also present on the cell-surface of HUVECs. At the time, only 1 other 
report by Das et al. (107) described the detection ATP synthase on the cell-surface of A549 
human lung carcinoma cells and since this finding was unexpected, it was attributed to aberrant 
trafficking in an unstable tumor cell line or a cell culture artifact. Although the concept of 
ectopic localization of mitochondrial pro teins was initially met with much skepticism, other 
research groups also reported identifying plasma membrane proteins that were in fact 
mitochondrial matrix proteins, but that possessed extramitochondrial functions (108, 109). 
Additional reports confirmed angiostatin binding to cell-surface expressed FJ-Fo ATP synthase 
on sorne tumor cells such as A549 human lung carcinoma cells and K562 human 
erythroleukemia cells (107, 110), as well as on the cell-surface of other normal cell types such 
as keratinocytes and adipocytes (111, 112). It has also been recentlY demonstrated that the 
V gamma9V delta2 T cell receptor on gammadelta T cells interacts with cell-surface expressed 
Fj-ATP synthase in association with apolipoprotein A-Ion tumor cells, promoting an innate 
anti-tumor response (113). Further investigation revealed that several of the enzymes and 
components of the mitochondrial electron transport chain as well as ATP synthesis generating 
mechanisms are located on the plasma membrane of endothelial cells. 
It was hypothesized that endothelial cell-surface ATP synthase is responsible for 
maintaining intracellular pH in the acidic tumor microenvironment. Binding of angiostatin to 
endothelial cell-surface ATP synthase inhibits the proton pump and causes the intracellular pH 
to decrease leading to endothelial cell apoptosis (114, 115). 
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Magnetic resonance imaging (MRI) measurements of the in vivo pH of the tumor 
extracellular environment reveals that it is between pH 5.6 to 7.6 on average, whereas the 
extracellular pH of normal tissue is between 7.2 to 7.6 (116). These MRI measurements reflect 
the average pH value of various cell types including stromal and endothelial cells. Tumor cells 
however, are able to maintain a normal intracellu1ar pH (117). It was hypothesized that 
endothelial cell-surface ATP synthase is responsible for maintaining intracellular pH in the 
acidic tumor microenvironment. Although angiostatin can bind and inhibit ATP synthase over a 
pH range of 6.5 to 7.5, it has been reported to be more potent at low extracellular pH, and 
therefore the tumor microenvironment is ideal to maximize its anti-tumor effect (116). Binding 
of angiostatin to endothelial cell-surface ATP synthase inhibits the proton pump and causes the 
intracellular pH to decrease, which leads to the inhibition of metabolic enzymes that require a 
pH of 7.0 and results in endothelial cell apoptosis (114, 115). In addition, it was reported that 
angiostatin does not inhibit proliferation of endothelial cells cultured at a normal pH (116). 
This implies that angiostatin's target is implicated in pH maintenance and suggests that 
angiostatin-induced inhibition of the proton flux via A TP synthase causes endothelial cells to 
become more sensitive to pH stress. Further research is being pursued to investigate whether 
other pH-lowering compounds possess anti-angiogenic properties (118). 
1.3.5.2 Angiostatin Binds Endothelial Cell-Surface avP3Jntegrin 
Takada et al. (119) have shown that angiostatin binds to the uvP3-integrin on the surface 
ofChinese hamster ovary (CHO) cells and bovine arterial endothelial (BAE) cells in an EACA-
dependent manner. They demonstrated that the binding was dose-dependent, saturable and 
blocked by integrin-specific antibodies as well as the RGD (arginine-glycine-aspartic acid) 
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peptide. Integrin-expressing cells bound to KI-5, KI-4 and KI-3, but not to full-Iength Pig. 
They also demonstrated that plasmin, unlike PIg, is a ligand for av~3-integrin and induces 
endothelial cell migration. Plasmin-induced cell migration was strongly inhibited by 
angiostatin. Specific localization of the protease domain of plasmin the integrin on the cell 
surface is necessary to maintain its function. Angiostatin, and possibly other Plg kringles, block 
this interaction. Further investigation is required to determine the molecular basis for 
angiostatin-integrin interaction, as there are no RGD motifs found in either human or mouse 
Plg or angiostatin sequences. Cell binding assays have not yet revealed whether the interaction 
is direct or indirect, for example through a binding site that is different from but influenced by 
an integrin. In addition, there have been no reports to date describing a human integrin-human 
angiostatin interaction, and since av~3-integrin knockout cells still display angiogenic features, 
av~3-integrin is not absolutely required for angiogenesis. 
1.3.5.3 Angiostatin Binds Endothelial Cell-Surface Angiomotin 
In 2001, an additional novel receptor for angiostatin was discovered on the endothelial 
cell surface and was called "angiomotin" (64) since it plays a role in endothelial cell migration 
and capillary tube formation. Angiomotin was identified as an angiostatin-binding receptor in a 
yeast 2-hybrid system using a placental cDNA library, which is rich in vascular endothelium 
mRNAs. It is important to note that employing a yeast 2-hybrid approach to screen membrane 
proteins presents 2 limitations: post-translational protein modifications essential for angiostatin 
signaling cannot be precisely recapitulated in the yeast nucleus and functional cell-surface 
domains required for protein-protein interactions may bind with reduced or altered specificity 
(90). Angiomotin is composed of a conserved coiled-coil and PDZ binding domains (120) and 
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IS expressed in a variety of endothelial cell lines with particular high expression on 
microvascular and umbilical vein endothelial cells (64). Angiomotin was also found to be 
highly expressed on both capillaries and large vessels and its expression was observed to be 
restricted to endothelial cells. Angiomotin-transfected cells were capable of binding and 
intemalizing angiostatin (in a RGD-dependent fashion), leading to activation of focal adhesion 
kinase (F AK) activity. Since F AK is implicated in cell motility and adhesion-dependent cell 
survival, angiostatin binding was found to suppress migration and lead to apoptosis via a RGD-
independent FAK activation pathway (102). Endothelial cells expressing truncated angiomotin 
(deletion of 3 amino acids in the carboxy-terminal PDZ domain) were incapable of migrating 
and forming tubes in vitro (121). Furthermore, transgenic mice expressing truncated 
angiomotin died at embryonic day 9.5 due to non-migration of endothelial cells into the 
neuroectoderm and intersomitic regions (121). Endothelial cells exposed to exogenous 
angiomotin caused stabilization of established capillary tubes and increased invasion of 
endothelial cells derived from the formed tubules (122). Angiomotin remains to be confirmed 
as an angiostatin receptor using dose response, saturable binding kinetic and competitive 
antibody studies. AdditionaIly, angiomotin is not implicated in other angiostatin-induced 
effects such as inhibition of endothelial cell proliferation and promotion of endothelial cell 
death (90). 
1.3.5.4 Angiostatin Possesses Multiple Binding Targets 
In summary, the overall findings suggest that angiostatin binds several partners and 
cell-surface targets. Plg also binds multiple cell-surface, soluble and membrane-associated 
targets. Since Plg is activated during fibrinolysis, it participates in many binding events. 
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However, the kringle domains change their binding specificity once proteolytically cleaved to 
smaller fragments, since Plg does not seem to bind many of the targets that have been found to 
interact with its cleavage products (123-127). It is important to note that in light of the 
combinatorial complexity associated with different angiostatin fragments, it is highly likely that 
different investigators may be working with various angiostatin forms that may alter its binding 
specificity and therefore yield different conclusions regarding the key mediators of angiostatin 
action. It is also worthy to note that none of the angiostatin binding targets aforementioned are 
capable of affecting endothelial cell survival, proliferation, migration, mvaSlOn, 
morphogenesis, phenotype and gene expression (90). Thus, with the data available to date, 
angiostatin appears to induce its effects via interaction with multiple binding sites and receptors 
among which include FIFo ATP synthase (responsible for endothelial cell survival maintenance 
under pH stress), integrins (role in endothelial cell attachment, survival and migration) and 
angiomotin (implicated in endothelial cell migration) (90). 
1.3.6 Plasminogen Kringle 5 Protein 
Human Plg K5 (Figure 1.3) contains 80 amino acid residues and it possesses highest 
sequence homology (about 60%) with KI and lower, but still significant, homology with K2, 
K3 and K4 (61). Consistent with the lysine-binding properties of KI and K4, K5 also binds 
lysine residues, however in contrast to K4, K5 does not possess a lysine-ri ch cluster (61). 
1.3.6.1 Anti-Endothelial Cell Potency of Kringle 5 
The rationale of utilizing K5 as the anti-angiogenic therapeutic transgene for the 
purpose ofthis thesis is due to the fact that both proteolytic and appropriately folded 
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Figure 1.3. Schematic of the amino acid sequence of human plasminogen kringle 5. 
K5 displays the typical features of kringle domains, possessing 3 disulfide bonds, which 
form a double looped conformation. In order to form angiostatiI14.s, the 2 circled disulfide 
bonds must be reduced to allow for separation of the carboxyl terminal fragment from the 
kringle domains that form angiostatiI14.s. The black bar indicates LySS3h which is at the 
carboxy-terminus of angiostatiI14.s. This figure was obtained from Stathakis et al. (92). 
FIGURE 1.3 
recombinant K5 proteins exhibit substantially higher potency than any of the other individual 
kringle fragments. Of particular interest, it was shown by Cao et al. (128) that proteolytically-
derived as well as recombinant human K5 --on its own- displayed several orders of magnitude 
greater inhibitory effect on endothe1ial cell proliferation than Kl-4 (Figure 1.4). Moreover, Ji et 
al. (129) demonstrated that K5 also inhibits endothelial cell migration, which is an important 
process in angiogenesis. In addition, several studies report that K5 inhibits growth-factor 
stimulated angiogenesis by inducing cell-cycle arrest in G l and apoptosis specifically in 
proliferating endothe1ial cells (128-130). It has been reported that the K5 domain enables Plg to 
bind to HUVEC with high affinity (131). In vitro studies indicate that the overall order of 
kringle fragmentes) endothe1ial cell inhibition is as follows: K5>Kl-3>Kl-4>K1>K3>K2>K4. 
It is important to note that this ranking order may not be translatable in vivo, since K5 has a 
shorter half-life than either form of angiostatin. 
Further studies performed by Cao et al. (132) demonstrated that Kl-5, that is 
angiostatin plus K5, acts as a more potent anti-angiogenic agent than angiostatin (KI-4) alone 
in preventing blood vesse1 formation in the mouse comea (Figure 1.5). It was observed that 
upon implantation of a pellet of FGF (an angiogenic stimulator) in the comea, the growth of 
blood vessels was reduced in mice receiving injections of angiostatin as compared to the PBS-
treated control mice. However, blood vessel formation was most significantly reduced in those 
mice receiving injections of Kl-5. These results suggest that angiostatin and K5 work 
synergistically to markedly improve the angiostatic effect. Moreover, this same group also 
investigated whether Kl-5 could induce an anti-tumor response (132). Syngeneic C57BL6/J 
mi ce were subcutaneously implanted with murine fibrosarcoma tumor cells, followed by daily 
systemic subcutaneous injections ofKl-5. Consistent with theirprevious findings, Kl-5 
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Figure 1.4. Comparison of the anti-endothelial cell properties of angiostatin and 
kringle 5. (A) Bovine capiIlary endothelial ceIls (BCE) were stimulated to proliferate 
with bFGF and exposed to either purified human proteolytic kringle 5 (hK5), mouse 
recombinant K5 (mrK5) or human proteolytic angiostatin KI-4. Although aIl 3 agents 
inhibited BCE proliferation in a dose-dependent manner, the human and mouse K5 
prote in was significantly more potent than angiostatin KI-4. This figure was obtained 
from Cao et al. (128). (B) Human dermal microvascular endothelial ceIls were bFGF-
stimulated to migrate through gelatin-coated polycarbonate filters. Although a 
concentration-dependent inhibition of bFGF-stimulated endothelial ceIl migration was 
observed with angiostatin KI-4 and angiostatin KI-4.5, K5 induced the most potent 
inhibition of migration (50% inhibition of migration < 0.1 nM). Angiostatin KI-4.5 
possessed an ED50 of approximately 2.8 nM compared with 100 nM for angiostatin K 1-4. 
This figure was obtained from Soff et al. (60). 
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Figure 1.5. Synergistic inhibition induced by Kl-5. (A) KI-5 inhibits FGF-induced 
mouse corneal neovascularization more significantly than angiostatin (KI-4) as compared 
to PBS-treated mice. (B) Daily systemic subcutaneous KI-5 injections is more effective 
at reducing the tumor volume of subcutaneous fibrosarcoma tumors than KI-4 at the 
same dose as compared to PBS-treated control mice. This figure was modified from Cao 
et al. (132). 
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induced a 63% reduction in tumor volume as compared to the saline-treated mice. It is 
interesting to note that angiostatin at the same dose as KI-5 did not block tumor growth. This 
suggests that K5 may mediate its endothelial cell suppressive effects via an alternative 
mechanistic pathway as compared to angiostatin or that K5 is a more potent inducer of 
inhibitory regulators on endothelial cells. Therefore, in light of the anti-angiogenic potency of 
KI-5, it would be desirable to explore the use ofK5 alone as an angiostatic agent within a gene 
therapy setting for the treatment of cancer. 
1.3.6.2 Structural Features of Kringle 5 
The high efficacy, cell-type specificity and short amino acid sequence of K5 suggest 
that it possesses tremendous potential as an anti-angiogenic therapeutic agent. Due to its great 
promise, the majority of groups to date have focused their research efforts on assessing the 
anti-tumor ability of K5 and as a result, there is little evidence describing the structural and 
mechanistic features ofK5. It was reported that the lysine-binding site ofK5 is not involved in 
mediating its endothelial cell inhibitory properties, smce addition of trans-4-
aminomethylcyclohexane-I-carboxylic acid (t-AMCHA) had no effect in a migratory assay 
(133). In addition, alkylation as well as reduction of the disulfide bonds within K5 enhances its 
anti-migratory activity, suggesting that the kringle conformation may shield the functional 
elements of K5 from effectively interacting with endothelial cells (129). Reduction of 
angiostatin however, induces inactivation indicating that the kringle domains employ varying 
mechanisms to exert endothelial cell inhibition (88). 
Recently, Cai et al. (134) reported that a deletion mutant ofPlg K5 possesses enhanced 
anti-angiogenic properties when compared to the intact K5 protein in an oxygen-induced 
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retinopathy rat model. More specifically, PCR was used to delete 10 amino acids from the N-
terminus and 1 amino acid from the C-terminus, without disrupting the kringle domains. These 
findings suggest that the flanking amino acid arms ofK5, which reside outside of the disu1fide 
bond region, may not be essential for the angiostatic activity of K5 and may in fact prevent the 
functional elements of K5 from optimally interacting with endothelial cells. It is also possible 
that the deletion mutant may possess a different conformational structure than intact K5 due to 
the absence of these flanking amino acid arms. 
1.3.6.3 Preclinical Testing: Direct Use of Recombinant Kringle 5 Protein 
Zhang et al. (135, 136) employed a rat model of oxygen-induced retinopathy, which 
displays an overexpression of VEGF, pre-retinal neovascularization and haemorrhage. It was 
demonstrated that intravitreal injection of K5 prior to the development of neovascularization 
resulted in decreased neovascular tufts and pre-retinal vascular cells compared to control rats 
receiving PBS injections (135). Moreover, injection of K5 after the development of 
neovascularization inhibited the increase in the pre-retinal vascular cells (135). Therefore, K5 
possesses the ability to prevent the development as well as haIt the progression of retinal 
neovascularization (135). Injection of K5 did not induce any detectable inflammatory response 
in the retina or histological toxicity to retina neurons and pre-existing vessels (135). A 
subsequent report by Zhang et al. (136) utilizing the same rat model demonstrated that 
intravitreal injection of K5 reduced vascular permeability, without affecting permeability in 
normal rats. It was shown that K5 reduced vascular permeability at doses substantially lower 
than that required for inhibition of retinal neovascularization and that the K5-induced decrease 
in vascular permeability correlated with its ability to downregulate VEGF expression in the 
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retina (136). Moreover, K5 inhibited IGF-I-induced hyperpermeability, which is known to 
arise through upregulation of endogenous VEGF expression (136). Further studies by Zhang et 
al. (136) demonstrated that topical K5 administration delayed the onset of alkali-burn-induced 
comeal neovascularization and decreased areas of neovascularization in a dose-dependent 
manner. In addition, topical application of K5 post formation of comeal neovascularization 
induced regression in newly formed vessels and downregulated VEGF expression. 
Yang et al. (137) recently confirmed that recombinant human K5 protein inhibited 
proliferation and induced apoptosis of primary endothelial cells in a dose-dependent manner. 
They also confirmed that the in vitro inhibitory properties of K5 are specifie for endothe1ial 
cells, since K5 was unable to affect the proliferation of hepatoma cells. Ventral K5 injection 
suppressed the growth of grafted hepatoma tumor cells as well as prevented tumor growth by 
68% in an athymie hepatocarcinoma xenograft mouse model as compared to control-treated 
mice. K5 exerted a potent anti-angiogenic effect in both mouse mode1s as evidenced by a 
substantial reduction in microvesse1 density. Interestingly, it was shown that K5 induced 
apoptosis of tumor tissues in vivo as observed by increased cleavage of pro-caspase 3 in tumor 
tisssues. 
1.3.6.5 Putative Endothelial Cell-Surface Receptorsfor Kringle 5 
1.3.6.5.1 Voltage-Dependent Anion Channel 
In 2003, Pizzo and colleagues identified the first possible receptor for K5 as the 
voltage-dependent anion channel (VDAC1) present on the cell-surface of endothe1ial cells 
(138). VDACs are a group of proteins that form channels through the outer mitochondrial 
membrane and have also been observed in human ske1etal muscle, B lymphocytes and 
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hematopoietic cell plasma membranes (138-140). It is believed that VDACI is concentrated in 
caveolae and caveolae-related domains of the plasma membrane (l38, 141). Caveolae are 
lmown to cluster groups of fibrinolytic proteinases (l38). Caveolin-l and -2 are highly 
expressed in normal human endothelial cells (l38, 142). VEGF-induced endothelial cell 
proliferation leads to a decrease in the expression of caveolin-l (l38). Angiostatin has been 
shown to block VEGF-induced caveolin-l downregulation (143). 
It was reported that K5 mediates binding of Plg to the Plg activator streptokinase (SK) 
(144, 145). It was also found that sequence similarities between SK and the mitochondrial 
human VDACI exist, although no functional relationship between these proteins has been 
reported to date (146). The region of homology is between SK residues T~52_Lys283 and 
between VDACI residues Tyr224_Lys255 (146). Pizzo et al. (l38) generated antibodies against 
peptides within these regions and used them to identifY VDACI on the cell-surface of 
HUVECs by flow cytometry analysis. Purified K5 protein was found to bind with high affinity 
(KI = 28 nM) to endothelial cells and binding was inhibited by the generated antibodies (l38). 
Via its interaction with VDAC, K5 was shown to inhibit VEGF-stimulated HUVEC 
proliferation and interferes with signaling mechanisms regulating cytosolic intracellular free 
Ca2+ (l38). In addition, K5 binding to HUVEC induced a decrease in intracellular pH and 
hyperpolarization of the mitochondrial membrane (l38), an early feature of apoptosis. Highly 
purified VDACI was shown to bind K5 after reconstitution of the receptor into liposomes 
(l38). These findings suggest that VDACI is a receptor for K5. It was reported by Komatsu et 
al. (147) that cytosolic pH is increased in endothelial cells prior to angiogenesis and blood 
vessel repair. This group also demonstrated that cell proliferation is dependent on modulation 
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of intracellular Ca2+ concentration. Thus, K5 may act as an anti-angiogenic agent by interfering 
with both of these mechanisms in HUVEC. 
1.3.6.5.2 Glucose-Regulated Protein 78 Receptor 
More recently, it was reported by Davidson et al. (148) from Abbott Laboratories that 
K5 binds with high affinity to the glucose regulated protein 78 (GRP78), which was shown to 
be expressed on the surface of hypoxic or cytotoxic stressed tumor cells and on the surface of 
stimulated endothelial cells. GRP78, also referred to as BiP, is involved in regulating the 
function of the endoplasmic reticulum (ER) due to its roI es in protein folding and assembly, 
targeting misfolded proteins for degradation, ER Ca(2+ )-binding and controlling the activation 
of trans-membrane ER stress sensors (149). GRP78 possesses an anti-apoptotic property, thus 
stress induction of GRP78 represents an important pro-survival component of the unfolded 
protein response (149). Most notably, the discovery of cell-surface expressed GRP78 on a wide 
variety of stressed cancer cells may be further exploited to develop anti-cancer therapeutics. It 
has been reported that when tumor cells are exposed to stressful conditions such as hypoxia or 
cytotoxic stress, the emergence of an apoptosis-resistant phenotype emerges, which has been 
linked to GRP78 cell-surface expression. 
Davidson et al. demonstrated that the peptide sequence PRKL YDY around the lysine-
binding pocket of K5 mediates apoptosis of proliferating endothelial cells and competes with 
K5 for binding to endothelial cells. An immobilized NH2-terminally biotinylated PRKL YDY 
peptide was used to isolate K5 binding proteins from endothelial cell surfaces. Tryptic peptides 
of the major eluted protein underwent mass spectrometric sequencing and revealed sequences 
corresponding to GRP78. Confirmation that GRP78 acts as a cell-surface receptor for K5 was 
performed using coprecipitation of biotinylated endothelial cell-surface proteins with S-tagged 
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K5. Equilibrium dialysis was used to demonstrate direct binding of recombinant GRP78 protein 
(yeast-derived) to 3HK5 (yeast-derived) in a concentration-dependent manner with a Kt = 0.25 
nM. It is important to note that the GRP78:K5 binding possesses a significantly lower 
dissociation constant compared to the VDAC:K5 binding, which suggests that GRP78 is more 
likely to be the main high affinity endothelial cell-surface binding receptor for K5. In addition, 
Pizzo et al. utilized confluent, static endothelial cell monolayers to examine K5 binding to 
VDAC, whereas Davidson et al. used subconfluent endothelial cell culture conditions since 
GRP78 was minimally exposed on confluent endothelial cells. Therefore, under static, 
confluent culture conditions other proteins maya more significant role for K5 binding. It has 
also been reported that VDAC pro teins get chaperoned to the cell-surface by heat shock or 
glucose-regulated proteins. Thus, it is possible that K5 binds to cell-surface expressed GRP78, 
which is associated with VDAC. Furthermore, Davidson et al. demonstrated that K5 induces 
apoptosis of several hypoxic tumor cells that upregulate GRP78 and that caspase-7 is 
implicated in mediating the apoptotic effect (148). It was also recently reported that the ATPase 
domain of GRP78 binds to procaspase-7, preventing activation of procaspase-7 and as a result, 
decreases the stress-induced cellular apoptotic response (150). Nuclear magnetic resonance 
studies performed by Davidson et al. using a recombinant GRP78 ATPase domain indicate that 
K5 binds directly to the ATPase domain of GRP78 and immunohistochemical analysis 
demonstrated that the A TPase domain of GRP78 is present on the extracellular surface of 
stressed tumor cells (148). It was thus proposed that K5 binding to the cell-surface expressed 
ATPase domain of GRP78 on stressed tumor cells leads to endocytosis of the K5:GRP78 
complex, whereby K5 competes with procaspase-7 for GRP78 binding resulting in caspase-7 
activation and promotion of apoptosis (148). To date, Davidson et al. provide the first 
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evidence that an anti-angiogenic agent possesses the ability to induce apoptosis of stressed 
tumor cells (148). It was postulated that K5 would induce apoptosis of stimulated tumor-
associated endothe1ial cells and the subsequent hypoxia would induce tumor cells to upregulate 
cell-surface GRP78, which would lead to tumor cell apoptosis via K5 binding (148). 
Future studies may reveal other novel binding receptors/partners for K5, which can be 
exploited for therapeutic anti-cancer purposes. Moreover, further investigation on the biology 
of K5 may divulge that K5 possesses a broader cell specificity than initially be1ieved, targeting 
other cell types in addition to stressed tumor cells and stimulated tumor-associated endothelial 
cells. 
1.3.6.6 Other Kringle-Containing Proteins 
Besides PIg, several other pro teins have been identified as containing internaI kringle 
domains and inc1ude the following: prothrombin, the unactivated form of thrombin, t-PA, u-
PA, apolipoprotein A, TrK-related tyrosine kinases and hepatocyte growth factor (88). 
Typically, kringle fragments have been characterized as protein recognition domains and 
usually display affinity for C-terminal lysine residues, which can be mimicked by EACA (88). 
Kringle domains have also been reported to interact with proteins that do not possess a C-
terminal lysine residue such as tetranectin, which binds to Plg K4, the pneumo coccus surface 
protein P AM, which binds to K2, factor Va, which binds to KI and K2 of prothrombin, and the 
NG2 proteoglycan, which binds to angiostatin (88). It is also common for kringle domains to be 
found in multiple tandem repeats as is the case for plasminogen, which contains 5 kringle 
domains and apolipoprotein, which contains at least 41 kringle repeats (151). Sorne of these 
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kringle-containing proteins possess angiostatic activity such as prothrombin kringle 2 (152) and 
NK4, which encompasses kringles 1 through 4 ofhepatocyte growth factor (153). 
1.4 CANCER GENE THERAPY 
Gene therapy involves the transfer of foreign genetic material into a patient in order to 
treat a particular disease. In the past decade, there has been much effort to develop cancer gene 
therapy as a novel strategy to treat cancer. Since cancer is a multi-stage disease, various gene 
therapy strategies have been examined such as: (i) transfer of toxic transgene products such as 
tumor suppressor genes or suicide genes/enzymes (pro-drug approach) or expression of 
antisense, ribozymes or smaIl interfering RNAs (siRNAs) for dominant oncogenes; (ii) 
expression of immunomodulatory cytokines, co-stimulatory molecules or tumor specifie 
antigens; (iii) expression ofmolecules affecting angiogenesis, ceIl adhesion and metastasis; (iv) 
chemosensitization and radiosensitization approaches; (v) chemoprotection of stem ceIls; (vi) 
expression of ceIl-surface receptors/ligands that target tumor ceIls; (vii) expression of 
transgenes with tumor-specific promoters and lastly, (viii) the use of replicating (oncolytic) 
vectors (154). 
Many malignancies are associated with loss oftumor suppressor genes such as p53, the 
retinoblastoma gene pRE and p16/NK4A (155). In order to induce apoptosis or ceIl cycle arrest, 
tumor suppressor genes have been introduced into tumor ceIls using a strategy known as "gene 
replacement" (156). It has been reported that p53 can also suppress angiogenesis and tumor 
invasion, which further enhances its anti-tumor effect (157, 158). Transfer oftumor suppressor 
genes has either been performed by directly injecting gene-expressing vectors into the tumor 
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mass, by using tumor-targeted vectors or in an ex vivo approach whereby tumor cells are killed 
as is the case for bone marrow purging prior to autologous bone marrow transplantation (154). 
The suicide gene therapy approach utilizes vectors expressing suicide genes whose 
protein product exposed to small molecular weight drugs results in cancer cell death (referred 
to as the suicide gene/enzyme pro-drug approach (154). For instance, a vector harboring 
bacterial cytosine deaminase in combination with systemic delivery of 5' -fluoro-cytosine can 
convert the pro-drug 5' -fluoro-cytosine to the cytotoxic drug, 5' -fluoro-uracil. The herpes 
simplex thymidine kinase gene has also been used in combination with ganciclovir, which 
pro duces phosphorylated ganciclovir as the toxic species. This approach is further enhanced by 
the "bystander effect" that ensues following the generation of the toxic gene product, which 
kills adjacent non-gene-modified tumor cells as weIl (154). Vector delivery can be performed 
via direct injection in the tumor, ex vivo or via tumor-targeted systemic administration. 
An alternative strategy involves inhibition of dominant oncogenes (154). Vectors 
containing antisense oligodeoxynucleotides, ribozymes or siRNAs can inhibit the expression of 
oncogenes such as ras and HER-2/neu. Both in vivo tumor targeting as weIl as ex vivo tumor 
ceIl killing can be utilized. These approaches can also be used to target specific growth factors 
and cytokines implicated in angiogenesis, such as VEGF. There are also other genes that play 
key roles in tumor invasion and metastasis that are either deficient in tumor cells, such as 
maspin and TIMP-l, or overexpressed such as metalloproteinase enzymes, which can be 
specifically targeted and either enhanced or suppressed respectively using gene-expressing 
vectors that can be directly injected intratumorally or targeted to tumor-associated vasculature 
(154) 
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Strategies aimed at modulating the immune system to enable it to recognize cancerous 
cells as "foreign" cells have also been explored extensively. Immune escape is one of the 
mechanisms employed by tumor cells to avoid immune recognition and killing, thus developing 
methods to circumvent this escape is crucial. Tumor cells evade recognition by the immune 
system via the following mechanisms: lowering major histocompatibility class 1 (MHC-I) and 
MHC-II expression, decreased growth and differentiation of immune effector cells and via 
defects in the expression of costimulatory molecules (154). Immune modulatory approaches 
attempt to activate the immune system or alter the local immune microenvironment by 
introducing genes such as IL-2, IL-4, IL-12, tumor necrosis factor (TNF), IFN-y, GM-CSF, 
immunostimulatory genes (allogenic MHC antigens) or T-cell costimulatory molecules such as 
87.1 and 87.2 (154). Cell therapy approaches have been tested whereby autologous tumor cells 
are engineered with cytokines, immunostimulatory or costimulatory molecules and 
subsequently used as a vaccine to treat the patient. Other strategies involve engineering T-
lymphocytes or dendritic cells with cytokines to ameliorate their anti-cancer fighting properties 
as well as expressing variable regions of tumor-specific monoclonal antibodies to recognize 
and and kill tumor cells (154). 
Alternative approaches involve sensitizing cancer cells to chemotherapy and 
radiotherapy by transferring for example wild-type p53, which has been shown to have 
chemosensitizing effects (156), or the liver cytochrome P450 gene, which has demonstrated 
chemosensitization to oxazaphosphorines, like cyclophosphamide and ifosfamide, that require 
activation by cytochrome enzymes (154). Another strategy involves engineering hematopoietic 
stem cells with drug resistant genes such as the multi drug resistant-l gene (MDR-l) to 
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increase their resistance to cytotoxic drug therapy (154). This approach allows patients to 
receive higher doses of chemotherapeutic agents. 
1.4.1 Anti-Angiogenic Gene Therapy Strategies 
Delivery of anti-angiogenic proteins can be performed using 2 main strategies. The tirst 
approach utilizes systemic gene therapy, whereby gene-engineered vectors are injected into the 
patient in order to provide high levels of circulating angiostatic agents (159). Preclinical animal 
models and early Phase l clinical trials using this approach to test the efticacy of angiostatin or 
endostatin did not demonstrate toxicity (66, 160). A caveat is the possibility that systemic 
vector administration could result in potential adverse effects, especially when employing viral-
based vectors (5). The second approach utilizes tumor-targeted anti-angiogenic gene therapy, 
which aims to increase the levels of angiostatic agents within the local tumor 
microenvironment (161). High gene expression is maintained in the tumor region and thus 
possible systemic toxicity due to the biological properties of the anti-angiogenic agent or the 
vector is avoided. One major shortcoming associated with this approach is that the tumor may 
be inaccessible for vector delivery of the protein of interest, either due to the tumor location or 
multiple metastases (5). 
1.4.2 Cancer Gene Delivery Vectors 
A gene delivery vector enables the transfer of genetic material into target cells. There 
are two main types of vectors currently employed to deliver the therapeutic gene of interest for 
cancer gene therapy strategies: viral-based and non-viral based. Virus es evolved natural 
mechanisms to deliver their genomes into cells therefore they are ideal vectors to deliver 
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foreign DNA. The most frequently used viral vectors are derived from retroviruses, 
adenoviruses and adeno-associated viruses (AA Vs). Non-viral vectors are comprised of either 
plasmid DNA or chemically synthesized compounds. The use of viral vectors is advantageous 
for use in anti-angiogenic cancer gene therapy since: (1) the majority of gene therapy vectors 
can be easily manufactured and purified to high titers; (2) they are stable and can be stored for 
a long duration; (3) they can be engineered to specifically bind tumor-associated endothelial 
cell markers as well as selectively express genes long-term in tumor vasculature and (4) they 
can be engineered to directly kill tumor-derived endothelial cells upon binding. Selection of the 
optimal vector type is based on the following criteria: (1) target cell type- tumor cells or host 
cells as well as developmental nature of the target cells (epithelial origin, hematopoietic stem 
ceIls, neuronal cells or skin cells etc.); (2) cell-cycle status oftarget ceIl- active mitotic division 
or quiescent; (3) gene transfer efficiency requirement; (4) vector targeting and vector tropism 
required to be able to administer the vector locally or systemicaIly; (5) duration of transgene 
expression- short-term or long-term; (6) development of adverse effects due to vector-mediated 
gene therapy- (for example: the presence of pre-existing antibodies against the vector) and 
ability to cease therapy in the event of a harmful side-effect; (7) vector should not be capable of 
integrating into reproductive cells and; (8) size of the gene to be delivered (154). 
1.4.2.1 Retroviral Vectors 
Retroviruses are composed of 2 positive single RNA strands, which upon infection into 
the target cells are copied by the viral reverse transcriptase into double-stranded DNA 
(dsDNA). The dsDNA then migrates to the nucleus where it stably integrates into the genome 
of dividing target cells (162). The most commonly used retro virus is the Moloney Murine 
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Leukemia Virus (MoMuLV), which is composed of a double stranded RNA genome tlanked by 
5' and 3' long terminal repeats (LTR). The transfer ribodeoxynuc1eic acid (tRNA) primer binds 
adjacent to the 5'LTR and reverse transcription is initiated. This region also contains splice 
donor and encapsulation sequences, gag, pol and env genes, which encode for the viral 
structural proteins ribonuc1eoprotein core (gag); protease (pro), reverse transcriptase/RNaseH 
and integrase enzymes (pol); and the envelope glycoproteins (env). In order to generate 
recombinant retroviral vectors, coding sequences from gag, pol and env genes are replaced by 
the cDNA of the therapeutic gene of interest (up to 8 kb). Deletion of required viral sequences 
necessitates that these genes be expressed in trans in what are referred to as "packaging" cell 
lines. Retroviral packaging cell lines constitutively express the gag, pol, pro and env genes, 
which provide the necessary helper sequences for viral propagation, however these genes are 
expressed without their packaging sequence (154). A plasmid encoding the therapeutic gene of 
interest with minimal viral sequences is subsequently transferred into packaging cells, resulting 
in the generation of replication incompetent retro viral partic1es, which are able to transfer the 
therapeutic gene into target cells. The minimal viral sequences comprise the following: (1) the 
long terminal repeats (LTRs), (2) the primer binding site, (3) the polypurine tract (PPT) and (4) 
the packaging sequence (163). Retroviral infection into the target cell genome requires that the 
viral envelope glycoprotein attach to the cell-surface receptors of the target cell (164). 
MoMuLV-derived vectors employ 2 different envelope glycoproteins to induce gene transfer 
into target cells: the ecotropic glycoprotein, which binds an amino acid transporter present only 
on murine cells (165), and the amphotropic glycoprotein, which binds a phosphate transporter 
that is present on most cell types inc1uding rodents and humans (166). Subsequent to viral entry 
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into the cytoplasm, the viral RNA is reverse-transcribed into DNA and undergoes random 
integration into the host cell genome (164). 
The use of retro viral vectors is advantageous since they preferentially gene-modify 
dividing cells, except for lentiviral vectors (a subc1ass of retroviruses), and they induce stable 
integration and expression of the therapeutic transgene in the genome of the target cell. 
Typically, transgenes up to 8-10kb in size could be introduced within retro viral vectors. Viral 
titers range from 105 to 106 infectious partic1es per mL and can be concentrated to more than 
1012 infectious partic1es per mL when the viral partic1es incorporate the G-glycoprotein from 
the vesicular stomatitis virus enve10pe (167). 
There are sorne limitations associated with the use of retroviral vectors. Although 
retro viral vectors can stably integrate the transgene expression cassette into the genome of the 
target cell, accidentaI random integration into the host chromosome has occurred and caused 
de1eterious effects such as activation of specific protooncogenes by insertional mutagenesis or 
suppression of tumor suppressor genes (154). Random integration has been shown to cause 
leukemia even when using replication incompetent retro viral vectors. This phenomenon has 
been observed in mice mode1s and in humans with severe combined immunodeficiency disease 
who received bone marrow transplants transduced with a therapeutic retroviral vector (164). 
Transplantation of the retrovirally gene-modified autologous bone marrow cells resulted in 
development of leukemia only after a long delay. This suggests that mutagenesis due to random 
integration may involve other factors such as the characteristics of the particular retro viral 
preparation (retroviral vector may carry "passenger" noncoding regulatory RNAs possessing 
the ability to upregulate genes affecting cell proliferation) (164, 168). Another major 
disadvantage is the possible generation of replication competent retroviruses (ReR). There has 
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been no report to date describing such an event however, it is possible that a replication-
incompetent retro viral vector administered in vivo could recombine with endogenous virus es to 
create a new RCR virus. 
1.4.2.1.1 Inhibition of Tumor Angiogenesis Using Retroviral Vectors 
Several independent groups have utilized retroviral gene therapy to deliver anti-
angiogenic proteins long-term in preclinical tumor models. Most studies have used the 
MoMuL V -based retroviral vectors. Since these viral vectors can only infect dividing cells, 
replication-deficient, third-generation lentiviral vectors based on the human immunodeficiency 
virus-l have been developed to overcome this limitation (5). 
Our laboratory is the first to test the efficiacy of K5 protein alone in the context of a 
gene therapy strategy for brain (169) and breast cancer (170). Our approach exploits the use of 
ex vivo retroviral gene transfer to gene-modify tumor cells prior to implantation and further 
assessment in vivo. Other groups have also employed ex vivo retroviral gene transfer to test the 
efficacy of various angiostatic agents. Scappaticci et al. (171) showed that a combination 
treatment of retrovirally delivered angiostatin and endostatin induced a synergistic effect in 
animal models of melanoma and leukemia by prolonging the survival of animaIs receiving the 
combination treatment when compared to animaIs receiving either protein alone. Tanaka et al. 
(172) demonstrated that implantation of ex vivo retrovirally-engineered platelet factor-4-
expressing glioma cells gave rise to smaller and less vascularized tumors when compared to 
control non-gene-modified tumors. Consistent with these results, Machein et al. (173) also 
observed suppression of tumor growth in a rat model when orthotopically implanting glioma 
cells that were retrovirally-modified ex vivo with the dominant negative Flkl (lacks 
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intracellular signaling domain). It is important to highlight that retroviral vectors are efficient at 
stably transducing tumor cells ex vivo, however their efficiency decreases substantially when 
they are used for direct in vivo gene transfer in pre-established tumors. 
1.4.2.2 Lentiviral Vectors 
Recombinant lentiviral vectors have also been used for gene transfer. Similar to 
retroviral vectors, lentiviral vectors integrate in host-cell chromosomes (174). They can be 
exploited for applications that require long-term transgene expression. Elimination of viral 
open reading frames from recombinant vectors allows for a nonimmunogenic gene delivery 
approach, however immunogenicity could develop against the transgene itself and from the 
virion-associated antigens that enter cell at the time of infection (174). The use of lentiviral 
vectors is attractive since they can transduce non-dividing cells (both ex vivo and in vivo) and 
possess stable and relatively large genomic capacity. Stable transmission of large genomic 
fragments allows for improved transgene expression. The development of third-generation 
packaging systems derived from HIV -1 will allow for a broader investigation of lentiviral-
mediated gene transfer. Risk of insertional mutagenesis and low viral titer limit the use of 
lentiviral vectors. The development of improved lentiviral vector targeting is currently 
underway using virions pseudotyped with alternative envelopes or genetically engineered 
envelope substitutes (174). Lentiviral vectors are therapeutically useful for strategies that 
require efficient gene transfer in stem cells, T lymphocytes and tumor cells. 
1.4.2.3 Adenoviral Vectors 
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Adenoviruses are double-stranded DNA non-enveloped viruses that replicate in the 
nucleus outside the chromosome and are capable of infecting a wide variety of cells, including 
dividing and non-dividing cells (154). Adenoviral vectors can be prepared at extremely high 
titers in the range of 1012 plaque-forming units (PFU) per mL, which is sufficient for in vivo 
use. Adenoviruses attach to target cells using a fiber protein that binds to the 
Coxsackie/adenovirus receptor (CAR) and enter cells by receptor-mediated endocytosis (154). 
Adenoviral vectors have a larger packaging capacity compared to retroviruses and thus can 
accommodate large transgene sequences (30-35kb) (154). In contrast to retroviruses, 
adenoviruses do not integrate into the genome of the infected cell and this feature minimizes 
the development of malignancy. The non-integrating nature of adenoviral vectors leads to high 
but transient transgene expression. In addition, adenoviruses elicit a strong host immune 
response and this also contributes to the short-lived transgene expression. There are 3 main 
concems associated with the use of adenoviral vectors: (1) organ inflammation due to immune 
reactions against the vector, (2) the development of tolerance to the vector that could result 
from disease upon infection with wild-type adenoviruses (cause respiratory infections) and (3) 
the generation ofreplication competent adenoviruses (175). 
Several replication-defective adenoviral vectors for cancer therapy are in late-stage 
clinical trials, including Advexin (lntrogen Therapeutics), which expresses wild-type p53, and 
GV AX (Cell Genesys), which expresses GM-CSF and is used for the ex vivo generation of 
autologous cancer vaccines (176). Other adenovirus-based gene therapies in early-stage trials 
include TNFerade (Gen Vec), which expresses TNF-a and EG009 (Ark Therapeutics), which 
expresses HSV-TK (176). 
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Another approach involves the use of replication selective adenoviruses. Deletion of 
viral genes necessary for efficient replication in nonnal cells but expendable in tumor cells has 
been used to engineer replication selectivity (176). ONYX-15 was the first adenovirus designed 
using this strategy. McConnick hypothesized that an adenovirus with deletion of a gene 
encoding a p53-inhibitory protein, EIB-55-kDa, would be selective for tumors that had already 
inhibited or lost p53 function (176). More than 230 patients have been treated with ONYX-15 
via different administration routes and ONYX-15 was reported to be well tolerated (176). 
1.4.2.4 Adeno-Associated Vectors (AA Vs) 
AA Vs are single-stranded DNA viruses that are derived from a non-pathogenic and 
defective human parvovirus that often coexists with adenoviruses. AA Vs replicate and 
integrate in the nucleus in the presence of a helper virus (177). Thus, AA Vs require co-
infection with another virus, typically an adenovirus or a herpes simplex virus. Although 90% 
of humans show evidence of prior infection with AA V s, it has not been associated with human 
disease (177, 178). Wild-type AA Vs integrate at a specifie region on chromosome 19 however, 
AA Vs integrate randomly since the Rep protein necessary for site-directed integration is 
lacking (178). Similar to retroviral vectors, all coding sequences within AA V s are deleted and 
thus the development of an immune response toward viral proteins is avoided. AA Vs are 
relatively safe and nonimmunogenic, provide high titers and possess the ability to infect many 
cell types among which include quiescent cells, hematopoietic cells as well as tenninally 
differentiated cells. AA V s are integrating vectors and thus long-tenn gene expression has been 
achieved, lasting up to 1 year post-infection. However, due to the small size of AA Vs, only 
small inserts of up to 5kb can be packaged. AA V s also possess potential risks such as (J) the 
59 
presence of contaminating adenovirus which may cause adverse effects, (2) the potential for 
insertional mutagenesis and (3) the generation of wild-type AA Vs due to recombination 
between the vector and the packaging plasmid (179). 
1.4.2.5 J7accinia J7ectors 
The poxvirus vaccinia has been extensively used clinically for smallpox vaccination. 
Vaccinia virus is a large virus with a double envelope surrounding an 186-kb DNA genome. 
Vaccinia vectors have been utilized in human clinical trials to deliver genes encoding tumor-
associated antigens and cytokines. The vectors have been administered via different routes 
including intratumoral, subcutaneous and intradermal. One major disadvantage of vaccinia 
vectors is that they are replication-competent viruses, which poses a safety concem in 
immunosuppressed cancer patients. This problem has been addressed by developing vectors 
based on other poxviruses, such as fowl pox and canary pox, which do not replicate in humans. 
Despite this effort, vaccinia and other poxvirus vectors express a large number of viral proteins 
in addition to the cytokine or tumor-associated antigen of interest. As a consequence, the 
antiviral immune response tends to dominate the antitumor immune response and this effect has 
limited the use of these vectors. 
1.4.2.6 Herpes Simplex J7irus Type 1 J7ectors 
The Herpes simplex virus type 1 (HSV-1) is another large virus used in cancer gene 
therapy. The genome is a linear, double-stranded DNA molecule (180). Replication-defective 
HSV -1 vectors, which cannot pro duce infectious progeny and thus have reduced toxicity to 
infected cells, can be generated by deleting one or more of the immediate early genes essential 
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for virus repli cation (180). The main advantage of replication-defective HSV-1 vectors for 
cancer gene therapy is their large cloning capacity, which has been exp10ited to deliver distinct 
therapeutic genes to the heterogeneous population of cells within a solid tumor (180). 
Oncolytic viral therapy represents a promising strategy for treating cancer that involves 
replication-competent viral vectors that can replicate in situ in tumor cells, induce oncolytic 
activity by direct cytocidal effects and then spread throughout the tumor (181). In addition, 
these vectors are capable of transferring and expressing foreign genes in host cells (181). HSV-
1 possesses many features that make it attractive for cancer therapy: it infects most tumor cell 
types, its life cycle is well studies, its genome has been sequenced, the function of the majority 
of genes has been identified, the genes can be manipulated and the large size of the genome 
(181). HSV -1 is a neurotropic virus and many of the genes necessary for neuropathogenicity 
are nonessential and can be mutated (181). Therefore, HSV-1 is particularly useful for brain 
tumor therapy. The therapeutic benefits of oncolytic HSV-1 vectors depend on the extent of 
both intratumoral viral repli cation and induction of host antitumor immune responses (181). 
Third-generation oncolytic HSV -1 vectors possess enhanced properties and retain the safety 
features of second-generation vectors (pathogenicity substantially attenuated by genetically 
engineering mutations in two different genes). This approach has features that make it very 
attractive for clinical application: tumor cells are targeted irrespective of their genetic makeup, 
it can be combined with conventional therapies such as surgery, radiation therapy and 
chemotherapy, combination with immunotherapy has potential synergistic effects and it can act 
as a vehicle for gene delivery in vivo (181). It has been demonstrated in several clinical trials 
that oncolytic HSV -1 vectors can be administered safely in humans and CUITent efforts are 
underway to improve antitumor efficacy without compromising safety. 
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1.4.2.7 Non-Viral Vectors 
Non-viral vectors transfer genetic material without utilizing a viral particle such as 
naked DNA plasmids amplified in bacteria or eukaryotic ceIls, as weIl as chemically 
synthesized oligonucleotides (182). Plasmid DNA can harbor up to 15kb of genetic material 
and requires cationic liposomes or receptor-mediated targeting in order to efficiently enter a 
target cell. Synthesized oligodeoxynucleotides contain between lOto 25 bases and are 
generally used to alter processmg, translation or stability of targeted RNA. 
Oligodeoxynucleotides can also be used to inhibit DNA transcription or as decoys to 
transcription factors. The main advantage of using non-viral vectors is the absence of risk for 
generating replication competent viruses. However, one major drawback is the typically 
transient expression of plasmid-encoded genes. Potential risks associated with the use of non-
viral vectors include: (1) the possibility of insertional mutagenesis if the plasmid integrates and 
(2) toxicities induced by the compounds used to facilitate cell entry (183). 
1.4.3 Future of Cancer Gene Therapies 
Although several cancer gene therapies have entered clinical trials and have 
demonstrated safe and well-tolerated results, evidence of significant clinical efficacy has not 
been forthcoming. The main reason for the lack of successful treatment involves the 
inefficiency of targeting tumor cells using systemic delivery methods. Preclinical data indicates 
that tumor-targeted gene delivery approaches using tumor-specific promoters holds greater 
promise and remains to be tested in clinical trials. It is believed that cancer gene therapies will 
be most efficacious if used as adjuvants and in conjunction with CUITent treatment modalities 
such as chemotherapy and radiation therapy. 
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1.5 SPECIFIC RESEARCH AIMS 
The main objective of the research presented in this thesis was to develop novel anti-
anglOgemc gene therapy strategies for cancer. The specific research aims were as 
follows: 
1. To determine whether retrovirally gene-modified human U87 glioma cells 
producing soluble human plasminogen kringle 5 protein could suppress tumor 
progression and angiogenesis in an orthotopic brain cancer model; 
2. To determine whether human plasminogen kringle 5 protein, when secreted by 
retrovirally gene-engineered murine DN3 mammary adenocarcinoma cells, IS 
dependent upon innate immune effector cells to mediate its anti-cancer effect; 
3. To determine whether recombinant human angiostatin protein, in addition to its 
strong anti-angiogenic activity, can also exert inhibitory action on macrophages. 
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CHAPTER2 
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CHAPTER2 
Plasminogen Kringle 5-Engineered Glioma Cells Block Migration of Tumor-
Associated Macrophages and Suppress Tumor Vascularization and Progression. 
Reference: Perri SR, Nalbantoglu J, Annabi B, Koty Z, Lejeune L, François M, Di Falco 
MR, Béliveau R, Galipeau J. Plasminogen Kringle 5-Engineered Glioma Cells Block 
Migration of Tumor-Associated Macrophages and Suppress Tumor Vascularization and 
Progression. Cancer Research. 2005 Sept 15;65(18): 8359-65. 
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2.1 ABSTRACT 
Angiostatin, a weIl characterized angiostatic agent, is a proteolytic cleavage 
product of human plasminogen encompassing the first four kringle structures. The fifth 
kringle domain (K5) of human plasminogen is distinct from angiostatin, and has been 
shown -on its own- to act as a potent endothelial cell inhibitor. We propose that tumor-
targeted K5 cDNA expression may act as an effective therapeutic intervention as part of a 
cancer gene therapy strategy. In this study, we provide evidence that eukaryotically-
expressed His-tagged human K5 cDNA (hK5His) is exported extracellularly and 
maintains predicted disulfide bridging conformation in solution. Functionally, hK5His 
protein produced by retrovirally-engineered human U87MG glioma cells suppresses in 
vitro migration of both human umbilical vein endothelial cells and human macrophages. 
Subcutaneous implantation of Matrigel™ -embedded hK5His-producing glioma cells in 
NOD-SCID mice reveals that hK5His induces a marked reduction in blood vessel 
formation and significantly suppresses the recruitment of tumor-infiltrating 
CD45+Mac3+Grl- macrophages. TherapeuticaIly, we demonstrate in a nude mouse 
orthotopic brain cancer model that tumor-targeted K5 expression is capable of effectively 
suppressing glioma growth and promotes significant long-term survival (>120 days) of 
test animaIs. These data suggest that plasminogen K5 acts as a novel two-pronged anti-
cancer agent, mediating its inhibitory effect via its action on host-derived endothelial 
cells and tumor-associated macrophages, resulting in a potent, clinically-relevant anti-
tumor effect. 
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2.2 INTRODUCTION 
Glioblastomas are very aggresslve solid tumors characterized by 
hypervascularization and extensive tumor cell invasion into normal brain parenchyma 
(49) . CUITent therapeutic modalities primarily target rapidly dividing malignant cells and 
include combinations of surgery, radiotherapy and chemotherapy (49, 184). However, 
these therapies remain ineffective with more than 90% of patients experiencing local 
reCUITence and a 5-year survival rate of only 9% (185). 
The urgent need for the development of potent anti-glioma therapeutics as weIl as 
the importance of angiogenesis in glioma growth (186, 187) has fueled the identification 
and characterization of numerous anti-angiogenic agents, aimed at interrupting new 
vessel formation and ultimately arresting tumor growth. The use of anti-angiogenic 
agents as therapeutics is an appealing approach targeting nonmalignant endothelial cells 
that form the tumor vasculature and indirectly affects tumor ceIls, thus minimizing the 
risk of toxicity. In addition, the problem of drug resistance associated with conventional 
chemotherapy agents, is avoided since normal endothelial cells are genetically stable 
unlike tumor cells (188). Moreover, the blood-brain barrier is another obstacle often 
encountered with therapies targeting malignant cells within the brain and may be 
exploited with anti-angiogenic strategies by maintaining the angiogenic inhibitor within 
the brain vasculature for a prolonged period. Although angiogenesis inhibition offers 
several advantages over traditional therapeutic approaches, it is expected to induce a 
cytostatic effect resulting in tumor stabilization not eradication. Furthermore, single agent 
anti-angiogenic therapy may lead to a compensatory increase in the production of other 
angiogenic factors, which may then sustain angiogenesis (1). Despite these limitations, it 
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is now weIl recognized that angiostatic agents either singly or in combination with other 
treatment modalities could offer superior therapeutic benefits than currently attainable 
(189-195), converting the tumor into a controIled, quiescent chronic disease. Direct 
delivery of purified recombinant anti-angiogenic proteins however necessitates large 
quantities and repeated administration of the therapeutic gene product for a prolonged 
period of time (66, 104). To circumvent the pitfalls associated with conventional 
treatments, we have developed a potent anti-angiogenic gene therapy strategy for brain 
cancer. Moreover, since malignant gliomas localize within the CNS and do not form 
distant metastases (196), they represent an attractive target for local gene therapy, which 
provides high and sustained local production of the desired therapeutic agent and offers a 
viable alternative to existing therapeutic interventions. 
Several inhibitors of angiogenesis exist endogenously as proteolytic cleavage 
products of larger precursor molecules. Angiostatin, a well characterized anti-angiogenic 
agent discovered by O'Reilly and colleagues in Folkman's laboratory, was initially 
identified as an endothelial cell growth inhibitor present in urine and plasma of animaIs 
harboring solid tumors (59, 197), is an internaI cryptic fragment of human plasminogen 
(PIg) encompassing the first four kringle (KI-4) domains (Figure. 2.1A). The K5 domain 
of Plg has been expressed as a recombinant protein in bacteria and been found to be more 
potent than KI-4 or any of the Plg kringles expressed individually in inhibiting growth 
factor stimulated proliferation of endothelial cells in vitro (86, 128). It has also been 
demonstrated that kringle domains 1-5 (KI-5) act as more potent endothelial cell 
inhibitors in vitro and are more effective in suppressing fibrosarcoma tumor growth in 
vivo as compared to KI-4 alone (132). We propose that the K5 domain could serve as a 
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potent angiostatic agent on its own and that it may act as a useful therapeutic transgene 
within a cancer gene therapy strategy. To test this hypothesis, we have developed a 
human K5-expressing retroviral vector and tested its efficacy in vivo using an orthotopic 
brain cancer model. 
2.3 MATERIALS AND METHODS 
2.3.1 Cell Culture Reagents. 
293GPG pantropic retrovirus-packaging cell line (198) was a gift from Dr. 
Richard C. Mulligan (Children's Hospital, Boston, MA). Human glioma U87MG cellline 
(199) was a gift from Dr. Stéphane Richard (Lady Davis Institute, Montreal, Quebec, 
Canada). Freshly isolated primary human umbilical endothelial cells (HUVEC) were 
generously provided by Dr. Mark Blostein (Lady Davis Institute) and maintained in 
endothelial-basal media (EBM-2; Cambrex, Walkersville, MD) supplemented with EBM-
2 SingleQuots. Fresh human peripheral blood mononuc1ear cells were obtained from 
normal volunteers and maintained in DMEM-F12 (Wisent Technologies) supplemented 
with 2% human serum and 500U/ml granulocyte/macrophage colony stimulating factor 
(GM-CSF; Immunex, Thousand Oaks, CA). 
2.3.2 Soluble Human Kringle 5-HisTag Expression Vector, Protein Purification & 
Detection. 
pBLAST -hK5 cDNA (InvivoGen, San Diego, CA) encodes for hK5 and contains 
a 5' interleukin-2 signal peptide (IL-2sp) coding sequence. A 3' 6-histidine tag was PCR 
c10ned to generate IL-2sp/hK5/HisTag (hereafter hK5His). Conditioned media was 
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collected from hK5His stably transfected human kidney 293T cells, concentrated using a 
Centricon® Plus-20 column (Millipore, Billerica, MA) and purified using a Ni-NTA-
based resin affinity chromatography purification system (Novagen, San Diego, CA). 
Immunoblot analysis was performed on eluted fractions using a polyclonal anti-His 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA). 
2.3.3 Proteomic Analysis of Purified Soluble hK5His. 
Lyophilized hK5His samples were resuspended ln water:5% acetonitrile 
(ACN):O.l % trifluoroacetic acid (TFA), desalted using reverse phase C18 ZipTips 
(Millipore, Billerica, MA), eluted with water:70% ACN :0.1 % TF A. The eluate was 
spotted onto a matrix assisted laser desorption ionization (MALDI) sample plate and 
analyzed using a MALDI-Time of Flight (ToF) Voyager-DE (Applied Biosystems, Foster 
City, CA). The eluted fraction was also spotted onto polybrene coated TF A filter disks 
for Edman degradation-based N-terminal sequence analysis using a Pro cise 492 
automated microsequencer (Applied Biosystems). One eluate aliquot was treated with 
10mM dithiothreitol for lhr, diluted with 80lll of 50mM Ambic containing lOOng of 
Trypsin gold (Promega, Madison, WI) and digested ovemight. For dual enzyme digest, 
the eluted fraction was first digested ovemight with immobilized trypsin (Pierce, 
Rockford, IL) followed by an ovemight digestion with lOOng of Endoproteinase-Asp-N 
(Roche Diagnostics, Laval, Quebec, Canada). Digested solutions were ziptipped and 
eluted onto a MALDI sample plate. Peptide fragment analysis was performed with an 
Ultima MALDI-Quadrupole ToF mass spectrometer (Waters Limitée, Dorval, Quebec, 
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Canada). Spectra analysis and peptide identity assignment was perfonned using Biolynx, 
a software tool ofMasslynx v4.0 (Waters). 
2.3.4 VSV-G Pseudotyped Retroviral Vector Design, Synthesis and Titer 
Assessment. 
The bicistronic murine retrovector pIRES-EGFP was previously generated in our 
laboratory (200) and contains an enhanced green fluorescent protein (EGFP). The 
hK5His cDNA was ligated into pIRES-EGFP to generate phK5His-IRES-EGFP. VSV-G 
pseudotyped retroparticles encoding hK5His-IRES-EGFP were generated by tetracycline-
withdrawal as previously published (200, 201). Engineered retroparticles were devoid of 
replication-competent retro virus as detennined by GFP marker rescue assay utilizing 
conditioned media from target cens. The titer of the control GFP and hK5His 293GPG 
single clone population was assessed as previously described (201). 
2.3.5 Transduction of Human U87MG Glioma Cells. 
Glioma cens were transduced with hK5His-expressing retroviral particles as 
previously described (200). Stably transduced glioma cens were culture-expanded and 
sorted to obtain both polyclonal and single clone populations based on GFP expression 
using a Becton Dickinson F ACST AR sorter. 
71 
2.3.6 Western Blot Analysis. 
Conditioned media was collected from confluent control OFP and hK5His 
transduced U87 glioma ceIls, as weIl as stably transfected hK5His 293T cells (positive 
control), concentrated and detected by anti-His immunoblot analysis as previously 
mentioned. 
2.3.7 Migration Assays. 
HUVEC (lxl04) or human macrophages (5x104) were plated onto 0.15% 
gelatinlPBS-coated 8-flm pore chemotaxis membranes (Coming, Acton, MA) within 
Boyden chamber inserts. Migration assays were performed as previously described (202). 
HUVEC and macrophages were exposed to conditioned media from control OFP and 
hK5His transduced U87 glioma cells for 4 hours and 24 hours respectively under growth 
factor-stimulated conditions (EBM-2 SingleQuots) and serum-stimulation respectively. 
Each sample was tested in triplicate and the average number of migrating cells per field 
was assessed by counting 3 random high power fields per filter. 
2.3.8 In Vivo Matrigel™ Assay and Analysis of Cellular InnItrate by Cytometry. 
Culture-expanded U87 -OFP and U87 -hK5His-OFP cells were aliquoted to create 
50fll cell suspensions containing 2xl04 ceIls, mixed with 500fll Matrigel™ (BD 
Biosciences, San Jose, CA) at 4°C and implanted subcutaneously in the right lateral flank 
of 6-week old immunodeficient NOD-SCID mice (Charles River, Laprairie, Quebec, 
Canada). Four weeks post-implantation, mi ce were sacrificed, implants excised and 
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processed as previously described (203). To detennine the expIant cellular infiltrate, cell 
suspensions were stained with the following antibodies: purified rat anti-mouse 
CD16/CD32 (mouse Fc block) followed by APC-conjugated rat anti-mouse CD45, PE-
conjugated rat anti-mouse Mac-3, biotin-conjugated rat anti-mouse Ly-6G (Gr-l) and 
their corresponding isotypic controls. Biotinylated antibodies were revealed using PE-
Cy7-streptavidin (BD Phanningen, San Diego, CA). Cells were fixed with 1% 
parafonnaldehyde and events were acquired using a F ACSCalibur flow cytometer 
(Beckman Coulter, Fullerton, CA) and analyzed using the CellQuest software (BD). 
2.3.9 Matrigel™ Expiant Histochemistry. 
Explants were fixed in fonnalin, embedded in paraffin and 4 J.Lm sections were 
prepared in order to generate representative sections of the border and central regions of 
the explants. Sections were treated with xylene, rehydrated and antigen retrieval was 
perfonned using two microwave boils in a 10 mM sodium citrate buffer (pH 6.0) 
solution. Endogenous biotin activity was blocked using a kit (Zymed Laboratories, 
Markham, Ontario), sections were subsequently blocked with 2.5% bovine serum 
albumin in PBS and incubated with a rabbit polyc1onal raised against murine von 
Willebrand factor (vWF; N eomarkers, Fremont, CA dilution 1: 100) ovemight. After 
three washes, the sections were incubated with biotinylated goat anti-rabbit IgG antibody 
(BD Phanningen, dilution 1 :200) for 2 hours, washed and incubated with streptavidin-
peroxidase (VectorLabs, Burlingame, CA) for 1 hour prior to the addition of 3,3'-
diaminobenzidine (DAB) chromogenic substrate (VectorLabs). Meyer's hematoxylin was 
used for counterstaining. The blood vessel surface area of all vWF-positive vessels was 
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calculated using a Leica light microscope ocular micrometer (Lei ca Microsystems Inc., 
Richmond Hill, Ontario, Canada) at 400X magnification. Two observers counted 3 
random sections per expIant in each experimental group. The blood vessel surface area to 
total section surface area was calculated and expressed as a percent age. 
2.3.10 Stereotactic Intracerebral Surgery. 
CDI nu/nu female 6-week old athymic nude mlce (Charles River) were 
anesthetised usmg a ketamine-xylezine-saline-acepromazine cocktail (1 OOmglml, 
20mglml, 0.9%, IOmglml respectively) dosed at 1 OOIll/I OOg by i.p. injection. Mice were 
secured in stereotactic apparatus (KopfInstruments, Tujunga, CA) and incisor bar set to -
1.5. Midline incision made on scalp to expose Bregma & Lambda. Coordinates from 
Bregma were: AP: +0.5, LM: -2.0, DV: -4.4. A bUIT hole was made and a Hamilton 
syringe (IOIlI, 26 gauge needle, Hamilton Co., Reno, NV) was gently lowered. Cell 
suspension (IxIOs in 3111 ofHBSS) was injected at a rate ofO.251l1 per 3 minutes for 36 
minutes. 
2.3.11 Brain Tissue Analysis. 
After euthanasia, brains were processed for H&E staining as previously described 
(204). Digital images were retrieved using an Olympus microscope (Olympus America, 
Melville, NY). Tumor volumes were calculated using the formula length x width2 x 0.4. 
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2.4RESULTS 
2.4.1 MALDI-QToF Mass Spectrometry Analysis of Expressed Soluble hK5His 
Peptide Confirms Predicted Disulfide Bridging Conformation. 
The 381bp human Plg K5 domain cDNA, corresponding to amino acid residues 
447 to 546 of PIg, includes a 20 amino acid IL-2 signal sequence and a His-tag at the C 
terminus (Figure 2.lB), encodes for the hK5His protein with a kringle structure as 
predicted by previously published NMR structure study (205). Affinity chromatography 
was performed on pre-cleared conditioned media from stably transfected hK5His-
expressing 293T cells. Anti-His immunoblot, following SDS-PAGE separation (Figure 
2.2A, upper), demonstrates a major band of 15kDa (Figure 2.2A, lower). N-terminal 
amino acid sequencing indicated proper cleavage of the IL-2 signal sequence directly 
upstream of Ser20 and analysis by MALDI-QToF mass spectrometry revealed a major 
peak at 12108Da consistent with the predicted molecular weight of hK5His (Figure 
2.2B). To fully characterize cystinyl bridge structure and confirm kringle domain tertiary 
structure, an orthogonal digestion was carried out either with agarose-immobilized 
trypsin alone (Figure 2.2C) or with trypsin followed by incubation with Asp-N 
endopeptidase (Figure 2.2D) under reducing and non-reducing conditions. Peptide 
mapping of non-reduced single and dual protease hK5His digests by MALDI-QToF mass 
spectrometry confirmed the presence of disulfide bridges between Cys 17 -Cys 96, Cys38_ 
Cys79, and Cys67_Cys91 (by deduction). These findings demonstrate that Plg hK5His 
domain spontaneously adopts a tertiary structure consistent with native conformation as 
displayed within Plg when expressed by genetically-engineered eukaryotic cells. 
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Figure 2.1. Schematic illustration of human Plg and its kringle domains. (A) Plg is 
composed of 791 amino acids with a single N-linked glycosylation at Asn289 and a single 
O-linked glycosylation at Thr346. Angiostatin, a weIl known inhibitor of angiogenesis, 
encompasses the first three to four kringle structures of Plg. This is a modified schematic 
courtesy of Dr. M. R. Llimis and co-workers, Carnegie Mellon University, Pittsburgh, PA 
(www.chem.cmu.edu/groups/Llinas/res/structure/hpk.html). (B) Human kring1e 5 (hK5) 
consists of the last cryptic fragment of Plg (Cys462 _Cys541) and is composed of 80 amino 
acid residues with 3 distinct disulfide bonds. 
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Figure 2.2. Proteomic analysis of purified soluble hK5His. (A, upper) Silver stain 
perfonned on pooled eluted fractions detects purified protein at the expected molecular 
weight of 15kDa. (A, lower) Anti-His immunoblot analysis demonstrates the presence of 
soluble hK5His peptide in pooled eluted fractions. (B) Analysis of the purified hK5His 
peptide by MALDI-QToF mass spectrometry revealed a major peak at 12108Da 
consistent with the theoretical molecular weight of monomeric K5 at 12109.6Da. The 
doubly charged fonn and dimer are detectable at 6059Da and 24195Da respectively. (C, 
lelt) Expected peptide fragment of interest generated for hK5His protein digested with 
trypsin alone under oxidizing conditions. (C, right) MALDI-QToF mass spectra 
confinning Cys38:79 disulfide bond within hK5His. (D, left) Expected peptide fragment of 
interest generated for hK5His protein digested with trypsin followed by Asp-N 
endopeptidase treatment under oxidizing conditions. (D, right) Spectra confinning 
Cys17:96 and Cys38:79 disulfide bonds. 
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2.4.2 hK5His Protein Secreted by RetroviraUy Gene-Modified Human Glioma CeUs 
Inhibits In Vitro Endothelial CeU Migration. 
The hK5His cDNA was cloned into our previously published (200) bicistronic 
retro viral vector (Figure 2.3A). The hK5His retrovector plasmid was stably transfected 
into 293GPG retro viral packaging cells and retro virus producer cells were selected as 
described in Materials and Methods. Tetracycline-withdrawal from the culture media led 
to the production of VSVG-typed hK5His-GFP retroviral particles which were 
subsequently concentrated 100-fold by ultracentrifugation and a viral titer of -2.5xI06 
infectious particles/mL was obtained (data not shown). Concentrated VSVG-typed 
hK5His-GFP retroviral particles were utilized to transduce human glioma cells. The 
U87MG human glioblastoma cell line was selected for this study because it 
overexpresses vascular endothelial growth factor (VEGF) producing tumors in vivo that 
are characterized by increased vascularity, lack of necrosis and absence of peripheral 
invasion in early tumor development (49). Following retro viral transduction, single 
U87MG clones were selected and assessed for GFP expression by flow cytometry. The 
U87 single clone used for the study was sorted based on GFP expression and was 99% 
GFP positive (Figure 2.3B). To ensure hK5His transgene expression and proper secretion, 
anti-His immunoblot analysis was performed on conditioned supernatant collected from 
hK5His transduced human U87 glioma cells and detects a major 15kDa protein consistent 
with the predicted molecular weight of soluble hK5His (Figure 2.3C). Using a semi-
quantitative western blot titration curve, it was estimated that hK5His-GFP-expressing 
U87 cells secrete 0.5pM (or 7.5ng) of soluble hK5His per 106 cells per 24 hours (data not 
shown). To test the functionality of secreted hK5His from hK5His-GFP-expressing U87 
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Figure 2.3. Development and characterization of hK5His-GFP gene-modified cells. 
(A) Schematic illustration of the human hK5His-lRES-EGFP retroviral plasmid 
construct. The retrovector plRES-EGFP construct served as the control plasmid. (B) 
Flow cytometry analysis of untransduced (grey) and hK5His transduced (black) hum an 
U87 glioma cells. (C) Anti-His immunoblot analysis reveals functional secretion of 
hK5His migrating as a doublet at ~ 15kDa from retrovirally gene-modified U87 glioma 
cells and stably transfected 293T cells (positive control). (D) Conditioned media from 
hK5His transduced glioma cells inhibits HUVEC migration up to 75 ± 3%; bars, S.E.M. 
Statistical analysis was performed using the student (-test. 
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cens, a HUVEC migration assay was perfonned as it has been previously demonstrated 
that recombinant K5 protein is capable of inhibiting the migration of bovine capillary 
endothelial (BCE) cens (129). Soluble hK5His present in the conditioned media of 
hK5His-GFP-expressing U87 cens was capable of inhibiting growth factor-induced 
migration of HUVEC up to 75 ± 3% (P < 0.0004) as compared to conditioned media 
from GFP-expressing U87 cens (Figure 2.3D). This confinns the in vitro functionality of 
hK5His secreted by hK5His-GFP-expressing U87 cens. 
2.4.3 hK5His Blocks Glioma Associated Angiogenesis and Possesses Novel Anti-
Macrophage Properties. 
To further characterize the mechanism of action of soluble hK5His in vivo, we 
investigated whether hK5His could interfere with the tumor microenvironment. More 
specificany, we assessed whether soluble hK5His could affect the recruitment of host-
derived tumor-infiltrating endothelial as wen as inflammatory cens implicated in tumor 
angiogenesis. To test this hypothesis, 2xl04 U87-GFP (n = 10) or U87-hK5His-GFP (n = 
10) cens were Matrigel™ -embedded and implanted subcutaneously in NOD-SCID mice. 
To verify if tumor-secreted hK5His induced an anti-angiogenic effect in vivo, explants (n 
= 4) in each experimental group were retrieved 4 weeks post-implantation (Figure 2.4A) 
and stained with von Willebrand factor (vWF) antibody (Figure 2.4B). The section 
surface area occupied by vWF-positive blood vessels to total section surface area ratio 
was ca1culated and expressed as a percentage (Figure 2.4C). Our results demonstrate that 
soluble hK5His domain is capable of exerting a potent anti-angiogenic effect (P = 0.04) 
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Figure 2.4. hK5His acts as a potent anti-angiogenic agent. (A) Implant (arrow) 
retrieval 4 weeks post-implantation of 2 x 104 Matrigel™ -embedded U87-GFP or U87-
hK5His-GFP cells (representative images are shown at the same magnification). (B) 
Representative images of vWF-positive immunostained blood vessels (red arrows) from 
two different U87-GFP-containing (a, b) and U87-hK5His-GFP-containing (c, d) 
implants; magnification 200X. (C) The vWF-positive blood vessel surface area to total 
section surface area ratio is plotted as a percentage; bars, S.E.M. (S.E.M. for Matrigel™-
only group was based on 3 random section counts from 1 animal since remaining 
implants resorbed completely). Statistical analysis was performed using the student t-test. 
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in vivo when secreted by retrovirally-engineered glioma cells. The remaining explants (n 
= 6) in each experimental group were dissolved in a collagenase solution and single-cell 
suspensions were generated and counted. (Figure 2.5A, left). The hK5His-GFP explants 
contained about two thirds less cells than the control GFP explants (P = 0.01). The 
cellular infiltrate in the explants was analyzed for GFP expression as well as for cell 
surface marker expression to distinguish the various cell types present within the explants 
(Figure 2.5A, right). The GFP positive cell fraction representing glioma cells, is 
significantly reduced in the hK5His-GFP explants as compared to the control GFP 
explants (P = 0.03). It is important to note that the difference in absolute tumor cell 
number is not due to differences in the proliferation rates of the control GFP and hK5His-
GFP glioma cells, since both possess equivalent proliferation rates in vitro (Figure 2.6). 
Although immunocompromised NOD-SCID mice possess functional macrophages and 
granulocytes, they lack functional T and B lymphocytes. Flow cytometry analysis after 
three-color staining indicated that a substantial part of the cellular infiltrate consisted of 
CD45-positive hematopoietic cells (Figure 2.5B, left). More specifically, there was a 
reduced absolute number ofrecruited CD45+Mac+Grl+ (P = 0.04) cells, which represents 
the monocyte/macrophage fraction and CD45+Mac3+Grl- (P = 0.03) cells, which 
represents the macrophages present in the U87-hK5His-GFP-containing explants as 
compared to the control U87-GFP-containing explants (Figure 2.5B). There was no 
significant difference in the number of CD45+Mac3-Grl + (P = 0.43) cells, representing 
the infiltrated granulocytes present in the explants. 
In order to confirm our in vivo observations, we tested whether hK5His could 
,~ inhibit macrophage migration in vitro. A migration assay was performed using human 
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Figure 2.5. hK5His possesses novel anti-macrophage property and decreases 
migration potential of human macrophages. (A) Lejt, Absolute total cell count 
performed post-collagenase digestion of the explants. Right, Absolute number of GFP 
positive cells was enumerated using flow cytometry and represents the GFP-marked 
glioma ceIls; bars, S.E.M. (B) Absolute number of infiltrated CD45+ hematopoietic ceIls, 
CD4S+Mac3+Grl + monocytes/macrophages, CD4S+Mac3+Grr macrophages and 
CD4S+Mac3-Grl + granulocytes in the explants; bars, S.E.M. Statistical analysis was 
performed using the student (-test. (C) Macrophages were exposed to various conditioned 
media for 24 hoUTs under serum stimulation. Basal invasion represents migrating 
macrophages under serum-free conditions; bars, S.E.M. Insets, Representative stains of 
migrated cells from each experimental group; magnification 200X. Statistical analysis 
was performed using the student t-test. 
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monocytes isolated from peripheral blood mononuclear cells that were stimulated with 
GM-CSF to differentiate into CD206+ macrophages (data not shown). The ability of 
macrophages to migrate through a gelatin matrix was assessed under serum-stimulated 
conditions, where macrophages were directly exposed to conditioned media collected 
from GFP-expressing glioma cells and hK5His-GFP-expressing glioma cells. The results 
indicate that soluble hK5His decreases the migration potential of human macrophages by 
approximately 60% as compared to the GFP control (P = 0.007, Figure 2.5C). 
2.4.4 Glioma Targeted hK5His Expression Suppresses Tumor Growth and Prolongs 
Survival in an Experimental Orthotopic Brain Cancer Model. 
In order to test the efficacy of retrovirally-engineered glioma cells secreting 
hK5His in a clinically relevant proof-of-principle experiment, 105 U87-GFP (n = 5) and 
U87-hK5His-GFP cells derived from either a single clone (n = 5) and an independently 
generated polyclonal population (n = 5) were implanted intracerebrally in athymic nu/nu 
(nude) mice. Mice were sacrificed 32 days post-implantation, brains were removed and 
processed for H&E staining (Figure 2.7A). Tumor volumes from each experimental group 
were estimated from H&E-stained cryostat sections and calculated as described in 
Materials & Methods. Consistent with our previous study (204), brain tumors in the GFP 
control group had extensive growth. In contrast, the U87-hK5His-GFP-implanted mice 
possessed significantly reduced mean tumor volumes (0.35 ± 0.18mm3 for the single 
clone population and 0.07 ± 0.03mm3 for the polyclonal population) as compared to the 
~- control U87-GFP-implanted (12.23 ± 6.07mm3) mice (P = 0.04) (Figure 2.7B). 
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Figure 2.7. Suppression of intracerebral U87MG glioma growth by soluble hKSHis. 
(A) H&E-stained brain tissue sections from control U87-GFP implanted mice (n = 5) and 
U87-hK5His-GFP implanted mice (n = 5) 32 days post-implantation. Representative 
stains are demonstrated at the same magnification, 40X. (D) Tumor volumes were 
estimated from post-mortem H&E-stained brain sections obtained from mice implanted 
with U87-GFP, U87-hK5His-GFP single clone (sc) and U87-hK5His-GFP polyclonal 
(pc) cells. The experiment was performed twice with similar results; bars, S.E.M., 
Student (-test performed. (C) Kaplan-Meier long-term survival curve of mice implanted 
with control U87 -GFP (n = 10) and U87 -hK5His-GFP (n = 15) cells. Log-rank statistical 
test performed. 
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We perfonned a long-tenn in vivo study, where we evaluated the survival of the 
therapeutic cohort implanted with U87-hK5His-GFP cells (n = 15) and the control U87-
GFP-implanted (n = la) mice. Although all control mi ce succumbed to excessive tumor 
burden by ~8 weeks, the U87-hK5His-GFP-implanted mice possessed a clear survival 
advantage with 53% ofthe mice surviving over 120 days (P <0.0001) (Figure 2.7C). 
2.5 DISCUSSION 
This present study demonstrates that eukaryotically-expressed secreted hK5His 
protein preserves the prototypical native kringle disulfide bridging confonnation deemed 
essential for the angiostatic activity of plasminogen-derived peptide domains. lndeed, our 
cysteine bridging pattern data confinns the results of the only other study which 
characterizes the structure of recombinant K5 domain using NMR technology (205). We 
have shown that VSV -G pseudotyped retro viral vectors engineered to express human Plg 
hK5His domain can efficiently gene-modify human U87 glioma cells ex vivo. We also 
demonstrate that hK5His-engineered U87 cells can secrete biologically functional soluble 
hK5His protein capable of inhibiting growth factor-stimulated endothelial cell migration 
in vitro. 
Moreover, our in vivo data in immunodeficient NOD-SCID mice suggests that 
hK5His secreted by Matrigel™-embedded U87 engineered cells acts as a potent anti-
angiogenic agent by significantly decreasing blood vessel fonnation as well as a novel 
anti-macrophage agent by significantly preventing the recruitment ofhost-derived tumor-
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associated CD45+Mac3+Grl +/- monocytes/macrophages within the local tumor 
microenvironment. The involvement of tumor-associated macrophages in angiogenesis 
and tumor progression is a well established concept (206-208). Activated macrophages 
pro duce tumor necrosis factor-u and IL-l, inducing the production of VEGF and IL-8 in 
glioma cells, which further attracts and activates macrophages (209). Macrophage 
infiltration has been closely correlated with neovascularization and observed more 
frequently in grade IV glioblastomas than in grade II or III gliomas (209). 
It may be speculated that the potent anti-angiogenic properties of soluble K5 
mediating a reduction in tumor-associated endothelial cells, as evidenced by the lower 
surface area occupied by blood vesse1s in the U87-hK5His-GFP-containing explants, is 
partially responsible for the decreased infiltration ofhost-derived macrophages within the 
tumor area. We also demonstrate that soluble hK5His independently reduces macrophage 
migration in vitro, suggesting that the K5 domain can impart a direct inhibitory effect on 
macrophage motility. To date, the K5 peptide has been consistently characterized as an 
endothelial cell-specific inhibitor (128, 129) and Gonzalez-Gronow et al. (138) suggest 
that K5 mediates its effects by binding to the human voltage-dependent anion channel, 
which is a receptor present on human endothelial cells. Unlike K5, the mechanism of 
action of angiostatin has been studied more extensively and its endothelial cell binding 
sites include the cell surface-associated ATP synthase receptor (62), angiomotin (64) and 
integrin u v J33 (119). Although angiostatin mediates its inhibitory action primarily on 
endothe1ial cells, it has been reported by Moulton et al. (210) that it reduces plaque 
angiogenesis and atherosclerosis by reducing plaque-associated macrophages. However, 
Moulton et al. suggest that angiostatin, at doses that reduce endothelial cell sprouting, 
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does not directly inhibit monocytes since it do es not inhibit VEGF-induced monocyte 
migration in vitro. Thus, our findings provide novel mechanistic insight and suggest that 
soluble hK5His protein inhibits two unique cell types most critical for tumor 
angiogenesis, mediating a dual role as an anti-angiogenic agent via its anti-endothelial 
cell properties as weIl as an anti-tumor agent by reducing the infiltration of host-derived 
macrophages within the tumor microenvironment. 
We utilized a clinically relevant orthotopic implantation approach to test whether 
soluble hK5His could suppress glioma progression post-implantation of hK5His-GFP-
expressing U87 cells in athymic nu/nu mice. Stereotactic implantation procedures are 
particularly suitable for glioma gene therapy approaches allowing for constant long-
lasting transgene expression within the local tumor microenvironment and minimize the 
risk of toxicity as is often encountered with systemic therapies. Our data successfully 
demonstrates that soluble hK5His significantly decreases tumor growth by approximately 
97% as compared to controls. In doing so, soluble hK5His also promotes long-term 
survival, with 53% of U87-hK5His-GFP-implanted mice surviving past 120 days. We 
postulate that upon stereotactic implantation of our ex vivo retrovirally-engineered 
hK5His glioma ceIls, stable integration and sustained expression of the hK5His transgene 
~ 
in target U87 cells provided continuous release of soluble hK5His within the loco-
regional tumor microenvironment, resulting in potent suppression of tumor growth. We 
speculate that tumor-targeted delivery of hK5His via viral vectors such as pseudotyped 
retrovectors (200) and other gene delivery platforms would lead to similar results. 
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In summary, we pro vide compelling evidence that secreted hK5His protein 
expressed by engineered glioma cells possesses potent anti-angiogenic as well as novel 
anti-macrophage properties which block glioma progression and promote survival in an 
orthotopic experimental brain cancer model. Further studies on the pleiotropic effects of 
K5 peptide on host-derived angiogenic and macrophage response may offer new avenues 
of exploration for the development of therapeutic strategies for the treatment of glioma 
and other loco-regional refractory malignancies such as prostate and ovarian cancer. 
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CHAPTER3 
Plasminogen Kringle 5 Blocks Tumor Progression by Anti-Angiogenic and 
Pro-Inflammatory Pathways. 
Reference: Perri SR, Martineau D, Francois M, Lejeune L, Bisson L, Durocher Y, 
Galipeau J. Plasminogen Kringle 5 Blocks Tumor Progression by Anti-Angiogenic 
and Pro-Inflammatory Pathways. Molecular Cancer Therapeutics. 2007;6(2): 1-9. 
(Figure se!ected as Caver Art). 
Preface: In Chapter 2, we demonstrated that soluble human plasminogen kringle 5 (K5) 
protein produced by gene-modified human glioma cells possesses potent anti-angiogenic 
as well as novel macrophage inhibitory properties when tested in immunodeficient mice. 
In order to determine whether soluble K5 protein modulates other immune cellular 
effectors, we tested the efficacy of soluble K5 protein in a munne mammary 
adenocarcinoma model using mice with intact immune systems. 
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3.1 ABSTRACT 
Proteolytic processing of human plasminogen generates potent anti-angiogenic 
peptides such as angiostatin. The plasminogen kringle 5 (K5) domain - which is distinct 
from angiostatin - possesses potent anti-angiogenic properties on its own which can be 
exploited in cancer therapy. It has been recently observed that anti-angiogenic agents 
promote leukocyte-vessel wall interaction as part of their anti-tumor effect. Though we 
have previously shown that K5 suppresses cancer growth in tumor xenograft models, its 
modulation of inflammation in experimental mice with intact immune systems is 
unknown. To determine whether K5 possesses immune pro-inflammatory properties, we 
investigated the effects of K5 in an immune competent model of breast cancer and 
observed that tumor rejection is substantially reduced in NOD-SCID and BALB/c nude 
when compared to wild-type BALB/c mice, suggesting an important role for T -lymphoid 
cells in the anti-tumor effect of K5. Tumor expIant analysis demonstrates that K5 
enhances tumor recruitment of CD3+ lymphoid cells, in particular the NKT phenotype. 
We also observed a significant decrease in tumor-associated microvessel length and 
density consistent with anti-angiogenic activity. Histological analysis of K5 tumors also 
revealed a robust neutrophilic infiltrate, which may be explained by the neutrophil 
chemotactic activity of K5 as well as its ability to promote CD64 upregulation within the 
CD Il b + adhesive neutrophil population. In sum, our findings confirm that the K5 protein 
acts as a potent angiostatic agent and possesses a novel pro-inflammatory role via its 
ability to recruit tumor-associated neutrophils and NKT -lymphocytes, leading to a potent 
anti-tumor response. 
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3.2 INTRODUCTION 
Proteolytic cleavage products of plasminogen - as weIl as individual plasminogen 
kringle domains such as kringle 5 - possess anti-angiogenic properties whose use in 
cancer therapy is under much scrutiny (60, 86, 88, 128, 205, 211). It has been recently 
proposed that an array of angiostatic agents - including plasminogen derivatives like 
angiostatin - can significantly stimulate leukocyte-vessel wall interactions in vivo by the 
up-regulation of endothelial adhesion molecules in tumor vessels (212) and may enhance 
anticancer immune response and allow the immune system to overcome tumor immune 
resistance (213). However, in the setting of experimental peritonitis, angiostatin has also 
been shown to behave as an antiadhesive/anti-inflammatory substance (214). The sum of 
these observations readily supports the anti-angiogenic properties of angiostatin in the 
setting of pathological neovascularization, but its immune modulatory effects remain 
controversial. The fifth kringle domain of plasminogen (hereafter K5), when utilized on 
its own displays robust anti-angiogenic properties (86, 128, 211) and will also directly 
lead to apoptosis of anoxie tumor cells in vitro (148). These features make K5 an 
appealing anti-tumor biopharmaceutical with combined anti-tumoral as weIl as anti-
angiogenic properties. Indeed, we have previously demonstrated that genetic engineering 
of tumor cells for expression of K5 abolishes tumor growth in vivo, potently suppresses 
cancer-associated angiogenesis and will inhibit recruitment of tumor-associated 
macrophages in an immune deficient human tumor xenograft model (169). The latter 
observation suggests that K5 may possess immune modulatory properties on blood-
derived immune competent cells - in keeping with the observations made by others with 
angiostatin. To address the question of K5 influence on immunity, we compared the 
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biology of K5-engineered breast tumor cells in immune defective mice as well as in 
tumor MHC-matched mice with normal immune systems. As expected, we find that K5 
is a potent inhibitor of cancer-associated angiogenesis. However, we also observed that 
the anti-tumor effect of K5 is utterly dependent on an intact immune system, in particular 
on the T -lymphocyte subset, and that recruitment of polymorphonuclear cells is a 
dominant feature of K5 tumors. These observations provide new evidence that the K5 
plasminogen derivative possesses anti-angiogenic as well immune stimulatory anti-tumor 
properties. 
3.3 MATERIALS AND METHODS 
3.3.1 CeU Culture Reagents. 
293GPG pantropic retrovirus-packaging cell line (198) was a gift from Dr. 
Richard C. Mulligan (Children's Hospital, Boston, MA). Murine mammary 
adenocarcinoma DN3 cell line (215) was a gift from Dr. Moulay Alaoui-Jamali (Lady 
Davis Institute, Montreal, Quebec, Canada). 
3.3.2 VSV -G Pseudotyped Retroviral Vector Design, Synthesis and Titer 
Assessment. 
The bicistronic murine retrovector pIRES-EGFP was previously generated in our 
laboratory (200) and contains an enhanced green fluorescent protein (EGFP). The 
hK5His cDNA was ligated into pIRES-EGFP to generate phK5His-IRES-EGFP. The 
hK5 cDNA was histidine-tagged for protein detection and purification purposes, since 
there is no commercially available anti-human K5 antibody. VSV-G pseudotyped 
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retroparticles encoding hK5His-IRES-EGFP were generated by tetracycline-withdrawal 
as previously pub li shed (200, 201). Engineered retroparticles were devoid of replication-
competent retrovirus as determined by GFP marker rescue assay utilizing conditioned 
media from target cens. The titer of the control GFP and hK5His 293GPG single clone 
population was assessed as previously described (201). 
3.3.3 Transduction of Murine Mammary DAl3 Cells. 
DAl3 cens were transduced with hK5His-expressing retroviral particles as 
previously described (200). Stably transduced DAl3 cens were culture-expanded and 
sorted to obtain polyclonal populations based on GFP expression using a Becton 
Dickinson F ACST AR sorter. 
3.3.4 Western Blot Analysis. 
Conditioned media was conected from confluent DAl3-GFP control and hK5His-
GFP transduced DAl3 cens, concentrated and detected by anti-His immunoblot analysis 
as previously described (169). 
3.3.5 In Vivo Matrigel™ Assay and Analysis of Cellular InÏlltrate by Cytometry. 
Culture-expanded DAl3-GFP and DAl3-hK5His-GFP cens were aliquoted to 
create 50).11 ceIl suspensions containing 106 ceIls, mixed with 500).11 Matrigel™ (a semi-
solid matrix derived from a murine sarcoma ceIlline, BD Biosciences, San Jose, CA) at 
4°C and implanted subcutaneously in the right lateral flank of 6-week old 
immunocompetent BALB/c mi ce (Jackson Laboratories, Quebec, Canada). Three days 
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post-implantation mice were sacrificed, implants excised and processed as previously 
described (203). To determine the expIant cellular infiltrate, cell suspensions were stained 
with the following antibodies: purified rat anti-mouse CD16/CD32 (mouse Fc block) 
followed by APC-conjugated rat anti-mouse CD45, APC-conjugated rat anti-mouse CD3, 
PE-conjugated rat anti-mouse CD4, PE-Cy7-conjugated rat anti-mouse CD25, FITC-
conjugated rat anti-mouse CD8, PE-conjugated rat anti-mouse NK-T/NK and their 
corresponding isotypic controls. AlI antibodies were purchased from BD Pharmingen, 
San Diego, CA. Cells were fixed with 1 % paraformaldehyde and events were acquired 
using a F ACSCalibur flow cytometer (Beckman Coulter, Fullerton, CA) and analyzed 
using the CellQuest software (BD). 
3.3.6 Matrigel™ Expiant Histochemistry. 
Mice were sacrificed, implants excised, fixed in formalin, embedded in paraffin 
and 41lm sections were prepared in order to generate representative sections of the border 
and central regions of the explants. Sections were either stained with hematoxylin and 
eosin or underwent an antigen retrieval pro cess using two microwave boils in a 1 OmM 
sodium citrate buffer (pH 6.0) solution. Endogenous biotin activity was blocked using a 
kit (Zymed Laboratories, Markham, Ontario), sections were subsequently blocked with 
2.5% bovine serum albumin in PBS and incubated with a rabbit polyclonal raised against 
murine von Willebrand factor (vWF; Neomarkers, Fremont, CA dilution 1: 1 00) 
ovemight. After three washes, the sections were incubated with biotinylated goat anti-
rab bit IgG antibody (BD Pharmingen, dilution 1 :200) for 2 hours, washed and incubated 
with streptavidin-peroxidase (VectorLabs, Burlingame, CA) for 1 hour prior to the 
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addition of 3,3'-diaminobenzidine (DAB) chromogenic substrate (VectorLabs). Meyer's 
hematoxylin was used for counterstaining. The microvessel length was measured on 
thirty randomly selected vWF-positive vessels from each experimental group using an 
ocular and stage micrometer and the microvessel density was calculated by counting aIl 
vWF-positive vessels on 3 randomly selected sections from each group using a Leica 
light microscope (Leica Microsystems Inc., Richmond Hill, Ontario, Canada) at 400X 
magnification and dividing by the total section surface area. The mean number of vWF-
positive blood vessels per mm2 was plotted. 
3.3.7 Production of Purified Kringle 5 Protein. 
Human embryonic kidney 293 cells were transiently transfected in a large-scale 
system with a K5-containing expression vector, conditioned media was collected 72 
hours post-transfection, concentrated and purified using an immobilized metal affinity 
chromatography system (Novagen, La Jolla, CA). Eluted protein fractions were analyzed 
by anti-His immunoblot. Semi-quantitative anti-His immunoblot was performed to 
quantify the amount of K5 protein (data not shown). 
3.3.8 Neutrophil Isolation. 
Heparinized whole blood (50mL) was collected from a healthy human donor, 
layered over a Ficoll-density gradient and centrifuged at 1600rpm for 30 minutes. The 
polymorphonuclear neutrophil (PMN)-rich fraction was collected and resuspended in 
0.9% NaCl. Red blood cells (RBCs) were lysed by exposure to cold 0.2% NaCI for 30 
seconds, followed by neutralization with cold 1.6% NaCI and spun at 1000rpm for 5 
minutes. Lysis steps were repeated until RBC fraction was removed. Calcein AM 
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(Molecular Probes, Eugene, OR) (lOmg/mL) was added to a 5mL PMN suspension in 
Hank's Balanced Salt Solution (HBSS) and cells were incubated for 30 minutes at 37°C. 
PMN were then washed twice with PBS, counted and resuspended in OPTI-MEM to the 
desired concentration. 
3.3.9 Fluorescence-Based PMN Migration Assay. 
A 96-well 3f..lm pore size chemotaxis chamber (ChemoTx, Neuro Probe, 
Gaithersburg, MD) was utilized and the migration assay was performed as described by 
Frevert et al. (216). Briefly, the bottom chambers were filled with 29f..l1 of either 
increasing concentrations of purified hK5His protein (80 to 160ng) diluted in OP TI-
MEM or OPTI-MEM alone as a negative control. In order to determine the total 
fluorescence of PMN added to the top si de of the filter, 25f..l1 of each cell suspension (0, 
0.25, 0.5, 1.0, 2.0 3.0, 5.0 X 106 PMN/mL) was placed directly in duplicate wells in the 
bottom chamber. The polycarbonate filters were positioned on the loaded microplate and 
secured in place with corner pins. PMNs (7.5 x 104, 50f..l1) were placed directly onto the 
filter sites and the chamber was incubated for 7 hours at 37°C. The non-migrating cells 
on the top si de of the filter were removed by gently wiping the filter with a tissue. The 
chemotaxis filter was placed in a FLUOstar OPTIMA fluorescent plate reader (Fisher 
Scientific, Ottawa, Ontario, Canada) and the cells that migrated into the bottom chamber 
were measured by using the calcein fluorescence signal. The fluorescent plate reader was 
configured in order for the probe to be in a bottom-read position, which allows for 
detection of fluorescence in each well of the chemotaxis chamber (excitation, 485nm; 
/~ emission, 530nm). 
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3.3.10 Cell Staining. 
PMNs were exposed to increasing doses of purified hK5His protein (80, 120 or 
160ng) diluted in OPTI-MEM or OPTI-MEM alone as a negative control or phorbal 
myristate acetate as a positive control for 2 hours at 37°C. PMNs were then co-stained 
with PE-Iabeled anti-human CDllb antibody and biotin-Iabeled anti-human CD64 
antibody. Gene-modified DA/3 cells were stained with biotin-conjugated anti-H-2Kd 
(MHC-I) antibody. The biotinylated antibody was revealed using APC-streptavidin. 
Antibodies were purchased from BD Pharmingen, San Diego, CA. Cells were fixed with 
1 % paraformaldehyde and events were acquired using a F ACSCalibur flow cytometer 
(Beckman Coulter, Fullerton, CA) and analyzed using the CellQuest software (BD). 
3.4 RESULTS 
3.4.1 DA/3 mouse mammary tumor cellline retrovirally engineered to express 
plasminogen K5 domaine 
The human K5 histidine-tagged cDNA (hK5His) was cloned as previously 
described (169) into a bicistronic retroviral vector construct (200) (Figure 3.1A). The 
hK5His retrovector plasmid was stably transfected into 293GPG retroviral packaging 
cells and retrovirus producer cells were selected as described in Materials and Methods. 
Tetracycline-withdrawal from the culture media led to the production of VSVG-typed 
hK5His-GFP retro viral particles which were subsequently concentrated 100-fold by 
ultracentrifugation and a viral titer of ~2.5x106 infectious particles/mL was obtained. 
Concentrated VSVG-typed hK5His-GFP retroviral particles were utilized to transduce 
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Figure 3.1. Development and characterization of hKSHis-GFP gene-modified DAi3 
cells. (A) Human kringle 5 (hK5His) retrovector when integrated in DAl3 cells. hK5His 
consists of the last cryptic fragment of plasminogen (Cys462_Cys54I) and is composed of 
80 amino acid residues with 3 distinct disulfide bonds. (B) Anti-His immunoblot analysis 
reveals functional secretion of hK5His migrating at ~ 15kDa from retrovirally gene-
modified DAl3 cells. 
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the BALB/c-compatible DAl3 murine mammary cancer cell line. The DAl3 munne 
mammary adenocarcinoma cell line is estrogen independent and serves as a munne 
model of locally advanced breast cancer (215, 217-219). Following retroviral 
transduction, polyclonal gene-modified DAl3 cells were assessed for GFP expression by 
flow cytometry and sorted to obtain a 100% GFP-positive population. To ensure hK5His 
transgene expression and proper secretion, anti-His immunoblot analysis was performed 
on conditioned supernatant collected from hK5His transduced murine DAl3 mammary 
tumor cells and detects a major 15kDa protein consistent with the predicted molecular 
weight of soluble hK5His (Figure 3.1B). Using a semi-quantitative western blot titration 
curve, it was estimated that hK5His-GFP-expressing DAl3 cells secrete 0.02pmol/L (or 
0.25ng) of soluble hK5His protein per 106 cells per 24 hours (data not shown). 
3.4.2 Anti-tumor property of hK5His protein is dependent upon an intact immune 
system. 
We tested the efficacy of hK5His against breast cancer in mice with functional 
immune systems. One million DAl3 (n = 10), genetically engineered DAl3-GFP (n = 
10), or DAl3-hK5His-GFP (n = 10) polyclonal cells were implanted subcutaneously in 
immune competent BALB/c mi ce and animal survival was monitored over time. One 
year post-implantation, 65% of hK5His-GFP-implanted mice survived tumor-free (P < 
0.0001) as compared to 20% in both DAl3- and DAl3-GFP-implanted control mice 
(Figure 3.2A). The anti-tumor effect was severely diminished when 106 genetically 
110 
Figure 3.2. hK5His-GFP-implanted immunocompetent mice survive long-term and 
modulate the immune system to suppress tumor growth. Kaplan-Meier long-tenn 
survival of (A) immunocompetent Balb/c mice implanted subcutaneously with 106 non-
gene-modified DA/3 (n = 10), GFP-expressing DAl3 (n = 10) or hK5His-GFP-expressing 
DAl3 cells (n = 10). The experiment was perfonned twice with similar results. Kaplan-
Meier survival of (B) immunodeficient NOD-SCID mice and (C) athymic BALB/c nude 
mice implanted subcutaneously with 106 GFP-expressing DAl3 (n = 10, n = 6 
respectively) and hK5His-GFP-expressing DAl3 cells (n = 10, n = 6 respectively). (D) 
Kaplan-Meier survival of immunocompetent BALB/c mice implanted subcutaneously 
with irradiated 5 x 105 GFP-expressing DAl3 ("GFP", n = 10) or hK5His-GFP-
expressing DAl3 cells ("K5", n = 10) and challenged 14 days later (day 0 on graph) on 
the opposite flank with 5 x 105 non-irradiated GFP-expressing DAl3 cells. BALB/c mice 
("CTL", n = 10) were independently implanted subcutaneously with 5 x 105 non-
irradiated GFP-expressing DAl3 cells on the same day as the challenge as a technical 
control to demonstrate the tumor growth potential. Log-rank statistical test perfonned for 
aIl Kaplan-Meier graphs. 
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engineered DA/3-GFP (n = 10) or DA/3-hK5His-GFP (n = 10) polyclonal cells were 
implanted subcutaneously in immunodeficient non-obese diabetic severe combined 
immunodeficient (NOD-SCID) mice (Figure 3.2B). This mouse strain lacks functional 
endogenous T or B lymphocytes, due to a deficiency in the recombinase activating gene 
(RAG)-2 gene, which impairs rearrangement of separate gene elements of the 
immunoglobulin and T -cell antigen receptor genes and thus disrupts differentiation of 
both B and T -lymphocyte progenitor cells (220). Although hK5His-GFP-implanted mice 
succumbed to excessive tumor burden by 2 months post-implantation, their survival was 
significantly prolonged as compared to control mice (P < 0.0001), possibly due to the 
angiostatic property of hK5His protein. This observation suggests that the immune 
system is playing a role in the tumoricidal effects of hK5His protein. We proceeded to 
test whether the immune modulatory effect of hK5His protein was mediated via T 
lymphocytes by subcutaneously implanting 106 DA/3-GFP (n = 6) or DA/3-hK5His-GFP 
(n = 6) polyclonal cells in athymic BALB/c nude (T -lymphocyte deficient) mice 
(Figure 3.2C). Our results demonstrate that T lymphocytes are required for hK5His 
protein to exert its anti-tumor action, since all hK5His-GFP-implanted mice had to be 
sacrificed due to tumor development by 3 months post-implantation, albeit delayed 
survival compared to GFP-implanted control mice (P < 0.0005). In order to assess if 
hK5His protein elicited an adaptive systemic protective immune response, we 
subcutaneously implanted wildtype BALB/c mice with irradiated 5 x 105 DA/3-GFP (n = 
10) or DA/3-hK5His-GFP (n = 10) cells and 14 days later challenged the mi ce on the 
opposite flank with 5 x 105 non-irradiated DA/3-GFP cells (Figure 3.2D). Protective 
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immunity was not observed since there was no significant difference between the survival 
rate of challenged GFP-implanted and hKSHis-GFP-implanted mi ce (P = 0.37). 
3.4.3 hK5His protein expression by DAl3 ceUs leads to recruitment of CD3+ 
lymphocytes in vivo. 
To further characterize the immune cellular mediators involved in hKSHis protein 
anti-tumor effect, we embedded 106 DA/3-GFP (n = 4) or DA/3-hKSHis-GFP (n = 4) 
polyclonal cells in Matrigel™ and subcutaneously implanted the cells in 
immunocompetent BALB/c mice. Implants were retrieved 3 days post-implantation and 
collagenase-digested to obtain a single cell suspension. Cells in each experimental group 
were counted using a hemacytometer and the cellular infiltrate was analyzed by staining 
the single cell suspension with 4-color antibodies enabling the identification of different 
immune subsets by flow cytometry analysis. Our infiltrate analysis confirms that hKSHis 
protein secreted by gene-engineered DA/3 cells induces a potent host-derived cellular 
infiltrate including CD4S+ hematopoietic cells (Figure 3.3A). T-Iymphoid subset analysis 
(Figure 3.3B), demonstrates a substantial increase in the absolute number of infiltrated 
CD3+ lymphocytes (P < O.OOS), in particular CD3+NKT+ cells (P < O.OS). 
3.4.4 hK5His protein expression by DAl3 ceUs influences the quantity and sÎZe of 
tumor-associated microvasculature. 
We have previously demonstrated that hKSHis secretion by human glioma cells 
leads to a profound anti-angiogenic effect in NOD-SCID mice (169). To test whether 
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Figure 3.3. hKSHis possesses novel immunostimulatory property. (A) lefi Absolute 
total celI count performed post-colIagenase digestion of the explants 3 days post-
implantation of 106 GFP-expressing DA/3 (n = 4) or hKSHis-GFP-expressing DAl3 celIs 
(n = 4) embedded in Matrigel™; right Absolute number of infiltrated CD4S+ 
hematopoietic cells; bars, S.E.M. (B) Absolute number of infiltrated lymphoid cells: 
CD3+, CD3+CD4+, CD4+CD2S+, CD3+CD8+, CD8+CD2S+, CD3~KT+; bars, S.E.M. 
Statistical analysis was performed using the student t-test. 
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this effect was replicated in immune competent BALB/c mice, we embedded 106 DAl3 (n 
= 4), DAl3-GFP (n = 4) or DAl3-hK5His-GFP (n = 4) polyclonal cens in Matrigel™ and 
subcutaneously implanted the cens in BALB/c mice. One week post-implantation, the 
Matrigel™ plugs were retrieved (Figure 3.4A), sectioned and stained with von 
Willebrand factor (vWF) antibody (Figure 3.4B, left panel). The number (Figure 3.4C) as 
wen as the length (Figure 3.4B, right panel) ofblood vessels was significantly reduced in 
the hK5His plugs consistent with a potent anti-angiogenic effect in vivo. 
3.4.5 hK5His induces neutrophilic tumor infiltration. 
In an effort to understand the effect of hK5His on host-derived inflammation, we 
embedded 106 DAl3 (n = 4), DAl3-GFP (n = 4) or DAl3-hK5His-GFP (n = 4) polyclonal 
cens in Matrigel™ and subcutaneously implanted the cens in immunocompetent BALB/c 
mice. Implants were retrieved 3 days post-implantation, sectioned, stained with 
hematoxylin and eosin (H&E) and analyzed by a veterinary pathologist (co-Author: DM). 
The histological analysis revealed that there were almost no intact islet (acini) of tumor 
cells in the hK5His-containing implants as compared to the GFP-containing implants 
(Figure 3.5E, P = 0.0001), where there was a moderate number ofislets, sometimes acini, 
of intact tumor cens present at the periphery of the implants as seen in Figure 3.5A & c. 
The DAl3-hK5His-GFP tumor cells occurred as single cells, rarely in pairs, in contrast 
with the DAl3-GFP tumor cens which occurred in islets of at least 6 cens. Most of the 
DAl3-hK5His-GFP tumor cens observed were either necrotic or degenerated (Figure 
3.5D & F) and were often surrounded by inflammatory cells as compared to the DAl3-
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Figure 3.4. hK5His acts as a potent anti-angiogenic agent. (A) Implant (arrow) 
retrieval 1 week post-implantation of 106 Matrigel™ -embedded DAl3, DA/3-GFP or 
DAl3-hK5His-GFP cells (representative images are shown at the same magnification). 
(B) left panel Representative images of vWF-positive immunostained blood vessels 
(black arrows) from two different DAl3-GFP-containing (a, b) and DAl3-hK5His-GFP-
containing (c, d) implants; C, center of implant; B, border of implant; magnification 
160X; right panel The mean vWF-positive vessel length (Jlm) is plotted for both 
experimental groups; bars, S.E.M. (C) The microvessel density is plotted as the mean 
number of vWF-positive blood vessels divided by the mean section surface area (mm2); 
bars, S.E.M. Statistical analysis was perforrned using the student t-test. 
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Figure 3.5. hK5His protein induces dense pericapillary neutrophilic infiltra te. H&E-
stained Matrigel expIant sections retrieved 3 days post-implantation containing either 
GFP-expressing DAl3 cells (A, 2.5X & C, 20X) or hK5His-GFP-expressing DAl3 cells 
(B, 2.5X, D, 40X & E, 40X). (B) inflammatory infiltrate (red arrows) demonstrated, (C) 
eosinophils present along the border region (red arrows) and tumor islets composed of 6 
cells (black arrows) are depicted, (D & F) neutrophils within the center region as well as 
within the border capsule region (red arrows) and representative examples of necrotic 
tumors (black arrows) are shown. (E) Quantitative histological analysis representing the 
number of intact tumor cells per high power field (left) and the number of neutrophils per 
border region (right) composed of concentric layers of edematous immature connective 
tissue; bars. S.E.M. Statistical analysis was performed using the student t-test. 
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GFP tumor cells that appeared healthy (no vacuolation, no swelling, no loss of tinctorial 
affinity, acinar or islet architecture preserved). Both GFP- and hK5His-GFP-containing 
implants were incompletely surrounded by a capsule at the border regions (Figure 3.5C & 
F respectively) composed of concentric layers of edematous immature connective tissue 
(fibroblasts with variable numbers ofinflammatory cells). We observed that the hK5His-
GFP-containing implants were markedly thickened by a dense population of 
inflammatory cells (Figure 3.5B & D) composed of at least 50% neutrophils, qualified as 
suppurative inflammation. Enumeration confirmed a substantial increase in the number of 
infiltrated neutrophils in the hK5His-GFP-containing implants as compared to the control 
implants (Figure 3.5E, P = 0.0001). There were several eosinophils in the border zone of 
both groups. However, there was no significant difference in the number of infiltrated 
eosinophils between test and control (data not shown). 
3.4.6 hK5His protein is chemotactic for neutrophils and promotes their activation. 
In order to explain the enhanced recruitment of host-derived neutrophils within 
the hK5His-GFP-containing implants, we assessed the ability of soluble hK5His protein 
to act as a neutrophil chemoattractant. PMN isolated from heparinized human peripheral 
blood as described in the Materials and Methods were assayed for cell-surface expression 
of the adhesion marker CD Il b (Mac-1) by flow cytometry analysis, and were found to be 
strongly positive (Figure 3.6A). PMN were plated on the top surface of the migration 
filter and exposed to either increasing doses of purified hK5His protein (80, 120 or 
160ng) diluted in OPTI-MEM or OPTI-MEM a10ne as a control. We observed that 
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Figure 3.6. hK5His protein acts as a neutrophil chemoatfractant and promotes 
activation. (A) Expression of CD11b cell-surface adhesion marker on isolated PMN; 
isotype antibody (leJt), test antibody (right). (B) Relative fluorescence units (RFU) of 
migrated PMN toward either increasing doses of purified hK5His protein (80, 120, 
160ng) diluted in OPTI-MEM or OPTI-MEM alone. (C) Percent expression of 
CD11b+CD64+ PMN post-exposure to either increasing doses ofpurified hK5His protein 
(80, 120, 160ng) diluted in OPTI-MEM or OPTI-MEM alone or phorbal myristate acetate 
(PMA, lOf..lg/mL) as a positive control; bars, S.E.M. Statistical analysis was performed 
using the student (-test. 
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hK5His protein acts as a potent neutrophil chemoattractant and displays a dose-response 
effect (Figure 3.6B). Additionally, we demonstrate that neutrophil exposure to soluble 
hK5His protein induces increased cell-surface expression of the granulocyte activation 
marker CD64 (Fey receptor 1) within the CDllb+ (Mac-1) adhesive neutrophil subset 
(Figure 3.6C). These findings are consistent with our histological analysis and suggest 
that soluble hK5His protein produced by gene-modified DN3 cells acts as a strong 
neutrophil chemoattractant as weIl as promotes activation of neutrophils within the tumor 
microenvironment. 
3.4.7 MHC 1 expression in hK5His-expressing DA/3 cells. 
MHC 1 is a key molecule involved in immune surveillance and its level of 
expression may influence interaction with innate effectors (221-224). Therefore, we 
ascertained whether hK5His altered this phenotype. We assessed the cell-surface 
expression of major histocompatibility antigen (MHC) class 1 on GFP- and hK5His-GFP-
expressing DN3 ceIls by flow cytometry. Our results indicate that hK5His-GFP-
expressing DN3 ceIls express similar levels (54.4%) of MHC-I (H-2Kd) molecule as 
GFP-expressing DN3 ceIls (64.1 %) (P> 0.05) (data not shown). 
3.5 DISCUSSION 
We have previously demonstrated that tumor-expressed hK5His leads to a 
substantial anti-angiogenic effect and cure of human glioma orthotopic xenografts in a 
majority of athymic nu/nu nude mi ce (169). In the CUITent study, we observed that 
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NOD-SCID and athymic nude BALB/c mice with impaired T -lymphoid immune systems 
do not mount as effective an anti-tumor response to DA/3 cells expressing hK5His, when 
compared to immunologically normal rodents. Furthermore, despite apparent long term 
cures lasting more than 1 year in normal BALB/c mice, we were unable to demonstrate 
an effective adaptive immune response to tumor challenge, suggesting that components 
of the innate immune system play an important role in the effectiveness of K5 anti-tumor 
properties (Figure 3.2). These observations are congruent with the hypothesis that anti-
angiogenic compounds derived from plasminogen and other sources have pleiotropic 
effects, which likely involve a synergistic recruitment of an inflammatory anti-tumor 
response (212, 213). We have observed that tumor expression of hK5His leads to a 
robust CD3+ lymphoid tumor infiltration, in particular NKT cells, suggesting a role for 
these immune effector cells in K5-mediated tumor rejection (Figure 3.3). Histological 
examination of tumor implants confirmed a robust suppreSSIOn of cancer 
neovascularization (Figure 3.4) as well as a marked neutrophilic suppurative reaction 
(Figure 3.5). This neutrophilic infiltration may be mediated by soluble K5 protein, which 
we demonstrate acts as a chemoattractant for neutrophils and promotes upregulation of 
the CD64 granulocyte activation marker (Figure 3.6). This observation follows in the 
stead of the recently discovered property of an array of anti-angiogenic pharmaceuticals -
including plasminogen derivatives such as angiostatin - to alter the phenotype of cancer-
associated neovasculature in a manner which leads to enhanced tumor recruitment of 
leukocytes. Dirkx et al., recently reported that a synthetic angiogenesis inhibitor, anginex, 
enhances leukocyte-vessel wall interactions in tumor vessels by upregulating tumor 
endothelial VCAM-l and E-selectin expression, and subsequently increasing infiltration 
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of CD45+ leukocytes and cytotoxic CD8+ lymphocytes into the tumor to suppress tumor 
growth (212). Although Dirkx et al., report that angiostatin can also increase the 
leukocyte-vessel wall interaction in vivo, Chavakis et al., daim that angiostatin acts as an 
anti-adhesive and anti-inflammatory agent since it inhibits peritonitis-induced neutrophil 
emigration in vivo via its interaction with a4~ 1-integrin and Mac-1 (aM~2-integrin) 
(214). Our observation that K5 enhances recruitment ofNKT cells and neutrophils is in 
support of a pro-inflammatory mode of action and buttresses the theory that inflammation 
and microvascular suppression act synergistically in the observed anti-tumor effects of 
hK5. Our survival data in both immunodeficient NOD-SCID and BALB/c nude mice 
demonstrates that although host-derived neutrophils may be implicated in suppressing 
tumor progression, their presence is not sufficient in T -cell deficient mi ce to eradicate the 
tumor, suggesting a cooperative anti-tumor effect between these immune effector cells. 
There is precedence for combined lymphocytic and neutrophilic involvement in tumor 
rejection. Cairns et al., (225) reported that gene-engineered myeloma cells expressing 
lymphotactin induced infiltration of CD4+, CD8+ and neutrophils leading to effective 
tumor regression in vivo. Lee et al., (226) described that in vivo injection of IL-8-
transfected human ovarian cancer cells induced dramatic neutrophilic infiltration and 
resulted in decreased tumor growth. In the context of anti-angiogenic therapy, Pike et al., 
(227) also observed in vivo neutrophilic and lymphocytic infiltration in vasostatin 
(angiogenic inhibitor)-treated Burkitt lymphoma tumors, which led to tumor suppression. 
Work from Abbott Laboratories demonstrates that cancer cells rendered anoxic in 
vitro translocate GRP78 to the cell membrane which then serves as a ligand for K5. K5-
bound GRP78 thereafter initiates an apoptotic cascade (148). The significance of this 
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phenomenon was not tested in experimental animaIs; however it dearly buttresses the 
daim that K5 can directly affect the phenotype and cellular function of tumor cells. We 
did not observe an increased apoptosis index or reduced cell growth of K5-expressing 
DAl3 cells in standard tissue culture conditions or in a 3% oxygen hypoxic environment, 
nor were we able to detect membrane-bound GRP78 despite its intracellular abundance in 
DAl3 cells (data not shown). These observations suggest that K5 likely interacts with 
tumor cells via a plurality of pathways of which GRP78 may be one in certain 
circumstances. Thus, it may be speculated that hK5His protein breaks immune tolerance 
by inducing a cross-talk to occur between host-derived neutrophils and other innate 
infiltrating immune cells such as NKT -lymphocytes. Furthermore, K5 from DAl3 may 
lead to an altered adhesive phenotype of tumor-associated vessels and promote local 
recruitment of leukocytes from blood stream. 
In aggregate, our data confirms the anti-angiogenic potency of hK5His and 
suggests that hK5His protein also relies upon multiple innate cellular effectors to induce 
its in vivo anti-neoplastic effect. More specifically, our findings demonstrate that hK5His 
protein requires functional neutrophils and T-lymphocytes in order to induce optimal 
tumor rejection. Further studies on the pleiotropic effects of K5 protein on vasculature 
and inflammatory effector cells may provide new insights allowing K5 to be 
therapeutically exploited to treat cancer. 
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CHAPTER4 
Angiostatin Blocks Macrophage Migration. 
Reference: Perri SR, Annabi B, Galipeau J. Angiostatin Blocks Macrophage Migration. 
2007. (manuscript submitted to The FASEB Journal). 
Preface: Tumor-associated macrophages (T AM) play a pivotaI role in promoting tumor 
growth and metastasis. Thus, strategies to prevent the recruitment of T AM are appealing 
as potentiai anti-cancer therapeutics. In Chapter 2, we demonstrated that hum an 
plasminogen kringle 5 acts as an anti-macrophage agent by suppressing T AM recruitment 
in vivo and by blocking in vitro migration of human monocyte-derived macrophages. In 
Chapter 4, we investigated if other internaI plasminogen fragments possessing anti-
angiogenic activity such as angiostatin aiso induced macrophage inhibitory properties. 
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4.1 ABSTRACT 
In light of the involvement of tumor-associated macrophages (T AM) in the 
promotion of tumor growth and inetastasis, strategies to prevent TAM infiltration within 
the tumor microenvironment are currently under investigation. Our laboratory previously 
demonstrated that human plasminogen (PIg) kringle 5 (K5) protein blocks recruitment of 
host-derived tumor-infiltrating macrophages in vivo and suppresses the migration of 
human monocyte-derived macrophages in vitro. In addition, the recent observation that 
angiostatin reduces macrophage infiltration in an atherosclerosis model prompted our 
laboratory to further explore the use of angiostatin as a macrophage inhibitory agent. We 
demonstrate that angiostatin blocks migration ofboth murine peritoneal macrophages and 
human monocyte-derived CD206+ macrophages in vitro. Furthermore, we show that 
angiostatin leads to a decrease in the gelatinolytic activity of macrophage-produced 
matrix metalloproteinase-9, which may explain, in part, the observed angiostatin-
mediated inhibition of migration. Additionally, we detect the presence of the p-subunit of 
ATP synthase on the cell-surface of macrophages by immunoblot analysis. ATP synthase 
was previously found to be a receptor for angiostatin on the cell-surface endothelial cells. 
We propose that the presence of A TP synthase on the surface of macrophages may 
promote interaction with angiostatin and prevent migration, similar to what has been 
reported with endothelial cells. Our findings suggest that angiostatin holds promise as an 
inhibitory agent against macrophages. 
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4.2 INTRODUCTION 
It is weIl established that tumor-associated macrophages (TAMs) are implicated 
ln tumor progression and metastasis. T AMs are skewed toward the M2 phenotype 
(polarized type II macrophages) (228), which is oriented toward promotion of 
angiogenesis, tissue remodeling and repair (228). T AMs are typified by low cytotoxic 
potential against tumor cells due to reduced production of nitric oxide (NO) and pro-
inflammatory cytokines (229). T AMs may possess decreased inflammatory cytokine 
production as a consequence of their exposure to tumor-derived anti-inflammatory 
molecules such as interleukin (lL)-4, IL-10, transforming growth factor-~l and 
prostaglandin E2 (230, 231). Type II macrophages promote tumor cell proliferation and 
metastasis by producing an array of pro-angiogenic factors and metalloproteinases 
(MMP) as weIl as their involvement in signaling pathways regulating the function of 
fibroblasts in the tumor stroma (228,229,232,233). Several reports have demonstrated a 
correlation between infiltration of T AMs and prognosis in cancer patients, whereby 
increased macrophage infiltration resulted in worse prognosis (232, 234-236). T AMs 
have also been associated with immune suppression and tolerance (237) as weIl as 
inhibition of T cell responses by upregulating NO, prostaglandins, tumor necrosis factor-
a and arginase activity leading to apoptosis of activated T cells (238, 239). 
T AMs are derived from circulating monocytes and are recruited to the tumor 
microenvironment by tumor-produced monocyte chemotactic factors (240) sorne of 
which include: CCL2/monocyte chemoattractant protein (MCP)-l (produced by gliomas, 
sarcomas, lung, breast, cervix, ovary, melanoma and pancreatic cancer) (241-244), 
~' CXCL8/IL-8 (produced by breast and melanoma) (245, 246) and CCL5/RANTES 
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(Regulated on Activation, Normal T -cell Expressed and Secreted, produced by breast and 
melanoma) (247, 248). High expression of monocyte chemotactic factors is associated 
with increased macrophage infiltration (249). Upon T AM tumor infiltration, cancer cells 
sustain T AM survival, which subsequently induces T AMs to produce growth factors and 
matrix degradation enzymes leading to tumor proliferation, angiogenesis and invasion 
(230, 250-252). 
It would thus be desirable to further explore strategies to reduce T AM infiltration 
in the tumor microenvironment. Our laboratory demonstrated that human plasminogen 
kringle 5 (K5) domain acts as a potent anti-angiogenic agent as weIl as blocks migration 
of human monocyte-derived macrophages in vitro and substantially reduces CD45+Mac-
3 + Gr- r macrophage recruitment to the tumor microenvironment in vivo (169). 
Interestingly, it was reported by Moulton et al. (210) that angiostatin, another internaI 
proteolytic fragment of plasminogen encompassing the first 4 kringle domains, also 
reduced in vivo infiltration of Mac3+ macrophages in the plaque and surrounding vasa 
vasorum in an atherosc1erosis model. This finding prompted our laboratory to further 
investigate the use of angiostatin as an inhibitory agent against macrophages in order to 
develop a strategy to target T AMs to suppress tumor promotion and angiogenesis. 
4.3 MATERIALS & METHODS 
4.3.1 Macrophage Isolation. 
Murine peritoneal macrophages were isolated from C57B1/6 mi ce (Charles River, 
Laprairie, Quebec, Canada) by lavage of the abdominal cavity with RPMI solution. 
Harvested peritoneal macrophages were resuspended in media (RPMI containing 10% 
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fetal bovine serum, FBS and 1 % penicillin-streptomycin, pen/strep, Wisent Technologies, 
St. Bruno, Quebec, Canada), plated on non-adherent tissue culture dishes for 4 hours, 
non-adherent cens were removed, adherent fraction was trypsinized and used for further 
experiments. Fresh human peripheral blood mononuc1ear cens (PBMCs) were obtained 
from normal volunteers and maintained in DMEM-F12 (Wisent Technologies) 
supplemented with 2% human serum and 500U/ml granulocyte/macrophage colony 
stimulating factor (GM-CSF; Immunex, Thousand Oaks, CA) to induce differentiation of 
monocytes into macrophages. 
4.3.2 Macrophage Migration Assay. 
Murine or human macrophages (1.5x105) were plated onto 0.15% gelatin/PBS-
coated 5-J-lm pore chemotaxis membranes (Coming, Acton, MA) within Boyden chamber 
inserts. Murine macrophages were exposed to recombinant human Kl-3 protein (1.0 and 
5.0 J-lM) for 24 hrs. Human macrophages were exposed to Kl-3 (10 J-lM) for 4 hrs. 
Species-specific recombinant GM-CSF was used as a chemoattractant and diluted in 
serum-containing RPMI media. Each sample was tested in triplicate and non-migrating 
cens were removed by gently wiping the upper surface of the filter. The average number 
of migrating murine macrophages per field was assessed by counting 3 random high 
power fields per filter and plotted. The total number of migrating human macrophages 
per filter was counted and plotted. 
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4.3.3 Immunoblot Analysis. 
Cell-surface membrane proteins were isolated from munne macrophages and 
human umbilical vein endothelial cells (as a positive control) using the Cell-Surface 
Protein Isolation kit (Pierce, Rockford, IL), which biotinylates and purifies cell-surface 
membrane proteins. Immunoblot analysis was performed on isolated protein lysates using 
anti-a-subunit and anti-p-subunit ATP synthase antibodies (Molecular Probes, 
Burlington, Ontario, Canada). 
4.3.4 Apoptosis Assay. 
Murine peritoneal macrophages were plated on 60-mm dishes for 3 hours in 
RPMI media containing 10% FBS and 1% penlstrep. Non-adherent cells were removed 
by washing 3 times in PBS. Adherent macrophages were either exposed to 2.0 !lM or 
increasing concentrations of recombinant human angiostatin (KI-3) protein (0.1, 0.5, 1.0 
and 2.0 !lM) diluted in media for 16 ho urs in normal culture conditions. Whole-cell 
staining was performed using the poly-caspase FUCA-PI (fluorochrome-Iabeled 
inhibitors of caspases-propidium iodide) apoptosis kit (lmmunochemistry Technologies, 
Bloomington, MN) and staining was quantified by flow cytometry analysis. 
4.3.5 Gelatin Zymography. 
Murine macrophages were exposed to either 1 !lM recombinant human KI-3 
protein diluted in media or media alone for 24 hrs, conditioned media was collected and 
concentrated 4-fold. Gelatinolytic activity in conditioned media samples was assessed by 
gelatin zymography. An aliquot (20 ,ul) of the culture medium was subjected to sodium 
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dodecyl sulfate/polyacrylamide gel electrophoresis (SDSIPAGE) with a 7.5% (w/v) 
polyacrylamide gel containing 0.1 mg/ml gelatin. The gels were then incubated for 30 
minutes at room temperature twice in 2.5% (v/v) Triton X-lOO to remove SDS, then 
rinsed five times in doubly distilled water. The gels were incubated at 37°C for 20 hrs in 
20 mM NaCI /5 mM CaCh /0.02% (v/v) Brij-35/50 mM Tris / HCI buffer (pH 7.6), then 
stained with 0.1% Coomassie Brilliant Blue R-250, followed by destaining in 10% (v/v) 
acetic acid / 30% (v/v) methanol in water. Gelatinolytic activity was detected as 
unstained bands on a blue background and was quantified by densitometric measurement. 
4.4 RESULTS 
4.4.1 Characterization of Isolated Macrophages. 
We isolated both murine and human macrophages in order to test the effect of 
recombinant human angiostatin (Kl-3) exposure. Murine macrophages were harvested by 
peritoneal lavage of thioglycollate-stimulated C57BI/6 mice. A Giemsa stain was 
performed on a cytospin sample prepared immediately post-isolation and a representative 
stain is depicted in Figure 4.IA, whereby vacuole-containing macrophages and 
macrophages with engulfed particIes is demonstrated. Human monocyte preparations 
were isolated from peripheral blood mononucIear cells (PBMCs) of healthy donors by a 
standard leukaphoresis protocol. Monocytes were induced to differentiate by exposure to 
human recombinant granulocyte-macrophage-colony stimulating factor (GM-CSF) for 7 
days in normal culture conditions and a cell aliquot was subsequently stained with human 
anti-CD206 antibody, which detects a mannose receptor that is expressed on the plasma 
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Figure 4.1: Macrophage characterization. (A) Giemsa stain perfonned on a cytospin 
preparation of murine peritoneal macrophages. Representative stain of macrophages with 
ingested particles is demonstrated, 100X magnification. (B) Human monocyte-derived 
macrophages stained with human anti-CD206 antibody and analyzed by flow cytometry. 
Monocytes induced to differentiate into macrophages using human GM-CSF were 88%-
positive for the macrophage marker CD206. (C) Cell-surface membrane proteins from 
murine peritoneal macrophages "M" and human umbilical vein endothelial cells ("EC" as 
a positive control) were subjected to anti-a and anti-13 A TP synthase immunoblot 
analysis. Murine peritoneal macrophages express the l3-subunit of ATP synthase (52 kDa) 
on the cell-surface. 
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membrane of macrophages. Flow cytometry analysis demonstrates that monocyte-derived 
macrophages are 88% CD206+ (Figure 4.1B). 
It was reported by Moser et al. (62) that cell-surface expressed ATP synthase (a-
and j3-subunits) acts as a putative receptor for angiostatin on primary endothelial cells 
and that angiostatin exerts its anti-endothelial cell properties via binding to this receptor. 
We sought to determine whether either subunit of ATP synthase was expressed on the 
cell-surface of macrophages. The cell-surface membrane pro teins from murine peritoneal 
macrophages and human umbilical vein endothelial cells (HUVECs) (as a positive 
control) were isolated using a commercially available kit and subjected to either anti-a-
or anti-j3-subunit ATP synthase immunoblot analysis (Figure 4.1 C). The presence of the 
j3-subunit of ATP synthase was detectable on the cell-surface ofmurine macrophages as a 
band migrating at 52 kDa. Our results suggest that murine macrophages do not express 
a-subunit of ATP synthase since we were unable to detect a band at 55 kDa. Both the a-
and j3-subunit ATP synthase are detectable on the cell-surface of HUVECs. These 
findings suggest that angiostatin may affect macrophages, in addition to endothelial cells, 
by interacting with cell-surface expressed j3-subunit of A TP synthase. 
4.4.2 Angiostatin Inhibits Macrophage Migration. 
In light of the presence of the j3-subunit of ATP synthase on the cell-surface of 
murine macrophages, we tested the ability of recombinant human angiostatin (KI-3) 
protein to affect macrophage migration. Murine peritoneal macrophages (1.5 x 104) 
previously exposed to either KI-3 or media alone were plated on the upper chamber of 
gelatin-coated filters within modified Boyden chambers (Figure 4.2A). KI-3 was capable 
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Figure 4.2: Angiostatin inhibits macrophage migration. (A) Depiction of a modified-
Boyden chamber, whereby macrophages are plated on a gelatin-coated polycarbonate 5 
Jlm-pore filter in the upper chamber "A" and subjected to chemoattractants in the lower 
chamber "B". (B) Murine peritoneal macrophages were exposed to either RPMI or 1 JlM 
or 5 JlM recombinant angiostatin (Kl-3) protein for 45 minutes at 37°C culture 
conditions and subsequently plated in the upper chamber "A". Angiostatin inhibited the 
migration of macrophages chemoattracted by murine GM-CSF in a dose-dependent 
manner. The number of migrated macrophages per high power field (HPF) is shown; 
S.E.M. (C) Angiostatin (Kl-3) inhibits the migration of human macrophages 
chemoattracted by human GM-CSF. The total number of migrated macrophages lS 
shown; bars, S.E.M. Statistical analysis was performed using the student {-test. 
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of blocking the migration of macrophages chemoattracted by media containing 10% 
serum and 500 U/mL of recombinant murine GM-CSF in a dose-dependent fashion (1 
!JM, P < 0.005 and 5 !JM, P < 0.00005; Figure 4.2B). Consistent with these results, we 
also observed a Kl-3-induced suppression of migration when human monocyte-derived 
macrophages were utilized in a similar migration assay (P < 0.05, Figure 4.2C). These 
observations suggest that direct exposure of macrophages to Kl-3 protein may lead to 
interaction with cell-surface expressed p-subunit of ATP synthase, which may decrease 
the migratory capacity of macrophages either by inducing macrophage apoptosis or by 
affecting downstream signa1ing mediators implicated in macrophage chemotaxis. 
4.4.3 Angiostatin Does Not Induce Caspase Activation in Macrophages. 
We investigated whether macrophages exposed to Kl-3 led to apoptotic cell 
death. Murine peritoneal macrophages were exposed to either increasing doses of Kl-3 
(0.1, 0.5, 1.0 and 2.0 !JM) diluted in serum-containing media or serum-containing media 
alone for 16 hrs in normal culture conditions. Cells were harvested and subsequently 
stained with a commercially available fluorescence-based FUCA/PI kit, which 
selectively stains cells containing active caspases. Results reveal that KI-3 was unable to 
induce cell death at the doses tested, as evidenced by negligible FUCA + staining as weIl 
as similar FUCA+PI+ staining as control-treated cells (Figure 4.3). The data suggests that 
KI-3 exposure to macrophages does not lead to cell death, even though angiostatin at the 
same dose has been reported to cause endothelial cell death. It may be postulated that Kl-
3 requires interaction with both cell-surface expressed Œ- and p-ATP synthase subunits to 
induce apoptosis, as was observed for endothelial cells. 
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Figure 4.3: Angiostatin does not indu ce macrophage apoptosis. Murine peritoneal 
macrophages were exposed to either increasing doses (0.1, 0.5, 1.0, 2.0 /lM) of 
recombinant Kl-3 protein or 10% serum-containing RPMI media as a control for 16 
hours in nonnal culture conditions. Cells were then stained with FLICAIPI and analyzed 
by flow cytometry. Kl-3 does not induce FLICA+ staining (ie: apoptosis) at the doses 
tested. The percentage of PI+ cells is not affected by KI-3 exposure. The upper most 
panel depicts typical FLICA + staining dot plot and was obtained from Immunochemistry 
Technologies. Representative flow cytometry dot plots with appropriate staining 
percentages are shown on the right panel. 
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4.4.4 Angiostatin Decreases the Gelatinolytic Activity of Macrophage-Derived 
MMP-9. 
In attempt to explain the mechanism by which KI-3 induces inhibition of 
macrophage migration, we decided to test whether the activity of key proteases 
implicated in cell chemotaxis/motility such as matrix metalloproteinase (MMP)-2 and -9 
were affected by KI-3 exposure. Murine peritoneal macrophages were exposed to 1 f-tM 
KI-3 for 24 hrs in normal culture conditions. Conditioned media was collected, 
concentrated 4-fold and subjected to gelatin zymography analysis. We observed that 
exposure of macrophages to K 1-3 led to a decrease in the ability of macrophage-derived 
soluble MMP-9 to lyse ge1atin as compared to control-treated cells (Figure 4.4). No 
change in the gelatinolytic activity of MMP-2 was detectable. We speculate that KI-3-
mediated decrease in the activity of macrophage-produced MMP-9 may be in part 
responsible for the observed a KI-3-induced migration blockade. 
4.5 DISCUSSION 
Our findings demonstrate that angiostatin (KI-3), which has been touted as a 
promising anti-angiogenic agent, possesses additional anti-tumoral properties by exerting 
inhibitory action on macrophages. More specifically, we show that recombinant human 
KI-3 protein blocks in vitro migration of murine peritoneal macrophages (Figure 4.2B) 
and human monocyte-derived CD206+ macrophages (Figure 4.2C). This result is 
consistent with that observed by Benelli et al. (253) who report that angiostatin is capable 
of inhibiting MCP-I-induced monocyte migration. Furthermore, we detect expression of 
the 13-subunit of ATP synthase on the cell-surface of macrophages by immunoblot 
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Figure 4.4: Angiostatin mediates decrease in MMP-9 gelatinolytic activity. Murine 
peritoneal macrophages were exposed to either 1 /lM KI-3 or media al one for 24 hrs. 
Conditioned media was concentrated 4-fold and run on a discontinuous polyacrylamide 
gel containing gelatin (enzyme substrate for the MMPs being tested). Macrophages 
exposed to Kl-3 possess decreased MMP-9 (95 kDa) activity. No change was observed 
in MMP-2 (72 kDa) activity. 
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analysis (Figure 4.1C). ATP synthase (both the u- and ~-subunits) was the first reported 
receptor for angiostatin and was found to be expressed on the cell-surface of endothe1ial 
cells (62). It was also recently reported that tumor cells express extracellular surface ATP 
synthase, where increased activity was observed under low extracellular pH (pHe) 
conditions typical of the tumor microenvironment (110). Angiostatin exposure under low 
pHe led to intracellular acidification of tumor cells and direct cytotoxicity (110). 
Consistent with these findings, we speculate that direct contact of macrophages with K1-
3 may promote interaction with cell-surface expressed ~-subunit of ATP synthase, 
causing inhibition of migration, similar to that observed by Moser et al. (62) with primary 
endothelial cells. To specifically determine whether angiostatin interacts via the 
macrophage cell-surface expressed ~-subunit of ATP synthase to suppress migration, we 
plan to assess the effect of adding an A TP synthase blocking antibody on migration. 
Further experiments need to be performed to confirm whether angiostatin induces 
macrophage apoptosis. Interestingly, we also observed a Kl-3-mediated decrease in the 
gelatinolytic activity of macrophage-produced MMP-9 (Figure 4.4). MMP-9 is linked 
with leukocyte transmigration as was recently observed by Kolaczkowska et al. (254) in a 
murine mode1 of induced peritonitis, whereby ge1atinase B-deficient mi ce (MMP-9 -/-) 
mice possessed impaired leukocyte infiltration compared to controls. MMP-9 has also 
been reported to be participate in lung-specific metastasis (255). Downregulation of 
MMP-9 activity may be associated with the observed angiostatin-mediated inhibition of 
macrophage migration. 
It is worthy to note that other well-characterized endogenous anti-angiogenic 
agents have also been reported to possess broadened cell specificity than initially 
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believed. For instance, Moulton et al. (210) reported that soluble VEGF receptor 1 (256) 
is capable of inhibiting plaque-associated endothelial cell sprouting as well as 
suppressing VEGF-induced migration of human blood monocytes through fibronectin-
coated transwell membranes. In an experimental model of bone metastasis induced by 
breast cancer cells that mimic metastasis observed in naturally occurring human breast 
cancer (257), it was shown that angiostatin acts as a very effective inhibitor of bone 
resorption by directly inhibiting cancer-induced bone destruction via direct inhibition of 
osteoc1ast activity and generation. Furthermore, our laboratory confirmed that human K5 
protein, another internaI c1eavage product of plasminogen, acts as a potent endothelial 
cell inhibitor (169) as has been observed by others (128). Moreover, we demonstrate that 
K5 directly inhibits in vitro migration of human monocyte-derived CD206+ macrophages 
and leads to a significant reduction in CD45+Mac-3+Gr-r macrophage infiltration within 
tumor implants (169). Additionally, we show that K5 protein is chemotactic for CDllb+ 
neutrophils in an in vitro chemotaxis assay and that K5-containing tumor implants 
possess a cellular infiltrate predominantly composed of neutrophils (170). Similarly, 
angiostatin was reported to inhibit IL-8- and macrophage inflammatory protein 2-induced 
neutrophil migration (253). 
Overall, we provide evidence supporting the use of angiostatin as a promising 
therapeutic agent against macrophages. We speculate that angiostatin's ability to suppress 
tumor-infiltrating leukocytes, in addition to its previously reported endothelial cell 
inhibitory properties as well as its direct cytotoxicity on tumor cells, could markedly 
enhance its effectiveness as an anti-cancer agent. Moreover, in light of angiostatin's 
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novel macrophage suppressive property, its utility could also be extended to target M2-
phenotypic macrophages implicated in immune regulation or tissue remodeling (258). 
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CHAPTER 5: DISCUSSION AND CONCLUSION 
5.1 Anti-Angiogenic Agents: From Bench to Bedside 
In 1971, Judah Folkman published a landmark reVlew ln the New England 
Journal of Medicine (186) proposing that tumors produced what he referred to as a 
"tumor angiogenesis factor" that was responsible for recruiting new blood vessels 
toward the tumor, allowing it the ability to grow and persist. Folkman also speculated that 
inhibition of this diffusible factor could prevent the tumor from progressing. Although his 
hypothesis was initially met with much skepticism, further research revealed that his 
notion was indeed correct. In the last 30 years, angiogenesis research has gained 
tremendous interest and has generated over 25 000 pub li shed reports. It is now well 
established that cancers require blood vessels to progress from premalignant, noninvasive 
growths into aggressive tumors that can metastasize to distant sites in the body. 
In light of the fact that anti-angiogenic therapy targets genetically stable vascular 
endothelial cells and not the tumor itself, researchers in the field explored various 
avenues to develop a pan-tumor therapy focused on eliminating tumor blood vessels with 
the goal to induce tumor regression. The initial anti-angiogenesis hype was dampened by 
animal and preliminary human clinical trials that revealed that different tumors possess 
different response rates toward anti-angiogenic therapy. There are several factors that 
could affect the treatment response such as the level of angiogenic factors produced by 
the tumor, expression of oncogenes and resistance to hypoxia (8). In a rat model of 
glioblastoma, anti-VEGF therapy induced, as expected, decreased tumor vessel density 
and increased apoptosis. An additional unexpected effect of the treatment was increased 
co-option of existing blood vessels, thus overcoming the requirement for the tumor to 
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initiate angiogenesis (259). Resistance to anti-angiogenesis therapy has been reported in 
several studies: TSP 1 therapy for glioblastomas (260), thalidomide therapy for renal cell 
carcinoma (261) and p53-negative tumors become less responsive to combinations of 
low-dose cytotoxic and anti-angiogenic agents (262). Anti-angiogenic therapy also has 
the ability to contribute to hypoxia due to the regression of oxygen-transporting blood 
vessels. As a result, hypoxia as weIl as VEGF-A production leads to the expression of 
anti-apoptotic genes (263, 264) and multidrug-resistance-associated proteins (265), and 
thus allows the tumor to become protected from the effects of cytotoxic drugs. 
Over 50% of human cancers possess mutations in p53 which can affect the 
angiogenic balance. For instance, tumor cells with p53 mutations are selected for based 
on their ability to survive in hypoxia (262) and have been reported to downregulate TSPI 
expression as weIl as upregulate VEGF-A expression (266). Consistent with these 
findings, wild-type p53 tumors inhibit VEGF transcription (78) and promote MDM2-
mediated ubiquitylation and proteasomal degradation of HIF-la, which is the main 
transcriptional activator of VEGF under hypoxia (77). In normal ceIls, hypoxia induces 
upregulation of VEGF-A and downregulation of TSP1, independent of p53 status. 
However, when normal cells are transformed with ElA and RAS, TSPI expression is 
decreased, independent of hypoxia, whereas VEGF-A expression remains normal (267). 
Further studies have implicated p53 in the regulation of tumor angiogenesis. Both 
Holmgren et al., (268) and Gautam et al., (269) demonstrate that introduction of wild-
type p53 induced dormancy and inhibited metastasis by affecting the TSPI :VEGF-A 
ratio, implying that mutations in p53 allow tumors the ability to circumvent the effects of 
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anti-angiogenic therapy. P53-mediated drug resistance should be overcome by utilizing a 
combination of anti-angiogenic regimens. 
Studies using the mouse model of pancreatic-islet carcinogenesis have also 
demonstrated that the success of anti-angiogenic treatment is dependent on the stage of 
disease (270). For instance, endostatin (39), MMP (8) and VEGF inhibitors (271, 272) 
are most effective in treating early-stage disease, by preventing the angiogenic switch 
from being tumed on in dysplastic lesions as weIl as inhibiting the progression of small 
solid tumors. These same anti-angiogenic therapies cannot stabilize or induce regression 
of bulky end-stage tumors. Conversely, other angiogenic inhibitors such as TNP-
470/AGM-1470 (8), which prevent endothelial cell proliferation and smooth muscle cell 
migration, are capable of reducing the size of bulky end-stage tumors, but have no effect 
on early-stage tumors. These observations suggest that there may be specific differences 
in the angiogenic vasculature of early versus late-stage tumors or in the regulation of 
angiogenesis induction during the growth of tumor vessels. It was demonstrated in a 
pancreatic-islet model (273) that combination of SU5416 (blocks VEGFR) and SU6668 
(blocks PDGFR and to a lesser extent FGFR and VEGFR) prevents the angiogenic switch 
and induces the regression of both small and large tumors with improved synergistic 
effects at aIl stages, as compared to single agent treatment. IdeaIly, for therapeutic 
purposes, it would be advantageous to be able to predict which combination of anti-
angiogenic agents synergisticaIly. Cline et al., (274) exposed endothelial cells to various 
anti-angiogenic agents and subsequently performed gene-expression profiling studies to 
predict which combination of anti-angiogenic therapies would most effectively inhibit 
tumor growth in animal models. Further studies in this area will help to more accurately 
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predict which combination of angiogenic inhibitors act synergistically in the clinical 
setting. 
Despite much success with the use of anti-angiogenic agents in pre-clinical 
studies, it is worthy to note that the tirst anti-angiogenic clinical trials failed to reduce 
tumor burden and did not prolong patient survival. However, clinical trials that failed 
attempted to treat aggressive refractory tumors of end-stage patients using endostatin or 
agents targeting VEGF signaling. Aggressive tumors develop mechanisms to overcome 
the effects of single anti-angiogenic therapy by activating alternative pathways, so in 
retrospect it is not surprising that these trials were unsuccessful. 
5.2 Adverse Effects Associated with Anti-Angiogenic Agents 
The reported toxicities associated with anti-angiogenic agents are not severe and 
consist of the following: hypertension, blood clotting, proteinurea and more rarely 
gastrointestinal performations of the bowel, which can be severe (275). Blood clot 
formation may be worsened by combining anti-angiogenic agents with certain regimens 
of chemotherapy, such as SU5416, a VEGFR2 antagonist, combined with gemcitabine 
and cisplatin. However, many grade 3 and grade 4 adverse effects have been manageable 
with medical treatment during ongoing therapy (276). Another concern with the use of 
anti-angiogenics therapeutically is the development of acquired resistance as was 
observed by Casanovas et al. (277) in a mouse model of pancreatic islet carcinogenesis. 
Following an initial period oftumor growth suppression, resistance to VEGFR2 blockade 
emerged as tumors re-grew during treatment. It was reported that resistance involved 
reactivation of tumor angiogenesis, independent of VEGF, and associated with hypoxia-
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rnediated induction of other pro-angtogemc factors, including rnernbers of the FGF 
farnily (277). It has also been recently reported that anti-VEGF agents under clinical 
deve10prnent can "prune away" 75% of turnor vesse1s, as well as possess the ability to 
affect Il of 17 organs analyzed by inducing substantial but reversible capillary regression 
(278). 
5.3 Avastin: A Clinically Successful Anti-Angiogenic Agent 
To date, the rnost clinically successful anti-angiogenic agent is A vastin 
(bevacizurnab), a hurnanized monoclonal antibody directed against VEGF, developed by 
Genentech. A vastin was tested in cornbination with conventional chemotherapy in a 
large-scale Phase III clinical trial and the cornbination treatment prolonged survival of 
patients with metastatic colorectal cancer when compared to chemotherapy alone (68). As 
a result, standard chemotherapy cornbined with A vastin was approved in 2004 by the 
Food and Drug Administration and other countries as first-line therapy for metastatic 
colorectal cancer. Moreover, Phase III clinical trials assessing A vastin cornbined with 
chemotherapy for the treatment of breast and non-small cell lung cancer have also 
generated successful results (279). 
5.4 Exploiting Gene Therapy Based on Lessons Learned from Anti-Angiogenic 
Clinical Trials 
Within the last decade, several angiogenic inhibitors have been discovered, with a 
rnajority consisting of endogenous proteins or fragments of larger precursor proteins 
normally present in the body. Clinical trials assessing the efficacy of anti-angiogenic 
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therapies have provided valuable insight (34) and emphasized the potential benefits of 
employing gene therapy strategies. 
1. Genetie stability of endothelial eells: Since endothelial cens are more geneticany 
stable than tumor cens, they possess a lower chance of accumulating mutations 
that lead to the development of early drug resistance (39). Thus, gene therapy 
approaches targeting endothelial cens via delivery of anti-angiogenic proteins are 
preferred over those aimed at tumor cens, which may cause the tumor to develop 
an escape mechanism. 
2. Use of metronomie dosing: Delivering anti-angiogenic agents continuously at 
low doses has proven to be more effective than the intermittent peaks associated 
with repeated administration of recombinant proteins (280). Gene therapy 
strategies can provide sustained expression of the therapeutic protein over a long 
duration. 
3. Harnessing the power of the angiogenie switeh: It has become evident that the 
angiogenic switch must be tumed on for tumor growth and progression (8). In situ 
tumors present in the body will only progress if there is an imbalance between the 
tumor-produced pro-angiogenic signaIs compared to the body' s ability to 
counteract these signaIs (281). The development of gene therapy techniques to 
boost the body's levels of endogenous angiogenic inhibitors can be exploited to 
balance the levels in order to promote tumor suppression. 
4. lnvolvement of multiple angiogenie pathways. The contribution of several 
angiogenic factors promotes tumor proliferation and progression. Conventional 
anti-angiogenic therapies attempt to target a number of pro-angiogenic mediators 
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by administering repeated, systemic boluses of multiple anglOgemc inhibitors 
(282). The use of gene therapy could facilitate the targeting of numerous 
angiogenic pathways since biologically relevant levels of several angiogenesis 
inhibitors could be delivered. 
Although recombinant angiostatic proteins have been found to possess unique anti-cancer 
properties, their utility as therapeutics poses several obstacles that need to be overcome to 
better elucidate mechanisms of action, dosing schedule and the overall biological 
effectiveness in the clinic. In addition, the structural complexity possessed by many of 
these inhibitors as well as the difficulty in cost-effectively manufacturing large quantities 
for clinical use also raises a concem. Optimized gene therapy strategies can be exploited 
to bypass sorne of the limitations associated with recombinant anti-angiogenic protein 
use. An ideal anti-angiogenic gene therapy approach involves the use of autologous cells 
that can be genetically-engineered with a vector in order to deliver sustained, biologically 
relevant quantities of the therapeutic protein for an extended period of time. 
Therapeutically, it is necessary that the cellular biopharmaceutical be gene-modified with 
a vector that is safe and po orly immunogenic, since repeated administration may be 
required over a period of several months to achieve disease stabilization and complete 
cancer regresSlOn. 
Overall, gene therapy approaches can bypass sorne of the limitations associated 
with conventional therapies. This led to the first gene therapy clinical trial, which aimed 
to treat X-linked SCID (also known as the gamma chain deficiency) in children. This is 
an inherited disease characterized by an early block in T and natural killer lymphocyte 
differentiation caused by mutations of the gene encoding the gamma chain cytokine 
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receptor subunit of IL-2, -4, -7, -9, and -15 receptors (283). Cavazzana-Calvo and 
colleagues employed the use of autologous CD34+ bone marrow stem cells that were ex 
vivo retrovirally gene-modified with the gamma chain gene (283). In 2000 and 2002, it 
was reported that the majority of patients were successfully treated (283, 284). However, 
the initial enthusiasm was quickly dampened 3 years post-therapy when 2 of the 10 
children developed leukemia-like conditions. The development of leukemia was linked to 
retroviral vector integration proximal to the LM02 proto-oncogene promoter, causing 
aberrant transcription and LM02 expression (285). This setback prompted investigators 
to develop better vectors, yet the possibility of oncogene activation by retroviral 
integrating vectors still remains a valid concem. Despite the results of the SCID clinical 
trial, gene therapy strategies still possess attractive features that can be exploited for the 
treatment of cancer. Most likely, anti-angiogenic gene therapies will provide the greatest 
benefit ifutilized as adjuvants and in combination with current treatment modalities. 
5.5 Development of a Novel A nti-Angiogenic Gene Therapy Strategy for Cancer 
In light of the importance of angiogenesis in tumor progression as well as the 
impediments associated with recombinant angiostatic protein use and the benefits of gene 
therapy, the main objective of this thesis was to develop a novel anti-angiogenic gene 
therapy strategy for cancer. The specific research aims were as follows: 
1. To determine whether retrovirally gene-modified human U87 glioma cells 
producing soluble human plasminogen kringle 5 protein could suppress tumor 
progression and angiogenesis in an orthotopic brain cancer model; 
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2. To determine whether human plasminogen kringle 5 protein, when secreted by 
retrovirally gene-engineered murine DA/3 mammary adenocarcinoma cells, lS 
dependent upon innate immune effector cells to mediate its anti-cancer effect; 
3. To determine whether recombinant human angiostatin protein, in addition to its 
strong anti-angiogenic activity, can also exert inhibitory action on macrophages. 
The rationale for use of human Plg K5 protein as the anti-angiogenic agent of choice for 
this thesis was based upon studies comparing the potency of internaI proteolytic 
fragments of human Pig. It was shown that proteolytically-derived purified human K5 
acts as a stronger inhibitor of in vitro bFGF-stimulated endothe1ial cell proliferation (128) 
and migration (60) than human proteolytic angiostatin (Kl-4). Additionally, it was 
demonstrated that Kl-5 is more potent than Kl-4 in suppressing in vitro bFGF-stimulated 
endothelial cell proliferation (132) and migration (60). Kl-5 also displayed strong 
inhibition ofbFGF-stimulated corneal neovascularization and tumor growth, whereas Kl-
4 at the same dose was complete1y ineffective (132). Therefore, these findings suggest 
that the cryptic K5 domain acts synergistically to markedly enhance the potency of Kl-4. 
5.5.1 Hypothesis 1 
In light of these reported observations, we decided to test the ability of K5 domain 
produced by retrovirally gene-engineered human U87 glioma cells to act as an anti-
angiogenic agent and assessed its efficacy in suppressing tumor progression in an 
orthotopic brain cancer model. Our results demonstrate that: 
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i) Soluble K5 protein spontaneously adopts a tertiary structure consistent 
with native conformation as displayed within Plg when expressed by 
genetically-engineered eukaryotic ceIls; 
ii) K5 protein produced by retrovirally gene-modified human U87 glioma 
cells is appropriately secreted and inhibits in vitro growth factor-
stimulated endothelial cell migration; 
iii) Soluble K5 protein blocks glioma-associated angiogenesis in vivo; 
iv) Soluble K5 protein possesses novel anti-macrophage properties, 
capable of suppressing in vitro migration of human monocyte-derived 
macrophages and prevents the recruitment of host-derived tumor-
infiltrating macrophages in vivo and; 
v) Glioma-targeted K5 expression suppresses tumor growth and pro longs 
survival in an experimental orthotopic brain cancer model. 
Since it has been reported that the tertiary conformation adopted by plasminogen kringles 
is necessary for maintenance of functional angiostatic activity, we confirm that 
eukaryotically-expressed Plg K5 protein preserves the prototypical native kringle 
disulfide bridging conformation. Indeed, our cysteine bridging pattern data is consistent 
with the only other report that characterized the structure of recombinant K5 domain 
using NMR technology (286). Functionally, we show evidence that soluble K5 protein 
produced by gene-engineered glioma cells is capable of suppressing growth factor-
induced endothelial cell migration in vitro, as has been previously reported using 
proteolytically-derived K5 protein (60). Our demonstration that soluble K5 protein acts as 
a potent angiostatic agent by reducing blood vessel formation in vivo validates the 
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concept that tumor cells can be ex vivo retrovirally gene-modified to secrete functional 
K5 protein capable of providing sustained expression in order to exert an anti-endothelial 
cell effect in vivo. Additionally, our observation that soluble K5 protein can substantially 
reduce the recruitment of in vivo host-derived tumor-infiltrating macrophages by 
imparting a direct anti-migratory effect, as shown in its ability to inhibit the migration of 
human monocyte-derived CD206+ macrophages in vitro, provides novel mechanistic 
insight. Until this point, K5 protein had been consistently characterized as an endothelial 
cell specific inhibitor. We provide first evidence that K5 possesses strong inhibitory 
properties against both tumor-infiltrating endothelial cells as well as tumor-associated 
macrophages, 2 of the key cellular mediators implicated in tumor angiogenesis. 
Leukocyte infiltration into tumors is analogous to the wound healing process, 
since recruited inflammatory cells are programmed by the tumor to divert to a wound-
healing phenotype (231). Thus, cancer is often referred to as "the wound that will not 
heal." Among leukocytes that are attracted toward the tumor, macrophages are the most 
multifunctional and can influence several processes such as angiogenesis, matrix 
degradation and cytotoxicity. Tumor-associated macrophages (TAMs) enter the tumor 
vasculature as blood monocytes and migrate to avascular areas of the tumor, differentiate 
and c1uster in hotspots (231). It has been reported that increased macrophage density is 
associated with increased angiogenesis and decreased survival rates (206). Recruitment 
of T AM has been inhibited by drugs such as linomide and thalidomide known to also 
possess anti-angiogenic properties (287). In fact, Moulton et al. (210) observed that 
angiostatin reduces plaque angiogenesis and atherosc1erosis by reducing plaque-
associated macrophages. Thus, our finding that soluble K5 protein exhibits inhibitory 
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action on two distinct cell types is consistent with what has been reported for other 
angiostatic agents. Furthennore, the ability of soluble K5 to directly inhibit macrophage 
migration suggests that K5 may interact with a cell-surface receptor expressed on 
macrophages that leads to a decrease in macrophage motility. 
Moreover, we demonstrate that soluble K5 protein mediates a potent anti-tumor 
response in an orthotopic glioma mode1 by significantly prolonging long-tenn survival in 
test animaIs. This validates the concept that tumor cells can be retrovirally gene-
engineered ex vivo to provide sustained expression of K5 protein within the loco-regional 
tumor microenvironment in order to induce tumor regression. Our findings also reveal 
that K5 protein mediates its anti-tumoral activity via 2 unique cell types implicated in 
tumor angiogenesis. 
Our study was the first to test the efficacy of plasminogen K5 protein in a gene 
therapy setting for the treatment of cancer. Angiostatin, the most commonly studied 
internaI plasminogen kringle fragment, has been tested within the context of gene therapy 
strategies. Joseph et al. (288) assessed the ability of intravenously injected recombinant 
adenovirus encoding human KI-3 protein (coupled to human serum albumin to increase 
the in vivo half-life) and failed to demonstrate an anti-tumor effect in human 
neuroblastoma xenografts, despite high circulating leve1s of KI-3 protein. Similar to the 
human U87 glioma modei empIoyed by our laboratory, the neuroblastoma mode1 utilized 
by Joseph et al. also secretes high levels of VEGF and their findings demonstrate that 
angiostatin is unable to reverse the pro-angiogenic phenotype of the tumor. Interestingly, 
it was recently shown that delivery of full-iength plasminogen kringles KI-5 by a single 
adenoviral intratumorai injection resuited in 40% tumor regression, arrested tumor 
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growth by 90% and induced substantial reduction in neovascularization in a human breast 
carcinoma model, whereas KI-3 did not lead to an anti-tumor effect (289). Overall, these 
findings support the notion that the K5 domain enhances the potency of angiostatin and 
that it can be utilized on its own as an effective anti-tumor protein using a retroviral gene 
therapy approach. 
5.5.2 Hypothesis 2 
Our finding that K5 protein acts as a 2-pronged anti-tumor agent inhibiting both 
endothelial cells and macrophages, prompted our laboratory to investigate whether K5 
mediated its anti-tumor effects by modulating other immune cell types. Angiostatin has 
been shown to possess immune modulatory properties by enhancing leukocyte-vessel 
interactions via upregulation of endothelial cell adhesion molecules (212). Angiostatin 
has also been shown to act as an anti-adhesive/anti-inflammatory agent in the setting of 
experimental peritonitis (214). Therefore, we assessed the immune modulatory activity of 
soluble K5 protein employing a murine mammary adenocarcinoma model in the context 
of a gene therapy strategy. We demonstrate that: 
i) Retroviral gene-engineered DN3 mammary adenocarcinoma cells can 
secrete soluble K5 protein; 
ii) Soluble K5 protein relies upon the innate immune system to exert an anti-
tumor effect in vivo; 
iii) Expression of soluble K5 protein by gene-modified DN3 cells within the 
tumor microenvironment leads to the recruitment of CD3+ lymphoid cells, 
more specifically natural killer T -lymphocytes; 
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iv) Expression of soluble K5 protein by gene-modified DAl3 cells within the 
tumor microenvironment reduces the quantity and size of tumor-associated 
vasculature; 
v) Soluble K5 protein induces massive neutrophilic infiltration within the in 
vivo tumor microenvironment and; 
vi) Purified K5 protein acts as a chemoattractant as well as promotes 
neutrophil activation in vitro. 
Our findings confirm that retroviral gene modification of murine mammary tumor cells 
leads to functional production of K5 protein in order to induce an anti-cancer response in 
vivo. Consistent with our previous study, we confirm that K5 acts as a potent anti-
angiogenic agent capable of reducing the quantity and size of blood vessels within the 
tumor microenvironment. Interestingly, we observed that soluble K5 protein is dependent 
upon an intact innate immune system to exert an effective long-term anti-tumor response. 
Despite the significant delay in the survival rate of K5-containing immunodeficient 
NOD-SCID and BALB/c nude mi ce as compared to control mi ce, aU animaIs eventually 
developed large tumors that exceeded acceptable endpoints and required euthanasia. 
Soluble K5 induced long-term survival only in immunocompetent BALB/c mice, 
suggesting the requirement of functional innate immune effector cells. More specifically, 
preferential recruitment of CD3+ lymphoid cells, with predominance for the natural killer 
T-Iymphocyte subset, was detected in K5-containing tumor explants. Further analysis 
revealed that soluble K5 also induced massive neutrophilic infiltration within the tumor 
microenvironment. We provide evidence that K5 protein acts as a strong neutrophil 
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chemoattractant and promotes neutrophil activation VIa upregulation of CD64 
granulocyte cell-surface marker. 
Overall, we demonstrate that in addition to the ability of K5 protein to act as a 
potent angiostatic agent, K5 also recruits CD3+ lymphocytes as well as neutrophils to 
cause in vivo tumor regression. Thus, K5 mediates its anti-tumor effect via anti-
angiogenic and pro-inflammatory modes of action. It has been previously reported that 
combined lymphocytic and neutrophilic infiltration leads to tumor rejection (225-227). 
5.5.3 Hypothesis 3 
In our first study, we observed that soluble K5 protein suppressed the recruitment 
of tumor-associated macrophages in vivo as well as prevented the migration of human 
monocyte-derived macrophages in vitro. Given this novel finding, we sought to 
determine whether angiostatin, another internaI plasminogen kringle fragment possessing 
angiostatic activity, also affects macrophages. The development of strategies to inhibit 
T AMs is warranted since T AMs play a key role in tumor progression and metastasis. Our 
results demonstrate that: 
i) Human recombinant angiostatin (KI-3) protein inhibits GM-CSF-induced 
migration of murine peritoneal macrophages; 
ii) Kl-3 protein inhibits migration of human monocyte-derived CD206+ 
macrophages and; 
iii) KI-3 protein decreases the gelatinolytic activity of macrophage-derived 
MMP-9. 
Our demonstration that angiostatin blocks macrophage migration is consistent with what 
has been observed by Benelli et al. (253), who report that angiostatin inhibits MCP-l-
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induced monocyte migration. We speculated that macrophages express a cell-surface 
receptor that angiostatin interacts with in order to mediate its anti-migratory effect. In 
fact, we found that macrophages express the ~-subunit of ATP synthase on the cell-
surface. A TP synthase was identified as the first possible receptor for angiostatin 
expressed on the cell-surface of endothelial cells (210), and more recently detected on the 
cell-surface oftumors in a low extracellular pH environment (110). Previous reports have 
also shown that angiostatin suppresses neutrophil migration in vitro (253) and inhibits 
integrin-mediated leukocyte adhesion (214). Therefore, similar to our observations with 
K5 protein, angiostatin also appears to possess multiple cell targets. Additionally, we 
observed a KI-3-mediated decrease in the ge1atinolytic activity of macrophage-produced 
MMP-9, which has been associated with leukocyte transmigration (254) and thus, may be 
linked with the ability of Kl-3 to block macrophage migration. These results suggest that 
angiostatin could be exploited to inhibit tumor-associated macrophages and its utility 
could also be extended to target M2-phenotypic macrophages implicated in tissue 
remode1ing or immune regulation (258). 
5.6 Summary of Findings 
In conclusion, the data presented in this thesis demonstrates that human 
plasminogen K5 protein can be efficiently secreted by retrovirally gene-engineered tumor 
cells to exert an anti-tumor effect in vivo in animal models of brain and breast cancer. 
Functionally, we have shown that soluble K5 protein acts as a potent anti-angiogenic 
agent by its inhibition of growth factor-induced endothe1ial cell migration in vitro and its 
ability to suppress tumor-induced vascularization in vivo. Furthermore, we have 
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discovered additional novel properties for soluble K5 protein that can be exploited 
therapeutically, including its ability to block tumor-associated macrophages, 
preferentially recroit CD3+ lymphoid cells (natural killer T -cells in particular) and act as 
a strong chemoattractant and activator for tumor-infiltrating neutrophils. Moreover, we 
have demonstrated that human plasminogen Kl-3 protein blocks the migration of 
macrophages and leads to a decrease in the gelatinolytic activity of macrophage-derived 
MMP-9. 
5. 7 Future Directions 
In view of these findings, it would be interesting to further identify and 
characterize binding receptors and downstream signaling mediators for both K5 and K 1-
3. A broader understanding of their modes of action on leukocytes might expand the 
therapeutic utility of these proteins, for instance in the setting of atherosclerosis. It would 
also be worthy to design combinatorial or fusion anti-angiogenic transgenes with 
differing targets in order to maximize therapeutic benefit such as K5 fused to soluble 
FLTI (which is an endogenous inhibitor ofVEGFRl). Phase III clinical trials using anti-
VEGF agents have demonstrated that tumors can escape the anti-VEGF effect by 
producing other pro-angiogenic agents to recroit blood vessels (279). It has also been 
shown that multi-targeted tyrosine kinase inhibitors such as sunitinib (which targets 
VEGFR2, PDGFR-~, FLT3 and c-Kit) that target several pathways implicated in both 
tumor growth and angiogenesis can be utilized as monotherapies to increase patient 
survival (279). Finally, anti-angiogenic gene therapies could be utilized as adjuvants with 
conventional treatment or in combination with CUITent treatment modalities such as 
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chemotherapy and radiation therapy. In fact, it was proposed by Teicher et al. (290) that 
combining anti-angiogenic therapy with chemotherapy would induce a synergistic effect, 
since both tumor and endothe1ial cells would be targeted. Although a number of 
preclinical studies have shown that angiostatic agents reduce the number of tumor-
associated blood vesse1s and antagonize the effect of chemotherapy and radiation therapy 
by impeding delivery (291), it has also been demonstrated that anti-VEGF therapies 
"normalize" tumor vasculature (291, 292). Vesse1 normalization induced by anti-VEGF 
agents like bevacizumab reverses sorne of the abnormalities possessed by tumor blood 
vessels by suppressing vesse1 leakiness and pruning immature growing blood vesse1s 
(291). As a result, normalization of tumor vessels creates mostly mature functional 
vesse1s and thus, the delivery of drugs and oxygen can be increased and ultimate1y lead to 
improved outcome (279). 
The studies presented III this thesis served to test the proof-of-concept that 
retroviral gene modification of tumor cells can lead to the production of biologically 
relevant levels of an anti-angiogenic agent in order to induce in vivo tumor regression. 
However, for clinical purposes, an autologous cellular de1ivery vehic1e, such as bone 
marrow stroma, could be employed. Our laboratory has validated the process of 
retrovirally gene-modifying marrow stromal cells for the in vivo delivery of therapeutic 
proteins in preclinical models ofmelanoma (203) and anemia (293). 
5.8 Concluding Remarks 
Overall, our findings extend the existing body of knowledge and propose novel 
avenues for the development of anti-angiogenic strategies against cancer. Our data also 
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highlights the importance of further investigating the immune modulatory properties of 
anti-angiogenic agents in order to enhance their anti-tumor effect. 
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KNOWLEDGE 
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CONTRIBUTION TO ORIGINAL KNOWLEDGE 
The data presented in this thesis has provided several original contributions to the 
existing body of scientific knowledge: 
vi) Soluble human plasminogen (PIg) kringle 5 (K5) protein spontaneously adopts a 
tertiary structure consistent with native conformation as displayed within Plg 
when expressed by genetically-engineered eukaryotic cells. 
vii) Human U87 glioma cells and murine DN3 mammary adenocarcinoma cells can 
be retrovirally gene-modified to secrete functional K5 protein. 
viii) Soluble K5 protein inhibits growth factor-stimulated endothelial cell migration in 
vitro. 
lx) Soluble K5 protein blocks glioma and mammary adenocarcinoma-associated 
angiogenesis in vivo by reducing the quantity and Slze of tumor-associated 
vasculature. 
x) Soluble K5 protein possesses novel anti-macrophage properties, capable of 
suppressmg in vitro migration of human monocyte-derived macrophages and 
prevents the recruitment ofhost-derived tumor-infiltrating macrophages in vivo. 
xi) Glioma-targeted K5 expression suppresses tumor growth and prolongs survival in 
an experimental orthotopic brain cancer model. 
xii) Soluble K5 protein is dependent upon the innate immune effector cells to exert an 
anti-tumor effect in vivo. 
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xiii) Expression of soluble K5 protein by gene-modified DAl3 cells within the tumor 
microenvironment leads to the recruitment of CD3+ lymphoid cells and more 
specifically natural killer T-Iymphocytes. 
xiv) Soluble K5 protein induces robust neutrophilic infiltration within the tumor 
microenvironment. 
xv) Purified K5 protein acts as a chemoattractant as well as promotes neutrophil 
activation in vitro. 
xvi) Human recombinant angiostatin (KI-3) protein inhibits GM-CSF-induced 
migration of murine peritoneal macrophages and blocks migration of hum an 
monocyte-derived CD206+ macrophages. 
xvii) KI-3 protein decreases the ge1atinolytic activity of macrophage-derived MMP-9. 
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Abstract 
Angiostatin, a well-characterized angiostatic agent, is a 
proteolytic c1eavage product of human plasminogen encom-
passing the first four kringle structures. The fifth kringle 
domain (K5) of human plasminogen is distinct from angios-
tatin and has been shown, on ils own, to act as a potent 
endothelial cell inhibitor. We propose that tumor-targeted 
K5 cDNA expression may act as an effective therapeutic 
intervention as part of a cancer gene therapy strategy. In this 
study, we provide evidence that eukaryotically expressed 
His-tagged human K5 cDNA (hK5His) is exported extracellu-
larly and main tains predicted disulfide bridging conformation 
in solution. Functionally, hK5His protein produced by retro-
virally engineered human U87MG glioma cells suppresses 
in vitro migration of both human umbilical vein endothelial 
cells and human macrophages. Subcutaneous implantation of 
Matrigel-embedded hK5His-producing glioma cells in non-
obese diabetic/severe combined immunodeficient mice 
reveals that hK5His induces a marked reduction in blood 
vessel formation and significantly suppresses the recruitment 
of tumor-infiltrating CD45+Mac3+Grl- macrophages. Thera-
peutically, we show in a nude mouse orthotopic brain cancer 
model that tumor-targeted K5 expression is capable of 
effectively suppressing glioma growth and promotes signifi-
cant long-term survival (> 120 days) of test animais. These data 
suggest that plasminogen K5 acts as a novel two-pronged 
anticancer agent, mediating ils inhibitory effect via its action 
on host-derived endotheJial cells and tumor-associated 
macrophages, resulting in a potent. c1inically relevant anti-
tumor effect. (Cancer Res 2005; 65(18): 8359-65) 
Introduction 
Glioblastomas are very aggressive solid tumors characterized 
by hypervascularization and extensive tumor cell invasion into 
normal brain parenchyma (1). Current therapeutic modalities 
primarily target rapidly dividing malignant cens and include 
combinations of surgery, radiotherapy, and chemotherapy (1, 2). 
However, these therapies remain ineffective with >90% of 
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patients experiencing local recurrence and a 5-year survival rate 
of only 9% (3). 
The urgent need for the development of potent antiglioma 
therapeutics as weIl as the importance of angiogenesis in glioma 
growth (4, 5) has fueled the identification and characterization of 
numerous antiangiogenic agents, aimed at interrupting new vessel 
formation and ultimately arresting tumor growth. The use of 
antiangiogenic agents as therapeutics is an appealing approach 
targeting nonmalignant endothelial cens that form the tumor 
vasculature and indirectly affects tumor cens thus minimizing the 
risk of toxicity, In addition, the problem of drug resistance 
associated with conventional chemotherapy agents is avoided 
because normal endothelial cells are genetically stable unlike 
tumor cells (6)_ Moreover, the blood-brain barrier is another 
obstacle olten encountered with therapies targeting malignant cells 
within the brain and may be exploited with antiangiogenic 
strategies by maintaining the angiogenic inhibitor within the brain 
vasculature for a prolonged period_ Although angiogenesis 
inhibition otIers severa! advantages over traditional therapeutic 
approaches, it is expected to induce a cytostatic effect resulting in 
tumor stabilization not eradication. Furthermore, single-agent 
antiangiogenic therapy may lead to a compensatory increase in 
the production of other angiogenic factors, which may then sustain 
angiogenesis (1)_ Despite these limitations, it is now weil 
recognized that angiostatic agents either singly or in combination 
with other treatment modalities could offer superior therapeutic 
benefits than currently atlainable (7-13), converting the tumor into 
a controlled, quiescent chronic disease, Direct delivery of purified 
recombinant antiangiogenic proteins however necessitates large 
quantities and repeated administration of the therapeutic gene 
product for a prolonged period of time (14, 15), To circumvent the 
pitfalls associated with conventional treatments, we have devel-
oped a potent antiangiogenic gene therapy strategy for brain 
cancer. Moreover, because malignant gIiomas localize within the 
central nervous system and do not form distant metastases (16), 
they represent an attractive target for local gene therapy, which 
provides high and sustained local production of the desired thera-
peutie agent and off ers a viable alternative to existing therapeutic 
interventions_ 
Severa! inhibitors of angiogenesis exist endogenously as proteo-
Iytic c1eavage products oflarger precursor molecules_ Angiostatin, a 
well-characterized antiangiogenic agent discovered by O'Reilly et al, 
in Folkman's laboratory, was initially identified as an endothelial 
cell growth inhibitor present in urine and plasma of animais 
harboring solid tumors (17, 18), is an internai cryptic fragment of 
human' pIasminogen encompassing the first four kringle (KI-4) 
domains (Fig. lA). The K5 domain of plasminogen has been 
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cxpressed as a recombinant protein in bacteria and been found to 
be more potent than KI-4 or any of the plasminogen kringles 
expressed individually in inhibiting growth factor stimulated 
proliferation of endothelial cells in vitro (I9, 20). It has a1so been 
shown that kringle domains 1-5 (KI-5) act as more potent 
endothelial cell inhibitors in vitro and are more effective in 
suppressing fibrosarcoma tumor growth in vivo compared with 
KI-4 alone (21). We propose that the K5 domain could serve as a 
potent angiostatic agent on its own and that it may act as a useful 
therapeutic transgene within a cancer gene therapy strategy. To test 
this hypothesis, we have developed a hum an K5-expressing 
retroviral vector and tested its efficacy in vivo using an orthotopic 
brain cancer mode!. 
Materials and Methods 
Cell culture reagents. 293GPG pantropic retrovirus-packaging cell line 
(22) was a gift from Dr. Richard C. Mulligan (Children's Hospital, Boston, 
MA). Human gIioma U87MG cell line (23) was a gift from Dr. Stéphane 
Richard (Lady Davis Institute, Montreal, Quebec, Canada). Freshly isolated 
primary human umbilical endothelial cells (HUVEC) were generously 
provided by Dr. Mark B10stein (Lady Davis Institute) and maintained in 
endothelial-basal media (EBM-2; Cambrex, Walkersville, MD) supplemented 
with EBM-2 SingleQuots. Fresh human peripheral blood mononuclear cells 
were obtained from normal volunteers and maintained in DMEM-FI2 
(Wisent Technologies, St-Bruno, QC, Canada) supplemented with 2% 
Figure 1. Schematic illustration 01 human plasminogen (Plg) and its kringle 
domains. A, plasminogen is composed 01 791 amino acids with a single 
N-linked glycosylation at Asn289 and a single O-linked glycosylation at Thf"4S. 
Angiostatin, a well-known inhibitor 01 angiogenesis, encompasses the lirst 
three to lour kringle structures 01 plasminogen. This is a modilied schematic 
courtesy 01 Dr. M.R. Uinas et al., Carnegie Mellon University, Pillsburgh, 
PA (hllp://www.chem.cmu.edu/groupslUinaslreslstructurelhpk.html). 
8, hK5 consists 01 the last cryptic Iragment 01 plasminogen (CYS'52 _Cys541) 
and is composed 01 8O-amino-acid residues with three distinct disuHide bonds. 
human serum and 500 units/mL granulocyte/macrophage colony stimulat-
ing factor (GM-CSF; Immunex, Thousand Oaks, CA). 
Soluble hm",m kringIe 5-hisTag expression vedor, protein purifi-
cation, and detec:tion. pBLAST-hK5 cDNA (InvivoGen, San Diego, CA) 
encodes for hK5 and contains a 5' interleukin-2 signal peptide (IL-2sp) 
coding sequence. A 3' 6-histidine tag was PCR c10ned to generate IL-2sp/ 
hK5/HisTag (hereafter hK5His). Conditioned medium was collected from 
hK5His stably transfected human kidney 293 T cells, concentrated using 
a Centricon Plus-20 column (Millipore, Billerica, MA) and purified using a 
Ni-NTA-based resin affinity chromatography purification system (Novagen, 
San Diego, CA). Immunoblot analysis was done on eluted fractions using 
a polyclonal anti-His antibody (Santa Cruz Biotechnology, Santa Cruz, CA). 
Proteornic aDaIysis of puri6ed soluble hK5His. Lyophilized hK5His 
samples were resuspended in water/5% acetonitrile/O.l % trifluoroacetic 
acid (TFA), desalted using reverse-phase CI8 ZipTips (Millipore), eluted 
with water/7O% acetonitrile/O.l % TFA. The eluate was spotted onto a 
matrix-assisted laser desorption ionization (MALDI) sample plate and 
analyzed using a MALDI time-of·flight (TOF) Voyager-DE (Applied 
Biosystems, Foster City, CA). The eluted fraction was also spotted onto 
polybrene-coated TFA filter dises for Edman degradation-based NH2 -
terminal sequence analysis using a Procise 492 automated microsequencer 
(Applied Biosystems). One eluate aliquot was treated with 10 mmol/L DIT 
for 1 hour, diluted with 80 fiL of 50 mmol/L Ambic containing 100 ng of 
Trypsin gold (Promega, Madison, Wl). and digested ovemight. For dual-
enzyme digest. the eluted fraction was first digested ovemight with 
immobilized trypsin (Pierce, Rockford, IL) followed by an ovemight 
digestion with 100 ng of Endoproteinase-Asp-N (Roche Diagnostics, Laval, 
Quebec, Canada~ Digested solutions were ziptipped and eluted onto a 
MALDI sample plate. Peptide fragment analysis was done with an Ultima 
MALDI-Quadrupole TOF mass spectrometer {Waters Limitée. Dorval, 
Quebec, Canada~ Spectra analysis and peptide identity assignment was 
done using Biolynx, a software tool of Masslynx v4.0 (Waters). 
VSV-G-pseudotyped retroviraJ vector design, synthesis, and titer 
assessrnent. 111e bicistronic murine retrovector pIRES-EGFP was previ-
ously generated in our laboratory (24) and contains an enhanced green 
fluoescent protein (EGFP). The hK5His cDNA was ligated into pIRES-EGFP 
to generate phK5His-IRES-EGFP. VSV-G-pseudotyped retroparticles encod-
ing hK5His-lRES-EGFP were generated by tetracycline withdrawal as 
previously publisbed (24, 25). Engineered retroparticles were devoid of 
replication-competent retrovirus as detennined by GFP marker rescue 
assay using conditioned medium from target cells. The titer of the control 
GFP and hK5His 293GPG single clone population was assessed as previously 
described (25). 
Transduction of human US7MG gIioma celIs. Glioma cells were 
transduced with hK5His-expressing retroviral particles as previously 
described (24). Stahly transduced gIioma cells were culture expanded and 
sorted to obtain both polyclonal and single clone populations based on GFP 
expression using a Becton Dickinson FACSTAR sorter. 
Western blot analysis. Conditioned medium was collected from 
confluent control GFP and hK5His-transduced U87 g1ioma cells, as weil 
as stably translëcted hK5His 293 T cells (positive control), concentrated, 
and detected by anti-His immunoblot analysis as previously mentioned. 
Migration auays. HUVEC (I X 104) or human macrophages (5 x 104) 
were plated onto 0.15% gelatin/PBS-coated 8-flm pore chemotaxis 
membranes (Corning. Acton, MA) within Boyden chamber inserts. 
Migration assays were done as previously described (26). HUVEC and 
macrophages were exposed to conditioned medium from control GFP and 
hK5His transduced US7 glioma cells for 4 and 24 hours, respectively, under 
growth factor-slimulated conditions (EBM-2 SingleQuots) and serum 
stimulation, respectively. Each sample was tested in triplicate and the 
average number of migrating cells per field was assessed by counting three 
random high-power fields per mter. 
ln vivo Malrigel assay and analysis of cellular infIltrate by 
cytornetry. Culture-expanded U87-GFP and U87-hK5His-GFP celIs were 
aliquoted to create 5O-fiL cell suspensions containing 2 x 104 celIs, rnixed 
with 500 fiL Matrigel (BD Biosciences, Sanjose;CA) at 4°C, and implanted 
s.c. in the right lateral flank of 6-week-old nonobese diabetic/severe 
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eombined immunodefieient (NOD-SClD) miee (Charles River, Laprairie, 
Quebee, Canada). Four weeks after implantation, miee \Vere sacrificed and 
implants exeised and processed as pre\~ously deseribed (27). To determine 
the expIant cellular infiltrate, cell suspensions were stained with the 
follo,,~ng antibodies: purified rat anti-mouse CDI6/CD32 (mouse Fe block) 
followed by APC-eonjugated rat anti-mouse CD45, PE-conjugated rat anti-
mouse Mac-3, biotin-conjugated rat anti-mouse Ly-6G (Gr-I), and their 
corresponding isotypie controls. Biotinylated antibodies \Vere revealed using 
PE-Cy7-strepta~din (BD PharMingen, San Diego, CA). Cells were fIXed with 
1% paraformaldehyde and events were acquired using a FACSCalibur fiow 
cytometer (Beckman Coulter, Fullerton, CA) and analyzed using the 
CelIQuest software (BD PharMingen). 
Matrigel expIant histochemistry. Explants were fixed in formalin, 
embedded in paraffin, and 4-f1m sections were prepared to generate 
representative sections of the border and central regions of the explants. 
Sections \Vere treated with xylene, rehydrated, and antigen retrieval was done 
using Iwo microwave boils in a 10 mmol/L sodium citrate buffer (pH 6.0) 
solution. Endogenous biotin acti~ty was blocked using a kit (Zymed 
Laboratories, M arkh am, Ontario, Canada), sections were subsequently 
blocked with 2.5% bo~ne serum a1bumin in PBS and incubated with a rabbit 
polyclonal raised against murine von Willebrand factor (vWF; Neomarkers, 
Fremont, CA dilution 1:100) overnight. After three washes, the sections were 
incubated with biotinylated goat anti-rabbit IgG antibody (BD PharMingen, 
dilution 1:200) for 2 hours, washed, and incubated with strepta~din­
peroxidase (Vector Labs, Burlingame, CA) for 1 hour before the addition of 
3,3' -diaminobenzidine chromogenic substrate (Vector Labs). Meyer's hema-
toxylin was used for counterstaining. The blood vessel surface area of ail vWF-
positive vessels was calculated using a Leica light microscope ocular 
micrometer (Leica Microsystems, Inc., Richmond Hill, Ontario, Canada) at 
400x magnification. Two observers counted three random sections per 
expIant in each experimental group. The blood vessel surface area to total 
section surface area was calculated and expressed as a percentage. 
Stereotactic intracerebral surgery. COI nu/nu female 6-week-oId 
athymic nude mice (Charles River) were anesthetized using a ketamine/ 
xylezine/saline/acepromazine cocktail (100 mg/mL. 20 mg/mL. 0.9%, 
10 mg/mL. respectively) dosed at 100 f1L/lOO g by i.p. injection. Mice were 
secured in stereotactic apparatus (Kopf Instruments, Tujunga, CA) and 
incisor bar set to -1.5. Midline incision made on scalp to expose Bregma 
and Lambda Coordinates from Bregma were AI', +0.5; LM, -2.0; and DY, 
-4.4. A burr hole \Vas made and a Hamilton syringe (IO-f1L 26-gauge needle, 
Hamilton Co., Reno, NV) was gently lowered. Cell suspension (1 x Hl" in 
3 f1L of HBSS) was injected at a rate of 0.25 f1L per 3 minutes for 36 minutes. 
Brain tissue analysis. After euthanasia, brains were processed for H&E 
staining as pre~ously described (28). Digital images \Vere retrieved using an 
OIympus microscope (Olympus America, Mel~lIe, NY). Tumor volumes 
were caIculated using the formula, length x width2 x 0.4. 
Results 
Matrix-assisted laser desorption ionization-quadrupole 
time-of-flight mass spectrometry analysis of expressed soluble 
hK5His peptide confirms predicted disulfide bridging confor-
mation. The 381-bp human plasminogen K5 domain cDNA, 
corresponding to amino acid residues 447 to 546 of plasminogen, 
includes a 20-amino-acid IL-2 signal sequence and a His-tag at the 
COOH terminus (Fig. lB) and encodes for the hK5His protein with 
a kringle structure as predicted by previously published nuclear 
magnetic resonance (NMR) structure study (29). Mfinity chroma-
tography was done on precIeared conditioned medium from stably 
transfected hK5His-expressing 293T cells. Anti-His immunoblot, 
following SDS-PAGE separation (Fig. 2A. top), shows a major band 
of 15 kDa (Fig. 2A. bottom). NH2-terminal amino acid sequencing 
indicated proper c1eavage of the IL-2 signal sequence directIy 
upstream of Ser20 and analysis by MALDI-Q TOF mass spectrom-
etry revealed a major peak at 12,108 Da consistent with the 
K5 Possesses Angiostatic and Antimacrophage Properties 
predicted molecular weight of hK5His (Fig. 2B). To fully 
characterize cystinyl bridge structure and confirm kringIe domain 
tertiary structure, an orthogonal digestion was carried out either 
with agarose-immobilized trypsin alone (Fig. 2C) or with trypsin 
followed by incubation with Asp-N endopeptidase (Fig. W) under 
reducing and nonreducing conditions. Peptide mapping of non-
reduced single and dual protease hK5His digests by MALDI-Q TOF 
mass spectrometry confirmed the presence of disulfide bridges 
among CYSJ7_Cys96, Cys38_Cys79, and Cys67_Cys9J (by deduction). 
These findings show that plasminogen hK5His domain spontane-
ously adopts a tertiary structure consistent with native conforma-
tion as displayed within plasminogen when expressed by 
genetically engineered eukaryotic cells. 
hK5His protein secreted by retrovirally gene-modified 
human g1ioma cells inhibits in vitro endothelial cell migra-
tion. The hK5His cDNA was c10ned into our previously published 
(24) bicistronic retroviral vector (Fig. 3A). The hK5His retrovector 
plasmid was stably transfected into 293GPG retroviral packaging 
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Figure 2. Proteomic analysis of purified soluble hK5His. A, silver stain done on 
pooled eluted fractions detects purified protein at the expected molecular weight 
of 15 kDa (top). Anti-His immunoblot analysis demonstrates the presence of 
soluble hK5His peptide in pooled eluted fractions (boNom). B, analysis of the 
purified hK5His peptide by MAlDl-Q TOF mass spectrometry revealed a major 
peak at 12,108 Da consistent with the theoretical molecular weight of monomeric 
K5 at 12.109.6 Da. The doubly charged form and dimer are detectable at 
6,059 and 24,195 Da, respectively. C, expected peptide fragment of interest 
generated for hK5His protein digested with trypsin alone under oxidizing 
conditions (/eft). C, MALDI-Q TOF mass spectra confirming Cys38:79 disulfide 
bond within hKSHis (right). D, expected peptide fragment of interest generated 
for hK5His protein digested with trypsin followed by Asp-N endopep,tidase 
treatment under oxidizing conditions (/eft). Spectra confirming Cys 7:96 and 
Cys38:79 disulfide bonds (right). 
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Figure 3. Development and characterization 01 hK5His·GFP gene·modified 
cens. A. schematic illustration 01 the human hK5His·IRES·EGFP retroviral 
plasmid construct. The retrovector pIRES·EGFP construct served as the control 
plasmid. B, Ilow cytometry analysis 01 untransduced (gray) and hK5His· 
transduced (black) human U87 glioma cens. C, anti·His immunoblot analysis 
reveals lunctional secretion 01 hK5His migrating as a doublet at -15 kDa Irom 
retrovirany gene-modilied U87 glioma cens and stably translected 293T cens 
(positive control). D, conditioned medium Irom hK5His-transduced glioma cens 
inhibits HUVEC migration up to 75 ± 3%. Bars, SE. Statistical analysis was 
done using Student's t test. 
cells and retrovirus producer cells were selected as described in 
Materials and Methods. Tetracycline withdrawal from the culture 
medium led to the production of VSV-G-typed hK5His-GFP 
retroviral particles that were subsequently concentrated lOO-fold 
by ultracentrifugation and a viral titer of - 2.5 x 106 infectious 
particles/mL was obtained (data not shown), Concentrated VSV-G-
typed hK5His-GFP retroviral particles were used to transduce 
human g1ioma cells. The U87MG human g1ioblastoma cell line was 
selected for this study because it overexpresses vascular endothelial 
growth factor (VEGF)-producing tumors in vivo that are charac-
terized by increased vascularity, lack of necrosis, and absence of 
peripheral invasion in early tumor development (1). Following 
retroviral transduction, single U87MG clones were selected and 
assessed for GFP expression by flow cytometry. The U87 single clone 
used for the study was sorted based on GFP expression and was 99% 
GFP positive (Fig. 3B). To ensure hK5His transgene expression and 
proper secretion, anti-His immunoblot analysis was done on 
conditioned supernatant collected from hK5His transduced human 
U87 g1ioma cells and detects a major 15-kDa protein consistent with 
the predicted molecular weight of soluble hK5His (Fig, 3C), Using 
a semiquantitative Western blot titration curve, it was estimated 
that hK5His-GFP-expressing U87 cells secrete 0.5 pmol/L (or 7.5 ng) 
of soluble hK5His per 106 cells per 24 hours (data not shown). To 
test the functionality of secreted hK5His from hK5His-GFP-
expressing U87 cells, a HUVEC migration assay was done as it has 
been previously shown that recombinant K5 protein is capable of 
inhibiting the migration of bovine capillary endothelial cells (30). 
Soluble hK5His present in the conditioned medium of hK5His-GFP-
expressing U87 cells was capable of inhibiting growth factor-
induced migration ofHUVEC up to 75 ± 3% (P < 0.0004) compared 
with conditioned medium from GFP-expressing U87 ceUs (Fig. 3D). 
This confirms the in vitro functionality of hK5His secreted by 
hK5His-GFP-expressing U87 ceUs. 
hK5His blocks glioma-associated angiogenesis and pos-
sesses nove) antimacrophage properties. To further characterize 
the mechanism of action of soluble hK5His in vivo, we investigated 
whether hK5His could interfere with the tumor microenvironment. 
More specifically, we assessed whether soluble hK5His could affect 
the recruitment of host-derived tumor-infiltrating endothelial as 
weIl as inllammatory ceUs implicated in tumor angiogenesis. To 
test this hypothesis. 2 x 104 U87-GFP (n = 10) or U87-hK5His-GFP 
(n = 10) ceUs were Matrigel embedded and implanted s.e. in NOD-
SCID mi ce. To verify if tumor-secreted hK5His induced an 
antiangiogenic effect in vivo, explants (n = 4) in each experimental 
group were retrieved 4 weeks after implantation (Fig. 4A) and 
stained with vWF antibody (Fig. 4B). The section surface area 
occupied by vWF-positive blood vessels to total section surface 
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Figure 4. hK5His acls as a potent antiangiogenic agent. A, implant (alTOW) 
retrieval4 weeks alter implantation 01 2 x 10' Matrigel-embedded U87-GFP 
or U87-hK5His-GFP celfs (representative images are shown at Ihe same 
magnificalion). 8, representalive images of vWF-posilive immunoslained blood 
vessels (recf arrows) lrom two differenl U87-GFP-conlaining (a and b) and 
U87-hK5His-GFP-containing (c and cf) implants; magnification, 2OOx. 
C, vWF-positive blood vessel surface area to lotal seclion surface area ratio is 
plotted as a percentage. Bars, SE (SE for Matrigel-only group was based on 
three random section counts Irom one animal because remaining implants 
resorbed completely). Stalistical analysis was done using Studenl's 1 test 
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area ratio was calculated and expressed as a percentage (Fig. 4C). 
Our results show that soluble hK5His domain is capable of exerting 
a potent antiangiogenic effect (P = 0.04) in vivo when secreted by 
retrovirally engineered g1ioma cells. The remaining explants (n = 6) 
in each experimental group were dissolved in a collagenase 
solution and single-cell suspensions were generated and counted. 
(Fig. SA, left). The hK5His-GFP explants contained about two thirds 
less cells than the control GFP explants (P = 0.01). The cellular 
infiltrate in the explants was analyzed for GFP expression as weil as 
for cell surface marker expression to distinguish the various cell 
types present within the explants (Fig. SA, right). The GFP-positive 
cell fraction representing g1ioma cells is significantly reduced in the 
hK5His-GFP explants compared with the control GFP explants 
A 14 
~ 
012 
X 
~10 
~ 
~ 8 
:1 
Z 6 
~ 4 
! 2 
~ o 
B 
~3.5 
E 3 
~ 2.5 
E 
c 
u. 
Q. 
:I: ] 
CD 
t) 
"C 
.. 
:1 2 
Z 
'i 1.5 
~1 
S 
~05 
o 
350 
300 
250 
200 
150 
~ 100 
CI 
:ë 50 
D U87-GFP 
• U87-K5-GFP 
* 
••• P= 0.03 
o U87-GFP 
• U87-K5-GFP 
o~--~----~----~--~ 
Supernatant Source 
Figure 5. hK5His possesses nover antimacrophage property and decreases 
migration potential of human macrophages. A, absolule lolal cell counl 
performed alter collagenase digestion 01 Ihe explanls (Ieft). Absolute number 
01 GFP positive ceUs was enumerated using Ilow cytometry and represents the 
GFP-marked glioma ceUs (righ/). Bars, SE. B, absolute number 01 inliltrated 
CD45+ hematopoietic ceUs, CD45+Mac3+Grl + monocytes/macrophages, 
CD45+Mac3+Grl- macrophages and CD45+Mac3-Grl+ granulocytes in the 
explants. Bars, SE. Statistical analysis was done using Student's t test. 
C, macrophages were exposed to various conditioned medium lor 24 heurs 
under serum stimulation. Basal invasion represents migrating macrophages 
under serum·lree conditions. Bars, SE. Inse/s, representative stains 01 migrated 
ceUs lrom each experimental group; magnification, 200 x . Statistical analysis 
was done using Student's / test. 
K5 Possesses Angiostatic and Antimacrophage Properties 
(P = 0.03). It is important to note that the difference in absolute 
tumor cell number is not due to differences in the proliferation 
rates of the control GFP and hKSHis-GFP glioma cells because both 
possess equivalent proliferation rates in vitro (Supplementary 
Fig. 1). Although immunocompromised NOD-SCm mice possess 
functional macrophages and granulocytes, they lack functional 
T and B lymphocytes. Flow c)'tometry anal)'sis after three-color 
staining indicated that a substantial part of the cellular infiltrate 
consisted of CD45-positive hematopoietic cells (Fig. 5B, left). More 
specificall)'. there was a reduced absolute number of recruited 
CD4S+Mac+Gr1+ (P = 0.04) cells, which represents the monocyte/ 
macrophage fraction and CD45'Mac3+GrC (P = 0.03) cells, which 
represents the macrophages present in the U87-hK5His-GFP-
containingexplants compared with the control U87-GFP-containing 
explants (Firr 5B). There was no significant difference in the number 
of CD4S+Mac3-Gr1+ (P = 0.43) cells representing the infiltrated 
granulocytes present in the explants. 
To confirm our in vivo observations, we tested whether hK5His 
could inhibil macrophage migration in vitro. A migration assay was 
done using human monocytes isolated from peripheral blood 
mononuclear cells that were stimulated with GM-CSF to differen-
tiate into CD206+ macrophages (data not shown). The ability of 
macrophages to migrate through a gelatin matrix was assessed 
under serum-stimulated conditions, where macrophages were 
directl)' exposed to conditioned medium collected from GFP-
expressing g1ioma cells and hK5His-GFP-expressing g1ioma cells. 
The results indicate that soluble hK5His decreases the migration 
potential oC human macrophages b)' - 60% compared with the 
GFP control (P = 0.007, Fig. 5C). 
Glioma-largeted hK5His expression suppresses tumor 
growth and prolongs survival in an experimental orthotopic 
brain cancer modeJ. To test the efficacy of retrovirally engineered 
g1ioma cells secreting hK5His in a c1inieally relevant proof-of-
principle experiment, 105 U87-GFP (n = 5) and U87-hK5His-GFP cells 
derived from either a single clone (n = 5) and an independentl)' 
generated polyclonal population (n = 5) were implanted intracere-
brally in athymie nu/nu (nude) mice. Mice were sacrificed 32 days 
after implantation and brains were removed and processed for H&E 
staining (Firr 6A). Tumor volumes from each experimental group 
were estimated from H&E-stained cryostat sections and calcu-
lated as described in Materials and Methods. Consistent with our 
previous study (28), brain tumors in the GFP control group had 
extensive growth. In contrast, the U87-hK5His-GFP-implanted 
miee possessed significantly reduced mean tumor volumes 
(0.35 ± 0.18 mm3 for the single clone population and 0.07 ± 
0.03 mm3 for the polyclonal population) compared with the control 
U87-GFP-implanted (12.23 ± 6.07 mm3) mice (P = 0.04; Fig. 6B). 
We did a long-tenn in vivo study, where we evaluated the 
survival of the therapeutic cohort implanted with U87-hK5His-GFP 
cells (n = 15) and the control U87-GFP-implanted (n = 10) miee. 
Although ail control miee succumbed to excessive tumor burden by 
- 8 weeks, the U87-hKSHis-GFP-implanted miee possessed a c1ear 
survival advantage with 53% of the mice surviving over 120 days 
(P < 0.0001; Fig. 6C). 
Discussion 
This present study shows that eukaryotieally expressed secreted 
hK5His protein preserves the prototypieal native kringle disulfide 
bridging conCormation deemed essential for the angiostatie activity 
of plasminogen-derived peptide domains. Indeed, our cysteine 
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Figure 6. Suppression 01 intracerebral U87MG glioma groWlh by soluble 
hK5His. A, H&E·stained brain tissue sections Irom control U87·GFP implanted 
mice (n = 5) and U87·hK5His·GFP implanted mice (n = 5) 32 days alter 
implantation. Representative stains are shown at the same magnificat ion, 40x. 
B, tumor volumes were estimated Irom postmortem H&E·stained brain sections 
obtained Irom mice implanted with U87·GFP, U87-hK5His-GFP single clone 
(sc), and U87-hK5His-GFP polyclonal (pc) ceUs. The experiment was done twice 
with similar results. Bars, SE. Student's t test. C, Kaplan-Meier long-term 
survival curve 01 mice implanted with control U87-GFP (n = 10) and 
U87-hK5His-GFP (n = 15) cells. Log-rank statistical test. 
bridging pattern data confirms the results of the only other study 
that characterizes the structure of recombinant KS domain using 
NMR technology (29). We have shown that VSV-G-pseudotyped 
retroviral vectors engineered to express human plasminogen 
hKSHis domain can efficiently gene modify human U87 g1ioma 
cens ex vivo. We also show that hKSHis-engineered U87 cells can 
secrete biologically functional soluble hKSHis protein capable 
of inhibiting growth factor-stimulated endothelial cell migration 
in vitro. 
Moreover, our in vivo data in immunodeficient NOD-SCm mice 
suggests that hKSHis secreted by Matrigel-embedded U87 engi-
neered cells acts as a potent antiangiogenic agent by significantly 
decreasing blood vessel formation as weil as a novel antimacro-
phage agent by significantly preventing the recruitment of 
host-derived tumor-associated CD4S+Mac3+Grl +/- monocytes! 
macrophages within the local tumor microenvironment. The 
involvement of tumor-associated macrophages in angiogenesis 
and tumor progression is a well-established concept (31-33). 
Activated macrophages produce tumor necrosis factor-a and IL-l, 
inducing the production of VEGF and IL-8 in g1ioma cells, which 
further attracts and activates macrophages (34). Macrophage 
infiltration has been c10sely correlated with neovascularization 
and observed more frequently in grade 4 g1ioblastomas than in 
grade 2 or 3 g1iomas (34). 
It may be speculated that the potent antiangiogenic properties of 
soluble K5 mediating a reduction in tumor-associated endothelial 
cens, as evidenced by the lower surface area occupied by blood 
vessels in the U87-hK5His-GFP-containing explants, is partially 
responsible for the decreased infiltration of host-derived macro-
phages within the tumor area. We also show that soluble hK5His 
independently reduces macrophage migration in vitro, suggesting 
that the K5 domain can impart a direct inhibitory effect on 
macrophage motiIity. To date, the K5 peptide has been consistently 
characterized as an endothelial cell-specific inhibitor (19, 30) and 
Gonzalez-Gronow et al. (3S) suggest that K5 mediates its effects by 
binding to the human voltage-dependent anion channel, which is a 
receptor present on hum an endothelial cells. Vnlike K5, the 
mechanism of action of angiostatin has been studied more 
extensively and its endothelial cell binding sites include the cell 
surface-associated ATP synthase receptor (36), angiomotin (37), 
and integrin IXvr'>3 (38). Although angiostatin mediates its inhibitory 
action primarily on endothelial cells, it has been reported by 
Moulton et al. (39) that it reduces plaque angiogenesis and 
atherosclerosis by reducing plaque-associaled macrophages. How-
ever, Moulton et al. suggest that angiostatin, at doses that reduce 
endothelial cell sprouting, does not directly inhibit monocytes 
because it does not inhibit VEGF-induced monocyte migration 
in vitro. Thus, our findings provide novel mechanistic insight and 
suggest that soluble hKSHis protein inhibits two unique cell types 
most critical for tumor angiogenesis, mediating a dual role as an 
antiangiogenic agent via its antiendothelial cell properties as weil 
as an antitumor agent by reducing the infiltration of host-derived 
macrophages within the tumor mieroenvironment. 
We used a c1inically relevant orthotopic implantation approach 
to test wh ether soluble hKSHis could suppress g1ioma progression 
after implantation of hK5His-GFP-expressing V87 cens in athymie 
nu/nu mice. Stereotactic implantation procedures are particularly 
suitable for g1ioma gene therapy approaches allowing for constant 
long-lasting transgene expression within the local tumor microen-
vironment and minimize the risk of toxicity as is often encountered 
with systemic therapies. Our data successfully shows that soluble 
hKSHis significantly decreases tumor growth by - 97% compared 
with controls. In doing so, soluble hK5His also promotes long-term 
survival, with S3% of U87-hKSHis-GFP-implanted mice surviving 
past 120 days. We postulate that upon stereotactic implantation of 
our ex vivo retrovirally engineered hK5His g1ioma cens, stable 
integration and sustained expression of the hKSHis transgene in 
target U87 cens provided continuous release of soluble hK5His 
within the loco-regional tumor microenvironment, resuIting in 
potent suppression of tumor growth. We speculate that tumor-
targeted delivery of hKSHis via viral vectors such as pseudotyped 
retrovectors (24) and other gene delivery platforms would lead to 
similar results. 
ln summary, we provide compelling evidence that secreted 
hKSHis prolein expressed by engineered g1ioma cens possesses 
potent antiangiogenic as weil as novel antimacrophage properties 
that block g1ioma progression and promote survival in an 
orthotopic experimental brain cancer model. Further studies on 
the pleiotropic effects of KS peptide on host-derived angiogenic 
and macrophage response may offer new avenues of exploration 
for the development of therapeutic strategies for the treatment of 
g1ioma and other loco-regional refractory malignancies snch as 
prostate and ovarian cancer. 
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The foHowing will confinn the safety and ethical conditions with regard to aH 
laboratories at the Lady Davis Institute for Medical Research of the Sir Mortimer B. 
Davis Jewish General Hospital. 
The Lady Davis Institute for Medical Research is a free-standing biomedical research 
institute attached to the Sir Mortimer B. Davis Jewish General Hospital, a major adult 
teaching hospital affiliated with McGill University. There is approximately 110,000 sq. 
ft. of laboratory space occupied by over 65 independent investigators aH of whom hold 
McGill University appointments in appropriate departments. At the present time we have 
approximately 100 graduate students and post-doctoral feHows registered with McGill 
University. Total external funding is in the range of $18 million (exclusive of overhead), 
which is large by Canadian standards. 
Prof essor Andrew Mouland functions as Chair of our Health and Safety Committee, 
while Prof essor John Hiscott, a virologist, heads the subcommittee of the Health and 
Safety Committee on Biohazards. 
Dr. Mouland affinns the safety program which addresses the question of radioactive 
material licence and Dr. Hiscott affinns the question of the use of recombinant DNA in 
the experiments. Dr. Lorraine Chalifour affinns the ethical use of animaIs. 
As a constituent part of McGill University the Institute foHows and meets aH of the 
requirements of the McGill Laboratory Biosafety Manual. For those rare circumstances 
not covered by the McGill Laboratory Biosafety Manual we use the following as 
reference guidelines: 
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- Biosafety in Microbiological and Biomedical Laboratories, 3rd edition (1993). U.S. 
Department of Health and Human Services (Public Health Service), Centers for Disease 
Control and Prevention, and the National Institutes of Health. U.S. Government Printing 
Office, Washington, D.C. 
- Laboratory Biosafety Manual, 2nd edition (1993). World Health Organization, Geneva, 
Switzerland. 
- Laboratory Biosafety Guidelines (1990). Medical Research Council of Canada and 
Laboratory Centre for Disease Control, Health Protection Branch, Health Canada, 
Ottawa, Canada. 
- Laboratory Safety, 2nd edition (1995). D.O. Fleming, J.H. Richardson, J.1. Tullis and D. 
Vesley, editors. ASM Press, Washington, D.C. 
- Guidelines for Research Involving Recombinant DNA Molecules (1996). U.S. 
Department of Health and Human Services, National Institutes of Health, Bethesda, M.D. 
Regular inspection of safety procedures are conducted by the Canadian Nuclear Safety 
Commission (CNSC) (annual), Contex Environment (laboratory health and safety 
consultants - several times per year), the Sir Mortimer B. Davis Jewish General Hospital 
Chairman of Infection Control - Dr. Mark Miller (monthly), the Canadian Council on 
Animal Cafe (bi-annually), the McGill animal Care Committee (monthly), as weIl as by 
the Hospital Fire Marshal - Mr. Thomas Prokos, and the City of Montreal Fire 
Department (semi-annually). 
The Lady Davis Institute (LDI) laboratories in which the research will be conducted are 
specially designed and equipped for scientific research and are used solely for that 
purpose. Specialized facilities are provided for the safe conduct of scientific research, 
including but not limited to, waste disposaI facilities for biohazardous, radioactive and 
chemical wastes, a level 3 containment facility and state-of-the-art animal facilities. An 
automatic sprinkler system (water) is installed throughout the building. Fire 
extinguishers are located in several locations on each of six floors, as are fire alarms. 
Fire doors and alarm pulls are marked. In general, the laboratories and animal rooms are 
designed to have pressure differentials negative to adjacent areas. Fume hoods are 
monitored on a semi-annual basis. Fume hoods exhaust to the outside. Biological safety 
cabinets are certified semi-annually. 
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